1
|
Hartmann A, Ansquer S, Brefel-Courbon C, Burbaud P, Castrioto A, Czernecki V, Damier P, Deniau E, Drapier S, Jalenques I, Marechal O, Priou T, Spodenkiewicz M, Thobois S, Roubertie A, Witjas T, Anheim M. French guidelines for the diagnosis and management of Tourette syndrome. Rev Neurol (Paris) 2024:S0035-3787(24)00524-1. [PMID: 38760282 DOI: 10.1016/j.neurol.2024.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Revised: 03/22/2024] [Accepted: 04/09/2024] [Indexed: 05/19/2024]
Abstract
The term "Gilles de la Tourette syndrome", or the more commonly used term "Tourette syndrome" (TS) refers to the association of motor and phonic tics which evolve in a context of variable but frequent psychiatric comorbidity. The syndrome is characterized by the association of several motor tics and at least one phonic tic that have no identifiable cause, are present for at least one year and appear before the age of 18. The presence of coprolalia is not necessary to establish or rule out the diagnosis, as it is present in only 10% of cases. The diagnosis of TS is purely clinical and is based on the symptoms defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). No additional tests are required to confirm the diagnosis of TS. However, to exclude certain differential diagnoses, further tests may be necessary. Very frequently, one or more psychiatric comorbidities are also present, including attention deficit hyperactivity disorder, obsessive-compulsive disorder, anxiety, explosive outbursts, self-injurious behaviors, learning disorders or autism spectrum disorder. The condition begins in childhood around 6 or 7 years of age and progresses gradually, with periods of relative waxing and waning of tics. The majority of patients experience improvement by the end of the second decade of life, but symptoms may persist into adulthood in around one-third of patients. The cause of TS is unknown, but genetic susceptibility and certain environmental factors appear to play a role. The treatment of TS and severe forms of tics is often challenging and requires a multidisciplinary approach (involving the general practitioner (GP), pediatrician, psychiatrist, neurologist, school or occupational physicians, psychologist and social workers). In mild forms, education (of young patients, parents and siblings) and psychological management are usually recommended. Medical treatments, including antipsychotics, are essential in the moderate to severe forms of the disease (i.e. when there is a functional and/or psychosocial discomfort linked to tics). Over the past decade, cognitive-behavioral therapies have been validated for the treatment of tics. For certain isolated tics, botulinum toxin injections may also be useful. Psychiatric comorbidities, when present, often require a specific treatment. For very severe forms of TS, treatment by deep brain stimulation offers real therapeutic hope. If tics are suspected and social or functional impairment is significant, specialist advice should be sought, in accordance with the patient's age (psychiatrist/child psychiatrist; neurologist/pediatric neurologist). They will determine tic severity and the presence or absence of comorbidities. The GP will take over the management and prescription of treatment: encouraging treatment compliance, assessing side effects, and combating stigmatization among family and friends. They will also play an important role in rehabilitation therapies, as well as in ensuring that accommodations are made in the patient's schooling or professional environment.
Collapse
Affiliation(s)
- A Hartmann
- Centre de référence national maladie rare "Syndrome Gilles de la Tourette", DMU neurosciences, groupe hospitalier Pitié-Sapêtrière, Sorbonne université, AP-HP, 75013 Paris, France.
| | - S Ansquer
- Service de neurologie, CHU de Poitiers, 86021 Poitiers, France
| | - C Brefel-Courbon
- Inserm, Department of Neurosciences, Parkinson Toulouse Expert Center, UMR1214, NS-Park/FCRIN Network and NeuroToul COEN center, Toulouse University Hospital, Toulouse, France
| | - P Burbaud
- Pôle des neurosciences cliniques, service de neurophysiologie clinique de l'enfant et de l'adulte, CHU de Bordeaux, hôpital Pellegrin, Bordeaux, France
| | - A Castrioto
- Inserm, U1216, service de neurologie, Grenoble institut neurosciences, CHU de Grenoble-Alpes, université Grenoble-Alpes, 38700 Grenoble, France
| | - V Czernecki
- Centre de référence national maladie rare "Syndrome Gilles de la Tourette", DMU neurosciences, groupe hospitalier Pitié-Sapêtrière, Sorbonne université, AP-HP, 75013 Paris, France
| | - P Damier
- Inserm, service de neurologie, CIC 1314, CHU de Nantes, Nantes université, 44093 Nantes, France
| | - E Deniau
- Centre de référence national maladie rare "Syndrome Gilles de la Tourette", DMU neurosciences, groupe hospitalier Pitié-Sapêtrière, Sorbonne université, AP-HP, 75013 Paris, France
| | - S Drapier
- Service de neurologie, CHU de Pontchaillou, 35000 Rennes, France
| | - I Jalenques
- Service de psychiatrie de l'adulte A et psychologie médicale, centre de compétences Gilles de la Tourette, CNRS, institut Pascal, Clermont Auvergne INP, CHU de Clermont-Ferrand, université Clermont-Auvergne, 63000 Clermont-Ferrand, France
| | - O Marechal
- Association française pour le syndrome Gilles de la Tourette (AFSGT), 92522 Neuilly-sur-Seine, France
| | - T Priou
- Centre de référence national maladie rare "Syndrome Gilles de la Tourette", DMU neurosciences, groupe hospitalier Pitié-Sapêtrière, Sorbonne université, AP-HP, 75013 Paris, France
| | - M Spodenkiewicz
- Service de psychiatrie, CHU de la Réunion, 97410 Saint-Pierre, La Réunion, France
| | - S Thobois
- Department of Neurology C, Expert Parkinson Center NS-PARK/FCRIN, hospices civils de Lyon, Pierre Wertheimer Neurological Hospital, Bron, France; CNRS, UMR 5229, Marc-Jeannerod Cognitive Neuroscience Institute, Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université Claude-Bernard Lyon 1, Oullins, France
| | - A Roubertie
- Inserm U 1298, service de neuropédiatrie, institut des neurosciences de Montpellier, CHU de Montpellier, Montpellier, France
| | - T Witjas
- Department of Neurology and Movement Disorders, Timone University Hospital, Aix-Marseille University, Marseille, France; Centre national de la recherche scientifique (CNRS), institut de neurosciences de la Timone (INT), Aix-Marseille University, 13005 Marseille, France
| | - M Anheim
- Service de neurologie, hôpitaux universitaires de Strasbourg, Strasbourg, France; Inserm-U964/CNRS-UMR7104, institut de génétique et de biologie moléculaire et cellulaire (IGBMC), université de Strasbourg, Illkirch, France; Centre de référence des maladies neurogénétiques rares, Paris, France; Fédération de médecine translationnelle de Strasbourg (FMTS), université de Strasbourg, Strasbourg, France.
| |
Collapse
|
2
|
Roubertie A, Opladen T, Brennenstuhl H, Kuseyri Hübschmann O, Flint L, Willemsen MA, Leuzzi V, Cazorla AG, Kurian MA, François-Heude MC, Hwu P, Zeev BB, Kiening K, Roujeau T, Pons R, Pearson TS. Gene therapy for aromatic L-amino acid decarboxylase deficiency: Requirements for safe application and knowledge-generating follow-up. J Inherit Metab Dis 2024; 47:463-475. [PMID: 37402126 DOI: 10.1002/jimd.12649] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 06/29/2023] [Accepted: 07/03/2023] [Indexed: 07/05/2023]
Abstract
The autosomal recessive defect of aromatic L-amino acid decarboxylase (AADC) leads to a severe neurological disorder with manifestation in infancy due to a pronounced, combined deficiency of dopamine, serotonin and catecholamines. The success of conventional drug treatment is very limited, especially in patients with a severe phenotype. The development of an intracerebral AAV2-based gene delivery targeting the putamen or substantia nigra started more than 10 years ago. Recently, the putaminally-delivered construct, Eladocagene exuparvovec has been approved by the European Medicines Agency and by the British Medicines and Healthcare products Regulatory Agency. This now available gene therapy provides for the first time also for AADC deficiency (AADCD) a causal therapy, leading this disorder into a new therapeutic era. By using a standardized Delphi approach members of the International Working Group on Neurotransmitter related Disorders (iNTD) developed structural requirements and recommendations for the preparation, management and follow-up of AADC deficiency patients who undergo gene therapy. This statement underlines the necessity of a framework for a quality-assured application of AADCD gene therapy including Eladocagene exuparvovec. Treatment requires prehospital, inpatient and posthospital care by a multidisciplinary team in a specialized and qualified therapy center. Due to lack of data on long-term outcomes and the comparative efficacy of alternative stereotactic procedures and brain target sites, a structured follow-up plan and systematic documentation of outcomes in a suitable, industry-independent registry study are necessary.
Collapse
Affiliation(s)
- Agathe Roubertie
- CHU Montpellier, Département de Neuropédiatrie, INM, Univ Montpellier, INSERM U 1298, Montpellier, France
| | - Thomas Opladen
- Division of Child Neurology and Metabolic Medicine, University Children's Hospital Heidelberg, Germany
| | - Heiko Brennenstuhl
- Division of Child Neurology and Metabolic Medicine, University Children's Hospital Heidelberg, Germany
- Institute Human Genetics, University Children's Hospital Heidelberg, Germany
| | - Oya Kuseyri Hübschmann
- Division of Child Neurology and Metabolic Medicine, University Children's Hospital Heidelberg, Germany
| | | | - Michel A Willemsen
- Department of Pediatric Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Vincenzo Leuzzi
- Department of Human Neuroscience-Unit of Child Neurology and Psychiatry, University of Rome La Sapienza
| | - Angels Garcia Cazorla
- Neurometabolism Unit, Department of Neurology, CIBERER and MetabERN, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Manju A Kurian
- Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, Great Ormond Street Institute of Child Health, University College London, London, UK
- Department of Neurology, Great Ormond Street Hospital for Children, London, UK
| | | | - Paul Hwu
- Department of Pediatrics and Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan
| | - Bruria Ben Zeev
- Pediatric Neurology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Karl Kiening
- Division of Stereotactic Neurosurgery, University Hospital Heidelberg, Germany
| | - Thomas Roujeau
- CHU Montpellier, Département de Neurochirurgie, Montpellier, France
| | - Roser Pons
- First Department of Pediatrics, National and Kapodistrian University of Athens, Aghia Sofia Hospital, Athens, Greece
| | - Toni S Pearson
- Division of Neurology, Nationwide Children's Hospital, Columbus, Ohio, USA
| |
Collapse
|
3
|
Colmard M, Rivier F, de Barry G, Roubertie A, Urtiaga-Valle S, Mercedes-Alvarez B, Combes C, Cambonie G, Milesi C, Meyer P. Efficacy of intravenous clonazepam for paediatric convulsive status epilepticus. Dev Med Child Neurol 2024. [PMID: 38263722 DOI: 10.1111/dmcn.15859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Revised: 12/22/2023] [Accepted: 12/27/2023] [Indexed: 01/25/2024]
Abstract
AIM To compare the efficacy of intravenous clonazepam (CLZ) for the initial management of convulsive status epilepticus (CSE) in children as a function of the first-line in-hospital dose used. METHOD This monocentric retrospective study included children who received a first dose of CLZ for CSE at Montpellier University Hospital, France, between January 2016 and June 2019. Data from medical records (clinical, treatment, course) were collected and compared as a function of the first CLZ dose used. RESULTS Among the 310 children treated for CSE, 105 received at least one CLZ dose (median age 3 years; quartile 1-quartile 3 [Q1-Q3] = 1 years 2 months-6 years 6 months). Among these 105 patients, 24 (22%) received a dose less than 0.03 mg/kg (low dose) and 69 (65%) received a dose of at least 0.03 mg/kg (high dose). Seizure cessation rate was not different between the low- and high-dose groups (62.5% vs 76%; odds ratio 0.53, 95% confidence interval [CI] 0.19-1.44, p = 0.29). The administration of a second dose of CLZ was more frequent in the low- than the high-dose group (37.5% vs 16%; odds ratio 3.2, 95% CI 1.1-9.1, p = 0.04). INTERPRETATION Our study did not find any difference in seizure termination rate as a function of CLZ dose in children with CSE. However, a second CLZ dose was more frequently needed in the group receiving low (less than 0.03 mg/kg) CLZ.
Collapse
Affiliation(s)
- Maxime Colmard
- Département de Neuropédiatrie, CHU de Montpellier, Montpellier, France
| | - François Rivier
- Département de Neuropédiatrie, CHU de Montpellier, Montpellier, France
- PhyMedExp, CNRS, INSERM, Université de Montpellier, Montpellier, France
| | - Gaëlle de Barry
- Département de Pharmacie clinique, CHU de Montpellier, Montpellier, France
| | - Agathe Roubertie
- Département de Neuropédiatrie, CHU de Montpellier, Montpellier, France
- INM, INSERM U1298, Université de Montpellier, Montpellier, France
| | | | | | - Clementine Combes
- Département de Réanimation Pédiatrique, CHU de Montpellier, Montpellier, France
| | - Gilles Cambonie
- Département de Réanimation Pédiatrique, CHU de Montpellier, Montpellier, France
| | - Christophe Milesi
- Département de Réanimation Pédiatrique, CHU de Montpellier, Montpellier, France
| | - Pierre Meyer
- Département de Neuropédiatrie, CHU de Montpellier, Montpellier, France
- PhyMedExp, CNRS, INSERM, Université de Montpellier, Montpellier, France
| |
Collapse
|
4
|
Fuchs F, Rodriguez A, Mousty E, Morin D, Roubertie A, Wells CF, Prodhomme O, Benoist JF, Dreux S, Faure JM, Willems M. Postnatal outcome of children with antenatal colonic hyperechogenicity. Prenat Diagn 2024; 44:28-34. [PMID: 38054546 DOI: 10.1002/pd.6475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 10/12/2023] [Accepted: 11/10/2023] [Indexed: 12/07/2023]
Abstract
OBJECTIVE To evaluate the postnatal outcome of children with antenatal colonic hyperechogenicity, currently considered as a sign of lysinuria-cystinuria, but which may also be a sign of other disorders with a more severe prognosis. METHOD We carried out a French multi-centric retrospective study via 15 Multidisciplinary Center for Prenatal Diagnosis from January 2011 to January 2021. We included pregnancies for which fetal colonic hyperechogenicity had been demonstrated. We collected the investigations performed during pregnancy and at birth as well as the main clinical features of the mother and the child. We then established the prevalence of pathologies such as lysinuria-cystinuria (LC), hypotonia-cystinuria syndrome (HC), or lysinuric protein intolerance (LPI). RESULTS Among the 33 cases of colonic hyperechogenicity collected, and after exclusion of those lost to follow-up, we identified 63% of children with lysinuria-cystinuria, 8% with lysinuric rotein intolerance, and 4% with hypotonia-cystinuria syndrome. CONCLUSION Management of prenatal hyperechoic colon should include a specialized consultation with a clinical geneticist to discuss further investigations, which could include invasive amniotic fluid sampling for molecular diagnosis. A better understanding of diagnoses and prognosis should improve medical counseling and guide parental decision making.
Collapse
Affiliation(s)
- Florent Fuchs
- CHU de Montpellier, Gynecology and Obstetrics, Montpellier, France
- Desbrest Institute of Epidemiology and Public Health (IDESP), University Montpellier, INSERM, Montpellier, France
| | - Alexis Rodriguez
- CHU de Montpellier, Gynecology and Obstetrics, Montpellier, France
| | - Eve Mousty
- Centre Hospitalier Universitaire de Nîmes, Gynecology and Obstetrics Nimes, Nimes, France
| | - Denis Morin
- CHU de Montpellier, Pediatric Nephrology, Montpellier, France
| | - Agathe Roubertie
- CHU de Montpellier, Pediatric Neurology, Montpellier, France
- Institute for Neurosciences of Montpellier, University Montpellier, INSERM, Montpellier, France
| | - Constance F Wells
- Medical Genetics Department, CHU de Montpellier, Montpellier, France
| | | | - Jean-François Benoist
- Hôpital Necker-Enfants Malades, Biochimie Métabolomique et Protéomique, Paris, France
| | - Sophie Dreux
- Hôpital Universitaire Robert Debré, Laboratoire de Biochimie-Hormonologie, Paris, France
| | | | - Marjolaine Willems
- Institute for Neurosciences of Montpellier, University Montpellier, INSERM, Montpellier, France
- Medical Genetics Department, CHU de Montpellier, Montpellier, France
| |
Collapse
|
5
|
Piarroux J, Dimopoulou E, Taieb G, Souvannanorath S, Roze E, Lion-François L, Spitz MA, Broussolle E, Laurencin C, Chanson JB, Belleville-Goffeney J, François-Heude MC, Meyer P, Khalil M, Dereure M, Doummar D, Chevassus H, Apartis E, Roubertie A. Clinical and Electrophysiological Characterization of Essential Tremor in 18 Children and Adolescents. Tremor Other Hyperkinet Mov (N Y) 2023; 13:46. [PMID: 38145278 PMCID: PMC10742103 DOI: 10.5334/tohm.803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 12/03/2023] [Indexed: 12/26/2023] Open
Abstract
Background Essential tremor (ET) is considered the most frequent abnormal movement in the general population, with childhood onset in 5 to 30% of the patients. Methods A multicenter, descriptive cross-sectional study enrolled patients ⩽18 years with a definite diagnosis of ET according to the International Parkinson and Movement Disorders Society criteria. Demographic data, clinical and electrophysiological characteristics of the tremor, neurological examination and impact on quality of life were collected. Results 9 males and 9 females were included (mean age of 13.9 years). Tremor was characterized by : upper limb onset at a mean age of 6.5 years; at enrollment, upper limbs localization, and involvement of an additional body region in 28% of the patients; kinetic tremor in all of the patients combined with postural tremor in 17 and rest tremor in 3; tremor mean frequency of 7.6 Hz, mean burst duration of 82.7 ms; identification of mild myoclonic jerks on the polymyographic recordings in 7 patients; altered quality of life with worse emotional outcomes in girls and when a disease duration >5 years was suggested. Discussion Childhood-onset ET is associated with delayed diagnosis and remarkable functional impact. Electromyographic identification of additional mild myoclonus is a new finding whose significance is discussed. Highlights ET onset involved upper limbs and at inclusion, 28% of the patients exhibited involvement of an additional body region.ET impacted quality of life for all patients.Girls and patients affected for >5 years reported worse emotional outcomes.Mild myoclonic jerks were identified on 7/17 polymyographic recordings.
Collapse
Affiliation(s)
- Julie Piarroux
- Department of Pediatric Neurology, Gui de Chauliac University Hospital, Montpellier, France
| | - Evgenia Dimopoulou
- Department of Pediatric Neurology, Gui de Chauliac University Hospital, Montpellier, France
| | - Guillaume Taieb
- University of Montpellier, CNRS (IGF), Department of Neurology, Montpellier, University Hospital 34295 Montpellier, France
| | - Sarah Souvannanorath
- Reference center for neuromuscular diseases, Henri-Mondor University Hospital, Assistance publique-Hôpitaux de Paris, Créteil, France
| | - Emmanuel Roze
- Department of Neurology, Salpêtrière Hospital, Sorbonne University and Assistance Publique - Hôpitaux de Paris, Paris, France
| | | | - Marie-Aude Spitz
- Department of Pediatry, Strasbourg University Hospitals, Strasbourg, France
| | - Emmanuel Broussolle
- Research Unit UMR 5229, Marc-Jeannerod Institute of Cognitive Science, French National Center for Scientific Research (CNRS), University of Lyon, Bron, France
- Department of Neurology C, Civil Hospices of Lyon, Pierre-Wertheimer Neurological Hospital, Bron, France
- Faculty of Medicine Lyon-Sud Charles-Mérieux, University of Lyon, Oullins, France
| | - Chloé Laurencin
- Department of Neurology C, Civil Hospices of Lyon, Pierre-Wertheimer Neurological Hospital, Bron, France
- Lyon Neuroscience Research Center (CRNL), INSERM U1028, CNRS UMR5292, University Lyon 1, Lyon F-69000, France
| | - Jean-Baptiste Chanson
- Department of Neurology, Strasbourg University Hospitals, Strasbourg, France and Reference centre for neuromuscular diseases Nord/Est/Ile-de-France, France
| | | | | | - Pierre Meyer
- Department of Pediatric Neurology, Gui de Chauliac University Hospital, Montpellier, France
| | - Mirna Khalil
- Clinical Investigation Center, Montpellier University Hospital, France. INSERM, CIC1411, Montpellier, France
| | - Maelle Dereure
- Clinical Research and Epidemiology Unit, La Colombière University Hospital, Montpellier, France
| | - Diane Doummar
- Department of Pediatric Neurology and developmental pathologies, Sorbonne University and Trousseau University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, APHP. SU, FHU I2D2, F-75012, Paris, France
| | - Hugues Chevassus
- Clinical Investigation Center, Montpellier University Hospital, France. INSERM, CIC1411, Montpellier, France
| | - Emmanuelle Apartis
- Department of Neurophysiology, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, INSERM U1127, CNRS UMR7225, UM75, ICM, 75013 Paris, France
| | - Agathe Roubertie
- Department of Pediatric Neurology, Gui de Chauliac University Hospital, Montpellier, France
- Institute for Neurosciences of Montpellier, INSERM U 1298, University of Montpellier, Montpellier, France
| |
Collapse
|
6
|
Wicker C, Roux CJ, Goujon L, de Feraudy Y, Hully M, Brassier A, Bérat CM, Chemaly N, Wiedemann A, Damaj L, Abi-Warde MT, Dobbelaere D, Roubertie A, Cano A, Arion A, Kaminska A, Da Costa S, Bruneel A, Vuillaumier-Barrot S, Boddaert N, Pascreau T, Borgel D, Kossorotoff M, Harroche A, de Lonlay P. Association between acute complications in PMM2-CDG patients and haemostasis anomalies: Data from a multicentric study and suggestions for acute management. Mol Genet Metab 2023; 140:107674. [PMID: 37542768 DOI: 10.1016/j.ymgme.2023.107674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Accepted: 07/29/2023] [Indexed: 08/07/2023]
Abstract
OBJECTIVES Patients with PMM2-CDG develop acute events (stroke-like episodes (SLEs), thromboses, haemorrhages, seizures, migraines) associated with both clotting factors (factor XI) and coagulation inhibitors (antithrombin, protein C and protein S) deficiencies. The aim of the study was to correlate acute events to haemostasis and propose practical guidelines. METHODS In this multicentric retrospective study, we evaluated clinical, radiological, haemostasis and electroencephalography data for PMM2-CDG patients hospitalized for acute events. Cerebral events were classified as thrombosis, haemorrhage, SLE, or "stroke mimic" (SM: normal brain imaging or evoking a migraine). RESULTS Thirteen patients had a total of 31 acute episodes: 27 cerebral events with 7 SLEs, 4 venous thromboses, 4 haemorrhages (3 associated with thrombosis), 15 SMs at a mean age of 7.7 years; 4 non-cerebral thromboses, one of which included bleeding. A trigger was frequently involved (infection, head trauma). Although sometimes normal at baseline state, factor XI, antithrombin and protein C levels decreased during these episodes. No correlation between haemostasis anomalies and type of acute event was found. DISCUSSION Acute events in PMM2-CDG are not negligible and are associated with haemostasis anomalies. An emergency protocol is proposed for their prevention and treatment (https://www.filiere-g2m.fr/urgences). For cerebral events, brain Magnetic Resonance Imaging with perfusion weight imaging and diffusion sequences, electroencephalogram and haemostasis protein levels guide the treatment: anticoagulation, antithrombin or fresh frozen plasma supplementation, antiepileptic therapy. Preventing bleeding and thrombosis is required in cases of surgery, prolonged immobilization, hormone replacement therapy. CONCLUSION Acute events in PMM2-CDG are associated with abnormal haemostasis, requiring practical guidance.
Collapse
Affiliation(s)
- Camille Wicker
- Centre de Référence des Maladies Héréditaires du Métabolisme, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, G2M, MetabERN, Paris, France; Centre de Compétence des Maladies Héréditaires du Métabolisme, Hôpital Universitaire de Strasbourg, Strasbourg, France
| | - Charles-Joris Roux
- Université Paris Cité, Paris, France; Service de Radiologie Pédiatrique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, Paris, France
| | - Louise Goujon
- Centre de Référence des Maladies Héréditaires du Métabolisme, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, G2M, MetabERN, Paris, France
| | - Yvan de Feraudy
- Service de Neurologie Pédiatrique, Hôpital Universitaire de Strasbourg, Strasbourg, France
| | - Marie Hully
- Service de Neurologie Pédiatrique, Médecine physique et réadaptation de l'enfant, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, Paris, France
| | - Anais Brassier
- Centre de Référence des Maladies Héréditaires du Métabolisme, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, G2M, MetabERN, Paris, France
| | - Claire-Marine Bérat
- Centre de Référence des Maladies Héréditaires du Métabolisme, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, G2M, MetabERN, Paris, France
| | - Nicole Chemaly
- Service de Neurologie Pédiatrique, Médecine physique et réadaptation de l'enfant, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, Paris, France
| | - Arnaud Wiedemann
- Centre de Référence des Maladies Héréditaires du Métabolisme, Hôpital Universitaire de Nancy, Nancy, France
| | - Lena Damaj
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Hôpital Universitaire de Rennes, Renne, France
| | - Marie-Thérèse Abi-Warde
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Hôpital Universitaire de Strasbourg, Strasbourg, France; Service de Neurologie Pédiatrique, Hôpital Universitaire de Strasbourg, Strasbourg, France
| | - Dries Dobbelaere
- Centre de Référence des Maladies Héréditaires du Métabolisme, Hôpital Universitaire Jeanne de Flandre de Lille, MetabERN, Lille, France
| | - Agathe Roubertie
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Hôpital Universitaire de Montpellier, Montpellier, France
| | - Aline Cano
- Centre de Référence des Maladies Héréditaires du Métabolisme, service de Neurologie pédiatrique, Hôpital Universitaire d'enfants La Timone de Marseille, MetabERN, Marseille, France
| | - Alina Arion
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Hôpital Universitaire de Caen, Caen, France
| | - Anna Kaminska
- Service d'Exploration Fonctionnelle, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, G2M, MetabERN, Paris, France
| | - Sabrina Da Costa
- Centre de Référence d'Endocrinologie des Maladies Rares, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, Paris, France
| | - Arnaud Bruneel
- Département de Biochimie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Bichat, Paris, France
| | - Sandrine Vuillaumier-Barrot
- Département de Biochimie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Bichat, Paris, France
| | - Nathalie Boddaert
- Université Paris Cité, Paris, France; Service de Radiologie Pédiatrique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, Paris, France
| | - Tiffany Pascreau
- Laboratoire d'Hématologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Paris, France
| | - Delphine Borgel
- Laboratoire d'Hématologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Paris, France
| | - Manoelle Kossorotoff
- Centre national de référence de l'AVC de l'enfant, Service de Neurologie Pédiatrique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Inserm U1266, Paris, France
| | - Annie Harroche
- Centre de Référence Maladies Hémorragiques constitutionnelles, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, Paris, France
| | - P de Lonlay
- Centre de Référence des Maladies Héréditaires du Métabolisme, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker-Enfants-Malades, Institut Imagine, G2M, MetabERN, Paris, France; Université Paris Cité, Paris, France; INSERM, Institut Necker-Enfants Malades, France.
| |
Collapse
|
7
|
Baide‐Mairena H, Coget A, Leboucq N, Procaccio V, Blanluet M, Meyer P, Malinge M, François‐Heude M, Moreno M, Geneviève D, Marelli C, Roubertie A. Infantile-onset parkinsonism, dyskinesia, and developmental delay: do not forget polyglutamine defects! Ann Clin Transl Neurol 2023; 10:1937-1943. [PMID: 37491839 PMCID: PMC10578886 DOI: 10.1002/acn3.51858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2023] [Revised: 06/04/2023] [Accepted: 07/13/2023] [Indexed: 07/27/2023] Open
Abstract
We present the phenotype of an infant with the largest ATN1 CAG expansion reported to date (98 repeats). He presented at 4 months with developmental delay, poor eye contact, acquired microcephaly, failure to thrive. He progressively developed dystonia-parkinsonism with paroxysmal oromandibular and limbs dyskinesia and fatal outcome at 17 months. Cerebral MRI disclosed globus pallidus T2-WI hyperintensities and brain atrophy. Molecular analysis was performed post-mortem following the diagnosis of dentatorubral-pallidoluysian atrophy (DRPLA) in his symptomatic father. Polyglutamine expansion defects should be considered when neurodegenerative genetic disease is suspected even in infancy and parkinsonism can be a presentation of infantile-onset DRPLA.
Collapse
Affiliation(s)
- Heidy Baide‐Mairena
- Département de NeuropédiatrieHôpital Gui de ChauliacMontpellierFrance
- Universitat Autònoma de BarcelonaBarcelonaSpain
| | - Arthur Coget
- Service de NeuroradiologieHôpital Gui de ChauliacMontpellierFrance
| | - Nicolas Leboucq
- Service de NeuroradiologieHôpital Gui de ChauliacMontpellierFrance
| | - Vincent Procaccio
- MitoLab, UMR CNRS 6015 – INSERM U1083, MitoVasc Institute, Angers University HospitalAngersFrance
| | - Maud Blanluet
- MitoLab, UMR CNRS 6015 – INSERM U1083, MitoVasc Institute, Angers University HospitalAngersFrance
| | - Pierre Meyer
- Département de NeuropédiatrieHôpital Gui de ChauliacMontpellierFrance
- Phymedexp, Montpellier University, Inserm, CNRSMontpellierFrance
| | - Marie‐Claire Malinge
- MitoLab, UMR CNRS 6015 – INSERM U1083, MitoVasc Institute, Angers University HospitalAngersFrance
| | | | - Mathis Moreno
- Département de NeuropédiatrieHôpital Gui de ChauliacMontpellierFrance
| | - David Geneviève
- Montpellier University, Inserm U1183MontpellierFrance
- Reference Center for Malformative Syndrome, Genetic Department, Montpellier HospitalMontpellierFrance
| | - Cecilia Marelli
- Expert Centre for Neurogenetic Diseases and Adult Mitochondrial and Metabolic Diseases, Department of NeurologyMontpellier University HospitalMontpellierFrance
- MMDNUniversity of Montpellier, EPHE, INSERMMontpellierFrance
| | - Agathe Roubertie
- Département de NeuropédiatrieHôpital Gui de ChauliacMontpellierFrance
- Institut des Neurosciences de Montpellier, INSERM U 1298MontpellierFrance
| |
Collapse
|
8
|
Tardieu M, Cudejko C, Cano A, Hoebeke C, Bernoux D, Goetz V, Pichard S, Brassier A, Schiff M, Feillet F, Rollier P, Mention K, Dobbelaere D, Fouilhoux A, Espil-Taris C, Eyer D, Huet F, Walther-Louvier U, Barth M, Chevret L, Kuster A, Lefranc J, Neveu J, Pitelet G, Ropars J, Rivier F, Roubertie A, Touati G, Vanhulle C, Tardieu E, Caillaud C, Froissart R, Champeaux M, Labarthe F, Chabrol B. Long-term follow-up of 64 children with classical infantile-onset Pompe disease since 2004: A French real-life observational study. Eur J Neurol 2023; 30:2828-2837. [PMID: 37235686 DOI: 10.1111/ene.15894] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 04/21/2023] [Accepted: 05/22/2023] [Indexed: 05/28/2023]
Abstract
BACKGROUND Classical infantile-onset Pompe disease (IOPD) is the most severe form of Pompe disease. Enzyme replacement therapy (ERT) has significantly increased survival but only a few studies have reported long-term outcomes. METHODS We retrospectively analyzed the outcomes of classical IOPD patients diagnosed in France between 2004 and 2020. RESULTS Sixty-four patients were identified. At diagnosis (median age 4 months) all patients had cardiomyopathy and most had severe hypotonia (57 of 62 patients, 92%). ERT was initiated in 50 (78%) patients and stopped later due to being ineffective in 10 (21%). Thirty-seven (58%) patients died during follow-up, including all untreated and discontinued ERT patients, and 13 additional patients. Mortality was higher during the first 3 years of life and after the age of 12 years. Persistence of cardiomyopathy during follow-up and/or the presence of heart failure were highly associated with an increased risk of death. In contrast, cross-reactive immunologic material (CRIM)-negative status (n = 16, 26%) was unrelated to increased mortality, presumably because immunomodulation protocols prevent the emergence of high antibody titers to ERT. Besides survival, decreased ERT efficacy appeared after the age of 6 years, with a progressive decline in motor and pulmonary functions for most survivors. CONCLUSIONS This study reports the long-term follow-up of one of the largest cohorts of classical IOPD patients and demonstrates high long-term mortality and morbidity rates with a secondary decline in muscular and respiratory functions. This decreased efficacy seems to be multifactorial, highlighting the importance of developing new therapeutic approaches targeting various aspects of pathogenesis.
Collapse
Affiliation(s)
- Marine Tardieu
- Centre de Référence des Maladies Héréditaires du Métabolisme ToTeM, Service de Médecine Pédiatrique, Hôpital Clocheville, Tours, France
| | - Céline Cudejko
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| | - Aline Cano
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| | - Célia Hoebeke
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| | - Delphine Bernoux
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| | - Violette Goetz
- Centre de Référence des Maladies Héréditaires du Métabolisme ToTeM, Service de Médecine Pédiatrique, Hôpital Clocheville, Tours, France
| | - Samia Pichard
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Métabolisme Pédiatrique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Anaïs Brassier
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Métabolisme Pédiatrique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Manuel Schiff
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Métabolisme Pédiatrique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - François Feillet
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Médecine Infantile, Hôpital Brabois Enfants; Unité INSERM NGERE U 1256, Campus Babrois-Santé, Vandœuvre-lès-Nancy, France
| | - Paul Rollier
- Service de Génétique Clinique, Site Hôpital Sud, Rennes, France
| | - Karine Mention
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service Néphrologie, Endocrinologie, Maladies Métaboliques et Hématologie Pédiatrique, Hôpital Jeanne de Flandre, Lille, France
| | - Dries Dobbelaere
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service Néphrologie, Endocrinologie, Maladies Métaboliques et Hématologie Pédiatrique, Hôpital Jeanne de Flandre, Lille, France
| | - Alain Fouilhoux
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service d'Endocrinologie et de Diabétologie Pédiatriques et Maladies Héréditaires du Métabolisme, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
| | - Caroline Espil-Taris
- Centre de Référence des Maladies Neuromusculaires AOC, Service de Neuropédiatrie, Hôpital des Enfants Pellegrin, Bordeaux, France
| | - Didier Eyer
- Service des Maladies Métaboliques, Hôpital de Hautepierre, Strasbourg, France
| | - Frédéric Huet
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Service de Pédiatrie Multidisciplinaire, Hôpital d'Enfants, Dijon, France
| | - Ulrike Walther-Louvier
- Centre de Référence des Maladies Neuromusculaires AOC, Service de Neuropédiatrie, Hôpital Gui de Chauliac, Montpellier, France
| | - Magalie Barth
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Service de Génétique, CHU Angers, Angers, France
| | - Laurent Chevret
- Service Pédiatrie et Urgences Pédiatriques, CH Saint-Brieuc, Saint-Brieuc, France
| | - Alice Kuster
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Service de Réanimation Pédiatrique, CHU Nantes, Nantes, France
| | | | - Julien Neveu
- Service de Neuropédiatrie, Hôpitaux Pédiatriques de Nice, CHU Lenval, Nice, France
| | - Gaele Pitelet
- Service de Neuropédiatrie, Hôpitaux Pédiatriques de Nice, CHU Lenval, Nice, France
| | - Juliette Ropars
- Centre de Référence Maladies Neuromusculaires AOC, Service de Neuropédiatrie, Hôpital Morvan, Brest, France
| | - François Rivier
- Centre de Référence des Maladies Neuromusculaires AOC, Service de Neuropédiatrie, Hôpital Gui de Chauliac, Montpellier, France
- PhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, France
| | - Agathe Roubertie
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Service de Neurologie Pédiatrique, Hôpital Gui de Chauliac; INM, INSERM U 1298, Université de Montpellier, Montpellier, France
| | - Guy Touati
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Gastro-entérologie, Hépatologie, Nutrition et Maladies Héréditaires du Métabolisme Pédiatrique, Hôpital des Enfants, Toulouse, France
| | - Catherine Vanhulle
- Service de Néonatalogie et Réanimation Pédiatrique, Hôpital Charles Nicolle, Rouen, France
| | - Emilie Tardieu
- Service de Santé Universitaire, Université Lumière Lyon 2, Lyon, France
| | - Catherine Caillaud
- Service de Biochimie Métabolique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Roseline Froissart
- Service de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Bron, France
| | - Murielle Champeaux
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| | - François Labarthe
- Centre de Référence des Maladies Héréditaires du Métabolisme ToTeM, Service de Médecine Pédiatrique, Hôpital Clocheville, Tours, France
- Inserm U1069, N2C, Université de Tours, Tours, France
| | - Brigitte Chabrol
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| |
Collapse
|
9
|
Papadopoulou MT, Welniarz Q, Roubertie A, Gras D, Milh M, Panagiotakaki E, Roze E. Effect of Oxygen Administration on Paroxysmal Motor Events in Alternating Hemiplegia of Childhood. Mov Disord 2023; 38:1759-1761. [PMID: 37466145 DOI: 10.1002/mds.29561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Accepted: 07/06/2023] [Indexed: 07/20/2023] Open
Affiliation(s)
- Maria T Papadopoulou
- Department of Clinical Epileptology, Sleep Disorders and Functional Neurology in Children, University Hospitals of Lyon (HCL), Member of the ERN EpiCARE, Lyon, France
| | - Quentin Welniarz
- APHP, Salpêtrière Hospital, DMU Neurosciences, Paris, France
- Sorbonne University, Inserm, CNRS, Paris Brain Institute, Paris, France
| | - Agathe Roubertie
- CHU Montpellier, Département de Neuropédiatrie, INM, Université de Montpellier, Inserm U 1298, Montpellier, France
| | - Domitille Gras
- Sorbonne University, Inserm, CNRS, Paris Brain Institute, Paris, France
| | - Mathieu Milh
- Department of Pediatric Neurology, AP-HM, La Timone Children's Hospital, Marseille, France
- Faculté de Médecine Timone, Aix Marseille Université, Inserm, MMG, U1251, ERN Epicare, Marseille, France
| | - Eleni Panagiotakaki
- Department of Clinical Epileptology, Sleep Disorders and Functional Neurology in Children, University Hospitals of Lyon (HCL), Member of the ERN EpiCARE, Lyon, France
| | - Emmanuel Roze
- APHP, Salpêtrière Hospital, DMU Neurosciences, Paris, France
- Sorbonne University, Inserm, CNRS, Paris Brain Institute, Paris, France
| |
Collapse
|
10
|
Laur D, Pichard S, Bekri S, Caillaud C, Froissart R, Levade T, Roubertie A, Desguerre I, Héron B, Auvin S. Natural history of GM1 gangliosidosis-Retrospective cohort study of 61 French patients from 1998 to 2019. J Inherit Metab Dis 2023; 46:972-981. [PMID: 37381921 DOI: 10.1002/jimd.12646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2023] [Revised: 06/11/2023] [Accepted: 06/27/2023] [Indexed: 06/30/2023]
Abstract
GM1 gangliosidosis is a rare lysosomal storage disorder associated with β-galactosidase enzyme deficiency. There are three types of GM1 gangliosidosis based on age of symptom onset, which correlate with disease severity. In 2019, we performed a retrospective multicentric study including all patients diagnosed with GM1 gangliosidosis in France since 1998. We had access to data for 61 of the 88 patients diagnosed between 1998 and 2019. There were 41 patients with type 1 (symptom onset ≤6 months), 11 with type 2a (symptom onset from 7 months to 2 years), 5 with type 2b (symptom onset from 2 to 3 years), and 4 with type 3 (symptom onset >3 years). The estimated incidence in France was 1/210000. In patients with type 1, the first symptoms were hypotonia (26/41, 63%), dyspnea (7/41, 17%), and nystagmus (6/41, 15%), whereas in patients with type 2a, these were psychomotor regression (9/11, 82%) and seizures (3/11, 27%). In types 2b and 3, the initial symptoms were mild, such as speech difficulties, school difficulties, and progressive psychomotor regression. Hypotonia was observed in all patients, except type 3. The mean overall survival was 23 months (95% confidence interval [CI]: 7, 39) for type 1 and 9.1 years (95% CI: 4.5, 13.5) for type 2a. To the best of our knowledge, this is one of the largest historical cohorts reported, which provides important information on the evolution of all types of GM1 gangliosidosis. These data could be used as a historical cohort in studies assessing potential therapies for this rare genetic disease.
Collapse
Affiliation(s)
- Domitille Laur
- Department of Paediatric Neurology, Hôpital Robert-Debré, AP-HP, Paris, France
| | - Samia Pichard
- Reference Centre for Inborn Errors of Metabolism, Necker Enfants-Malades Hospital, AP-HP, Paris, France
| | - Soumeya Bekri
- Metabolic Biochemistry Department, Rouen University Hospital, Rouen, France
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, Rouen, France
| | - Catherine Caillaud
- Biochemistry, Metabolomic and Proteomic Department, INSERM UMRS 1151, Necker Enfants Malades, Paris, France
| | - Roseline Froissart
- Service de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, CHU de Lyon, Bron, France
| | - Thierry Levade
- Laboratoire de Biochimie Métabolique, CHU de Toulouse, and INSERM UMR1037, CRCT (Cancer Research Center of Toulouse), Université Paul Sabatier, Toulouse, France
| | - Agathe Roubertie
- Département de Neuropédiatrie, CIC, CHU de Montpellier, INM, Univ Montpellier, INSERM U1298, Montpellier, France
| | - Isabelle Desguerre
- Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Pediatric Neurology Department, Necker-Enfants-Malades Hospital, AP-HP, Paris, France
| | - Bénédicte Héron
- Centre de Référence des Maladies Lysosomales, Service de Neurologie Pédiatrique, Hôpital Armand Trousseau-La Roche Guyon, APHP, Fédération Hospitalo-Universitaire I2-D2 AP-HP.Sorbonne-Université, Paris, France
| | - Stéphane Auvin
- Université Paris-Cité, INSERM NeuroDiderot, Paris, France
- Institut Universitaire de France (IUF), Paris, France
| |
Collapse
|
11
|
Ekmen A, Doulazmi M, Méneret A, Jegatheesan P, Hervé A, Damier P, Gras D, Roubertie A, Piard J, Mutez E, Tarrano C, Welniarz Q, Vidailhet M, Worbe Y, Gallea C, Roze E. Non-Motor Symptoms and Quality of Life in Patients with PRRT2-Related Paroxysmal Kinesigenic Dyskinesia. Mov Disord Clin Pract 2023; 10:1082-1089. [PMID: 37476308 PMCID: PMC10354617 DOI: 10.1002/mdc3.13795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Revised: 03/23/2023] [Accepted: 05/01/2023] [Indexed: 07/22/2023] Open
Abstract
Background Monoallelic pathogenic variants of PRRT2 often result in paroxysmal kinesigenic dyskinesia (PKD). Little is known about health-related quality of life (HrQoL), non-motor manifestations, self-esteem, and stigma in patients with PKD. Objectives We investigated non-motor symptoms and how they related to HrQoL in a genetically homogeneous group of PRRT2-PKD patients. We paid special attention to perceived stigmatization and self-esteem. Methods We prospectively enrolled 21 consecutive PKD patients with a pathogenic variant of PRRT2, and 21 healthy controls matched for age and sex. They were evaluated with dedicated standardized tests for non-motor symptoms, HrQoL, anxiety, depression, stigma, self-esteem, sleep, fatigue, pain, and psychological well-being. Results Patients reported an alteration of the physical aspects of HrQoL, regardless of the presence of residual paroxysmal episodes. Non-motor manifestations were frequent, and were an important determinant of the alteration of HrQoL. In addition, patients perceived a higher level of stigmatization which positively correlated with a delay in diagnosis (ρ = 0.615, P = 0.003) and the fear of being judged (ρ = 0.452, P = 0.04), but not with the presence of paroxysmal episodes (ρ = 0.203, P = 0.379). Conclusions Our findings have important implications for care givers concerning patient management and medical education about paroxysmal dyskinesia. PRRT2-PKD patients should be screened for non-motor disorders in routine care. A long history of misdiagnosis may play a role in the high level of perceived stigmatization. Improving knowledge about diagnostic clues suggestive of PKD is mandatory.
Collapse
Affiliation(s)
- Asya Ekmen
- Sorbonne Université, INSERM, CNRS, Paris Brain InstituteParisFrance
- APHP Hôpital de La Pitié Salpetriêre et Saint‐AntoineParisFrance
| | - Mohamed Doulazmi
- Sorbonne University, Adaptation Biologique et Vieillissement (UMR8256), Institut de Biologie Paris Seine, CNRSParisFrance
| | - Aurélie Méneret
- Sorbonne Université, INSERM, CNRS, Paris Brain InstituteParisFrance
- APHP Hôpital de La Pitié Salpetriêre et Saint‐AntoineParisFrance
| | - Prasanthi Jegatheesan
- Sorbonne Université, INSERM, CNRS, Paris Brain InstituteParisFrance
- APHP Hôpital de La Pitié Salpetriêre et Saint‐AntoineParisFrance
| | - Anais Hervé
- Sorbonne Université, INSERM, CNRS, Paris Brain InstituteParisFrance
| | | | - Domitille Gras
- Sorbonne Université, INSERM, CNRS, Paris Brain InstituteParisFrance
| | - Agathe Roubertie
- Département NeuropédiatrieINM, Université de Montpellier, INSERM, CHU MontpellierMontpellierFrance
| | - Juliette Piard
- Centre de Génétique Humaine, CHUBesançonFrance
- INSERM UMR1231, Génétique des Anomalies du DéveloppementUniversité de BourgogneDijonFrance
| | - Eugenie Mutez
- Univ. Lille, Inserm, CHU Lille, U1172—LilNCog—Lille Neuroscience and CognitionLilleFrance
| | - Clément Tarrano
- Sorbonne Université, INSERM, CNRS, Paris Brain InstituteParisFrance
- APHP Hôpital de La Pitié Salpetriêre et Saint‐AntoineParisFrance
| | - Quentin Welniarz
- Sorbonne Université, INSERM, CNRS, Paris Brain InstituteParisFrance
- APHP Hôpital de La Pitié Salpetriêre et Saint‐AntoineParisFrance
| | - Marie Vidailhet
- Sorbonne Université, INSERM, CNRS, Paris Brain InstituteParisFrance
- APHP Hôpital de La Pitié Salpetriêre et Saint‐AntoineParisFrance
| | - Yulia Worbe
- Sorbonne Université, INSERM, CNRS, Paris Brain InstituteParisFrance
- APHP Hôpital de La Pitié Salpetriêre et Saint‐AntoineParisFrance
| | - Cécile Gallea
- Sorbonne Université, INSERM, CNRS, Paris Brain InstituteParisFrance
| | - Emmanuel Roze
- Sorbonne Université, INSERM, CNRS, Paris Brain InstituteParisFrance
- APHP Hôpital de La Pitié Salpetriêre et Saint‐AntoineParisFrance
| |
Collapse
|
12
|
Mochel F, Gras D, Luton MP, Nizou M, Giovannini D, Delattre C, Aubart M, Barth M, De Saint-Martin A, Doummar D, Essid N, Garros A, Le Camus CH, Hoebeke C, The Tich SN, Perivier M, Rivera S, Rolland A, Roubertie A, Sarret C, Sevin C, Ville D, Sitbon M, Costa JM, Pons R, Garcia-Cazorla A, Vuillaumier S, Petit V, Boespflug-Tanguy O, De Vivo DC. Prospective Multicenter Validation of a Simple Blood Test for the Diagnosis of Glut1 Deficiency Syndrome. Neurology 2023; 100:e2360-e2373. [PMID: 37076312 PMCID: PMC10256121 DOI: 10.1212/wnl.0000000000207296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2022] [Accepted: 03/02/2023] [Indexed: 04/21/2023] Open
Abstract
BACKGROUND AND OBJECTIVE GLUT1 deficiency syndrome (Glut1DS) is a treatable neurometabolic disease that causes a wide range of neurologic symptoms in children and adults. However, its diagnosis relies on an invasive test, that is, a lumbar puncture (LP) to measure glycorrhachia, and sometimes complex molecular analyses of the SLC2A1 gene. This procedure limits the number of patients able to receive the standard of care. We wished to validate the diagnostic performance of METAglut1, a simple blood test that quantifies GLUT1 on the erythrocyte surface. METHODS We performed a multicenter validation study in France, involving 33 centers. We studied 2 patient cohorts: a prospective cohort consisting of patients with a clinical suspicion of Glut1DS explored through the reference strategy, that is, LP and analyses of the SLC2A1 gene, and a retrospective cohort that included patients previously diagnosed with Glut1DS. All patients were blind-tested with METAglut1. RESULTS We analyzed 428 patients in the prospective cohort, including 15 patients newly diagnosed with Glut1DS, and 67 patients in the retrospective cohort. METAglut1 was 80% sensitive and >99% specific for the diagnosis of Glut1DS. Concordance analyses showed a substantial agreement between METAglut1 and glycorrhachia. In the prospective cohort, the positive predictive value of METAglut1 was slightly higher than that of glycorrhachia. METAglut1 succeeded to identify patients with Glut1DS with SCL2A1 mosaicism and variants of unknown significance. DISCUSSION METAglut1 is an easily performed, robust, and noninvasive diagnostic test for the diagnosis of Glut1DS, which allows wide screening of children and adults, including those with atypical forms of this treatable condition. CLASSIFICATION OF EVIDENCE This study provides Class I evidence that a positive METAglut1 test accurately distinguishes patients with suspected GLUT1 deficiency syndrome from other neurologic syndromes as compared with invasive and genetic testing.
Collapse
Affiliation(s)
- Fanny Mochel
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York.
| | - Domitille Gras
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Marie-Pierre Luton
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Manon Nizou
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Donatella Giovannini
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Caroline Delattre
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Mélodie Aubart
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Magalie Barth
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Anne De Saint-Martin
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Diane Doummar
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Nouha Essid
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Alexa Garros
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Caroline Hachon Le Camus
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Celia Hoebeke
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Sylvie Nguyen The Tich
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Maximilien Perivier
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Serge Rivera
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Anne Rolland
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Agathe Roubertie
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Catherine Sarret
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Caroline Sevin
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Dorothee Ville
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Marc Sitbon
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Jean-Marc Costa
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Roser Pons
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Angels Garcia-Cazorla
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Sandrine Vuillaumier
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Vincent Petit
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Odile Boespflug-Tanguy
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| | - Darryl C De Vivo
- From the Hôpital La Pitié-Salpêtrière (F.M., M-P.L., C.D.), Assistance-Publique Hôpitaux de Paris, Inserm U1127; Sorbonne University (D.Gras), Inserm U1127, CNRS UMR7225, Paris Brain Institute; U1141 Neurodiderot (D.Gras), équipe 5 InDev, Inserm, CEA, UP UNIACT, Neurospin, Joliot, DRF, CEA-Saclay; Metafora Biosystems (M.N., V.P.); Institut de Génétique Moléculaire de Montpellier (D.Giovannini), Univ. Montpellier, CNRS; Service de Neurologie Pédiatrique (M.A.), Hôpital Necker-Enfants Malades, Assistance-Publique Hôpitaux de Paris; Service de Génétique (M.B.), Centre Hospitalier Universitaire Angers; Service de Neuropédiatrie (A.D.S-M.), Hôpital de Hautepierre, Strasbourg; Sorbonne Université (D.D.), Service de Neuropédiatrie-Pathologie du développement, Hôpital Trousseau AP-HP.SU, FHU I2D2, Paris; Service de Neurologie et Réanimation Pédiatrique (N.E.), APHP, Hôpital Raymond Poincaré, Garches; Service de Neurologie Pédiatrique (A.G.), Hôpital Nord, Grenoble; Service de Neurologie Pédiatrique (C.H.L.C.), et Unité de recherche clinique, module plurithématique sous axe pédiatrique CI 1436, Hôpital des enfants, CHU Toulouse; Service de Neurologie Pédiatrique (C.H.), Hôpital La Timone, Assistance-Publique Hôpitaux de Marseille; Service de Neuropédiatrie (S.N.T.T.), CRMR Epilepsies Rares, Hôpital Roger Salengro, Lille; Service de Neuropédiatrie et handicaps (M.P.), Hôpital pédiatrique Gatien de Clocheville, CHU de Tours; Pole Mère Enfant (S.R.), Centre Hospitalier de la Côte Basque, Bayonne; Service de Neuropédiatrie (A.R.), Hôpital Mère-Enfant, Nantes; Département de Neuropédiatrie, Centre d'investigation Clinique Inserm (A.R.), INM, Univ Montpellier, INSERM U 1298, CHU Montpellier, CIC1411; Service de Pédiatrie (C.Sarret), Hôpital Estaing, CHU Clermont-Ferrand; Service de Neurologie Pédiatrique (C.Sevin), Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris; Service de Neurologie Pédiatrique (D.V.), Hôpital Femme Mère Enfant, Centre Hospitalier de Lyon; Institut de Génétique Moléculaire de Montpellier (M.S.), Univ. Montpellier, CNRS; Laboratoire Cerba (J-M.C.), Saint-Ouen l'Aumône, France; Department of Pediatrics (R.P.), Aghia Sofia Hospital, University of Athens, Greece; Department of Neurology (A.G-C.), Hospital Sant Joan de Déu, Barcelona, Spain; Service de Biochimie et Génétique (S.V.), Hôpital Bichat Claude Bernard, APHP, Paris; CRMR Leukofrance Service de neuropediatrie (O.B-T.), Hôpital Robert Debré, AP-HP, Paris; UMR1141, Neurodiderot Université de Paris, France; Department of Pediatrics (D.C.D.V.), Columbia University Irving Medical Center, New York
| |
Collapse
|
13
|
François‐Heude M, Poulen G, Flamand Roze E, Nguyen Morel M, Gras D, Roch‐Toreilles I, Quintard A, Baroux G, Meyer P, Coubes P, Milesi C, Cambonie G, Baleine J, Sola C, Delye B, Dimopoulou E, Sanchez S, Gasnier M, Touati S, Zamora A, Pontal D, Leboucq N, Kouyoumdjian V, Lebasnier A, Sanquer S, Mariano‐Goulart D, Roujeau T, Roubertie A. Intraputaminal Gene Delivery in Two Patients with Aromatic L-Amino Acid Decarboxylase Deficiency. Mov Disord Clin Pract 2023; 10:811-818. [PMID: 37205256 PMCID: PMC10187009 DOI: 10.1002/mdc3.13685] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 12/24/2022] [Accepted: 01/20/2023] [Indexed: 03/21/2024] Open
Abstract
BACKGROUND Aromatic l-amino acid decarboxylase deficiency (AADCD) is a rare, early-onset, dyskinetic encephalopathy mostly reflecting a defective synthesis of brain dopamine and serotonin. Intracerebral gene delivery (GD) provided a significant improvement among AADCD patients (mean age, ≤6 years). OBJECTIVE We describe the clinical, biological, and imaging evolution of two AADCD patients ages >10 years after GD. METHODS Eladocagene exuparvovec, a recombinant adeno-associated virus containing the human complimentary DNA encoding the AADC enzyme, was administered into bilateral putamen by stereotactic surgery. RESULTS Eighteen months after GD, patients showed improvement in motor, cognitive and behavioral function, and in quality of life. Cerebral l-6-[18F] fluoro-3, 4-dihydroxyphenylalanine uptake was increased at 1 month, persisting at 1 year compared to baseline. CONCLUSION Two patients with a severe form of AADCD had an objective motor and non-motor benefit from eladocagene exuparvovec injection even when treated after the age of 10 years, as in the seminal study.
Collapse
Affiliation(s)
| | - Gaetan Poulen
- Département de NeurochirurgieCHU MontpellierMontpellierFrance
| | - Emmanuel Flamand Roze
- Assistance Publique ‐ Hôpitaux de Paris CHU Pitié‐SalpêtrièreDMU Neurosciences et Sorbonne Université, INSERM, CNRS, Institut du Cerveau et de la MoelleParisFrance
| | - Marie‐Ange Nguyen Morel
- Service de Neurologie PédiatriqueHôpital Couple Mère Enfant, CHU Grenoble AlpesLa TroncheFrance
| | - Domitille Gras
- U1141 Neurodiderot, Équipe 5 inDev, Inserm, CEA, UP, UNIACT, Neurospin, Joliot, DRF, CEA‐SaclayParisFrance
| | | | | | | | - Pierre Meyer
- CHU Montpellier, Département de NeuropédiatrieUniv MontpellierMontpellierFrance
- PhyMedExp, CNRS, INSERM, Université de MontpellierMontpellierFrance
| | - Philippe Coubes
- Département de NeurochirurgieCHU MontpellierMontpellierFrance
| | - Christophe Milesi
- Département de Réanimation PédiatriqueCHU MontpellierMontpellierFrance
| | - Gilles Cambonie
- Département de Réanimation PédiatriqueCHU MontpellierMontpellierFrance
| | - Julien Baleine
- Département de Réanimation PédiatriqueCHU MontpellierMontpellierFrance
| | - Chrystelle Sola
- Département d'Anesthésie‐RéanimationCHU Montpellier; Institute of Functional Genomics (IGF), Université de Montpellier, CNRS, INSERMMontpellierFrance
| | - Bénédicte Delye
- Département d'Anesthésie‐RéanimationCHU Gui de ChauliacMontpellierFrance
| | - Evgenia Dimopoulou
- CHU Montpellier, Département de NeuropédiatrieUniv MontpellierMontpellierFrance
| | - Stéphanie Sanchez
- CHU Montpellier, Département de NeuropédiatrieUniv MontpellierMontpellierFrance
| | | | - Souad Touati
- CHU Montpellier, Département de NeuropédiatrieUniv MontpellierMontpellierFrance
| | - Alberto Zamora
- CHU Montpellier, Département de NeuropédiatrieUniv MontpellierMontpellierFrance
| | - Daniel Pontal
- CHU Montpellier, Département de NeuropédiatrieUniv MontpellierMontpellierFrance
| | - Nicolas Leboucq
- Département de NeuroradiologieCHU MontpellierMontpellierFrance
| | | | - Adrien Lebasnier
- Département de Médecine NucléaireCHU MontpellierMontpellierFrance
| | | | | | - Thomas Roujeau
- Département de NeurochirurgieCHU MontpellierMontpellierFrance
| | - Agathe Roubertie
- CHU Montpellier, Département de NeuropédiatrieUniv MontpellierMontpellierFrance
- INM, Univ Montpellier, INSERM U 1298MontpellierFrance
| |
Collapse
|
14
|
Welniarz Q, Gras D, Roubertie A, Papadopoulou MT, Panagiotakaki E, Roze E. Oxygen Therapy: An Acute Treatment for Paroxysmal Dystonia in Alternating Hemiplegia of Childhood? Mov Disord 2023. [PMID: 36794704 DOI: 10.1002/mds.29357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 02/03/2023] [Indexed: 02/17/2023] Open
Affiliation(s)
- Quentin Welniarz
- Assistance Publique - Hôpitaux de Paris (APHP), Salpêtrière Hospital, Medical and Universitary Department (DMU) neurosciences, Paris, France.,Sorbonne University Inserm, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute, Paris, France
| | - Domitille Gras
- Sorbonne University Inserm, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute, Paris, France
| | - Agathe Roubertie
- CHU Montpellier, Département de Neuropédiatrie, Institut des. Neurosciences de Montpellier (INM) Université de Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM) U 1298, Montpellier, France
| | - Maria T Papadopoulou
- Department of Clinical Epileptology, Sleep Disorders and Functional Neurology, University Hospitals of Lyon (HCL), Member of the European Reference Network for rare and complex epilepsies (ERN EpiCARE), Lyon, France
| | - Eleni Panagiotakaki
- Department of Clinical Epileptology, Sleep Disorders and Functional Neurology, University Hospitals of Lyon (HCL), Member of the European Reference Network for rare and complex epilepsies (ERN EpiCARE), Lyon, France
| | - Emmanuel Roze
- Assistance Publique - Hôpitaux de Paris (APHP), Salpêtrière Hospital, Medical and Universitary Department (DMU) neurosciences, Paris, France.,Sorbonne University Inserm, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute, Paris, France
| |
Collapse
|
15
|
Cif L, Demailly D, Gehin C, Chan Seng E, Dornadic M, Huby S, Poulen G, Roubertie A, Villessot M, Roujeau T, Coubes P. Deep brain stimulation effect in genetic dyskinetic cerebral palsy: The case of ADCY5- related disease. Mol Genet Metab 2023; 138:106970. [PMID: 36610259 DOI: 10.1016/j.ymgme.2022.106970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Revised: 11/06/2022] [Accepted: 12/11/2022] [Indexed: 12/31/2022]
Abstract
BACKGROUND Cerebral Palsy (CP) represents a frequent cause of disability in childhood. Early in life, genetic disorders may present with motor dysfunction and diagnosed as CP. Establishing the primary, genetic etiology allows more accurate prognosis, genetic counselling, and planning for symptomatic interventions in homogeneous etiological groups. Deep brain stimulation (DBS) is recommended in refractory movement disorders, including isolated pediatric dystonias. For dystonia evolving in more complex associations in genetic CP, the effect of DBS is still understudied and currently only sporadically described. OBJECTIVES To report the effect of DBS applied to the globus pallidus pars interna (GPi) in children with complex movement disorders caused by pathogenic ADCY5 variants, diagnosed as dyskinetic CP previous to genetic diagnostic. METHODS We conducted a retrospective study on evolution of treatment with DBS in ADCY5-related disease. A standardized proforma including the different type of movement disorders and associated neurological signs was completed at each follow-up time, based on video recordings, as well as functional assessments used in children with CP. RESULTS Four children (mean of age, 13 ± 2.9 years) received GPi-DBS. The same de novo pathogenic missense variant (c.1252C > T, p.R418W) was identified in three out of four and a splice site variant (c.2088 + 2G > T) in one subject. Developmental delay and overlapping features including axial hypotonia, chorea, dystonic attacks, myoclonus, and cranial dyskinesia were present. The median age at DBS was 9 years and follow-up with DBS, 2.6 years. We identified a pattern of clinical response with early suppression of dystonic attacks, followed by improvement of myoclonus and facial dyskinesia. Effect on chorea was delayed and more limited. Two patients gained notable functional benefit related to sitting, standing, gait, use of upper limbs and speech. CONCLUSION ADCY5-related disease may benefit from GPi-DBS. The most significant clinical response relates to the early and sustained benefit on dystonic attacks and a variable but still positive response on the other hyperkinetic features. Genetic etiology of CP will contribute to further elucidate genotype-phenotype correlations and to refine DBS indication as network-related symptomatic interventions.
Collapse
Affiliation(s)
- Laura Cif
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France.
| | - Diane Demailly
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France
| | - Claire Gehin
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France
| | - Emilie Chan Seng
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France
| | - Morgan Dornadic
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France; Département de Neurologie, Centre Hospitalier Universitaire Montpellier, Montpellier, France
| | - Sophie Huby
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France; Département de Neurologie, Centre Hospitalier Universitaire Montpellier, Montpellier, France
| | - Gaetan Poulen
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France
| | - Agathe Roubertie
- Department of Neuropaediatrics, Gui de Chauliac Hospital, Montpellier University Hospital, University of Montpellier, Montpellier, France
| | - Matthieu Villessot
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France; Département de Neurologie, Centre Hospitalier Universitaire Montpellier, Montpellier, France
| | - Thomas Roujeau
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France
| | - Philippe Coubes
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France
| |
Collapse
|
16
|
Seker Yilmaz B, Baruteau J, Arslan N, Aydin HI, Barth M, Bozaci AE, Brassier A, Canda E, Cano A, Chronopoulou E, Connolly GM, Damaj L, Dawson C, Dobbelaere D, Douillard C, Eminoglu FT, Erdol S, Ersoy M, Fang S, Feillet F, Gokcay G, Goksoy E, Gorce M, Inci A, Kadioglu B, Kardas F, Kasapkara CS, Kilic Yildirim G, Kor D, Kose M, Marelli C, Mundy H, O’Sullivan S, Ozturk Hismi B, Ramachandran R, Roubertie A, Sanlilar M, Schiff M, Sreekantam S, Stepien KM, Uzun Unal O, Yildiz Y, Zubarioglu T, Gissen P. Three-Country Snapshot of Ornithine Transcarbamylase Deficiency. Life (Basel) 2022; 12:1721. [PMID: 36362876 PMCID: PMC9695856 DOI: 10.3390/life12111721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 10/24/2022] [Accepted: 10/25/2022] [Indexed: 11/16/2022] Open
Abstract
X-linked ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy. We audited the diagnosis and management of OTCD, using an online 12-question-survey that was sent to 75 metabolic centres in Turkey, France and the UK. Thirty-nine centres responded and 495 patients were reported in total. A total of 208 French patients were reported, including 71 (34%) males, 86 (41%) symptomatic and 51 (25%) asymptomatic females. Eighty-five Turkish patients included 32 (38%) males, 39 (46%) symptomatic and 14 (16%) asymptomatic females. Out of the 202 UK patients, 66 (33%) were male, 83 (41%) asymptomatic and 53 (26%) symptomatic females. A total of 19%, 12% and 7% of the patients presented with a neonatal-onset phenotype in France, Turkey and the UK, respectively. Vomiting, altered mental status and encephalopathy were the most common initial symptoms in all three countries. While 69% in France and 79% in Turkey were receiving protein restriction, 42% were on a protein-restricted diet in the UK. A total of 76%, 47% and 33% of patients were treated with ammonia scavengers in Turkey, France and the UK, respectively. The findings of our audit emphasize the differences and similarities in manifestations and management practices in three countries.
Collapse
Affiliation(s)
- Berna Seker Yilmaz
- Genetics and Genomic Medicine Department, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK
| | - Julien Baruteau
- Genetics and Genomic Medicine Department, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK
- National Institute of Health Research Great Ormond Street Biomedical Research Centre, London WC1N 1EH, UK
- Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK
| | - Nur Arslan
- Paediatric Metabolic Medicine Department, Dokuz Eylul University Faculty of Medicine, Izmir 35340, Turkey
| | - Halil Ibrahim Aydin
- Paediatric Metabolic Medicine Department, Baskent University Faculty of Medicine, Ankara 06490, Turkey
| | - Magalie Barth
- Centre de Référence des Maladies Héréditaires du Métabolisme, CHU Angers, 4 rue Larrey, CEDEX 9, 49933 Angers, France
| | - Ayse Ergul Bozaci
- Paediatric Metabolic Medicine Department, Diyarbakir Children’s Hospital, Diyarbakir 21100, Turkey
| | - Anais Brassier
- Reference Center for Inborn Errors of Metabolism, Necker University Hospital, APHP and University of Paris Cité, 75015 Paris, France
| | - Ebru Canda
- Paediatric Metabolic Medicine Department, Ege University Faculty of Medicine, Izmir 35100, Turkey
| | - Aline Cano
- Reference Center of Inherited Metabolic Disorders, Timone Enfants Hospital, 264 rue Saint-Pierre, 13005 Marseille, France
| | - Efstathia Chronopoulou
- Department of Inherited Metabolic Disease, Division of Women’s and Children’s Services, University Hospitals Bristol NHS Foundation Trust, Bristol BS1 3NU, UK
| | | | - Lena Damaj
- Centre de Compétence Maladies Héréditaires du Métabolisme, CHU Hôpital Sud, CEDEX 2, 35203 Rennes, France
| | - Charlotte Dawson
- Metabolic Medicine Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK
| | - Dries Dobbelaere
- Medical Reference Center for Inherited Metabolic Diseases, Jeanne de Flandre University Hospital and RADEME Research Team for Rare Metabolic and Developmental Diseases, EA 7364 CHRU Lille, 59000 Lille, France
| | - Claire Douillard
- Medical Reference Center for Inherited Metabolic Diseases, Jeanne de Flandre University Hospital and RADEME Research Team for Rare Metabolic and Developmental Diseases, EA 7364 CHRU Lille, 59000 Lille, France
| | - Fatma Tuba Eminoglu
- Paediatric Metabolic Medicine Department, Ankara University Faculty of Medicine, Ankara 06080, Turkey
| | - Sahin Erdol
- Paediatric Metabolic Medicine Department, Uludag University Faculty of Medicine, Bursa 16059, Turkey
| | - Melike Ersoy
- Paediatric Metabolic Medicine Department, Dr Sadi Konuk Reseach & Training Hospital, Istanbul 34450, Turkey
| | - Sherry Fang
- Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK
| | - François Feillet
- Centre de Référence des Maladies Métaboliques de Nancy, CHU Brabois Enfants, 5 Rue du Morvan, 54500 Vandœuvre-lès-Nancy, France
| | - Gulden Gokcay
- Paediatric Metabolic Medicine Department, Istanbul University Istanbul Faculty of Medicine, Istanbul 34093, Turkey
| | - Emine Goksoy
- Paediatric Metabolic Medicine Department, Cengiz Gokcek Children’s Hospital, Gaziantep 27010, Turkey
| | - Magali Gorce
- Centre de Référence des Maladies Rares du Métabolisme, Hôpital des Enfants—CHU Toulouse, 330 Avenue de Grande-Bretagne, CEDEX 9, 31059 Toulouse, France
| | - Asli Inci
- Paediatric Metabolic Medicine Department, Gazi University Faculty of Medicine, Ankara 06500, Turkey
| | - Banu Kadioglu
- Paediatric Metabolic Medicine Department, Konya City Hospital, Konya 42020, Turkey
| | - Fatih Kardas
- Paediatric Metabolic Medicine Department, Erciyes University Faculty of Medicine, Kayseri 38030, Turkey
| | - Cigdem Seher Kasapkara
- Paediatric Metabolic Medicine Department, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara 06800, Turkey
| | - Gonca Kilic Yildirim
- Paediatric Metabolic Medicine Department, Osmangazi University Faculty of Medicine, Eskisehir 26480, Turkey
| | - Deniz Kor
- Paediatric Metabolic Medicine Department, Cukurova University Faculty of Medicine, Adana 01250, Turkey
| | - Melis Kose
- Paediatric Metabolic Medicine Department, Faculty of Medicine, Izmir Katip Celebi University, Izmir 35620, Turkey
| | - Cecilia Marelli
- MMDN, University Montpellier, EPHE, INSERM, 34090 Montpellier, France
- Expert Center for Metabolic and Neurogenetic Diseases, Centre Hospitalier Universitaire (CHU), 34090 Montpellier, France
| | - Helen Mundy
- Evelina Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 7EH, UK
| | | | - Burcu Ozturk Hismi
- Paediatric Metabolic Medicine Department, Marmara University Faculty of Medicine, Istanbul 34854, Turkey
| | | | - Agathe Roubertie
- MMDN, University Montpellier, EPHE, INSERM, 34090 Montpellier, France
- Expert Center for Metabolic and Neurogenetic Diseases, Centre Hospitalier Universitaire (CHU), 34090 Montpellier, France
| | - Mehtap Sanlilar
- Paediatric Metabolic Medicine Department, Antalya Training and Research Hospital, Antalya 07100, Turkey
| | - Manuel Schiff
- Reference Center for Inborn Errors of Metabolism, Necker University Hospital, APHP and University of Paris Cité, 75015 Paris, France
| | - Srividya Sreekantam
- Birmingham Women’s and Children’s Hospital NHS Foundation Trust, Birmingham B4 6NH, UK
| | - Karolina M. Stepien
- Adult Inherited Metabolic Diseases, Salford Royal NHS Foundation Trust, Salford M6 8HD, UK
| | - Ozlem Uzun Unal
- Paediatric Metabolic Medicine Department, Kocaeli University Faculty of Medicine, Kocaeli 41380, Turkey
| | - Yilmaz Yildiz
- Paediatric Metabolic Medicine Department, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey
| | - Tanyel Zubarioglu
- Paediatric Metabolic Medicine Department, Istanbul University-Cerrahpasa Faculty of Medicine, Istanbul 34096, Turkey
| | - Paul Gissen
- Genetics and Genomic Medicine Department, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK
- National Institute of Health Research Great Ormond Street Biomedical Research Centre, London WC1N 1EH, UK
- Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK
| |
Collapse
|
17
|
Pachelli P, Giugliani L, Federhen A, Wang A, Russel A, Roubertie A, Chien YH, Lee NC, Tai CH, Wuh-Liang P. ELADOCAGENE EXUPARVOVEC GENE THERAPY IMPROVES MOTOR DEVELOPMENT IN PATIENTS WITH AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00856-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Maillard P, Baer S, Schaefer É, Desnous B, Villeneuve N, Lépine A, Fabre A, Lacoste C, El Chehadeh S, Piton A, Porter LF, Perriard C, Wardé MA, Spitz M, Laugel V, Lesca G, Putoux A, Ville D, Mignot C, Héron D, Nabbout R, Barcia G, Rio M, Roubertie A, Meyer P, Paquis‐Flucklinger V, Patat O, Lefranc J, Gerard M, de Bellescize J, Villard L, De Saint Martin A, Milh M. Molecular and clinical descriptions of patients with GABA A receptor gene variants (GABRA1, GABRB2, GABRB3, GABRG2): A cohort study, review of literature, and genotype-phenotype correlation. Epilepsia 2022; 63:2519-2533. [PMID: 35718920 PMCID: PMC9804453 DOI: 10.1111/epi.17336] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 06/16/2022] [Accepted: 06/16/2022] [Indexed: 01/05/2023]
Abstract
OBJECTIVE γ-Aminobutyric acid (GABA)A -receptor subunit variants have recently been associated with neurodevelopmental disorders and/or epilepsy. The phenotype linked with each gene is becoming better known. Because of the common molecular structure and physiological role of these phenotypes, it seemed interesting to describe a putative phenotype associated with GABAA -receptor-related disorders as a whole and seek possible genotype-phenotype correlations. METHODS We collected clinical, electrophysiological, therapeutic, and molecular data from patients with GABAA -receptor subunit variants (GABRA1, GABRB2, GABRB3, and GABRG2) through a national French collaboration using the EPIGENE network and compared these data to the one already described in the literature. RESULTS We gathered the reported patients in three epileptic phenotypes: 15 patients with fever-related epilepsy (40%), 11 with early developmental epileptic encephalopathy (30%), 10 with generalized epilepsy spectrum (27%), and 1 patient without seizures (3%). We did not find a specific phenotype for any gene, but we showed that the location of variants on the transmembrane (TM) segment was associated with a more severe phenotype, irrespective of the GABAA -receptor subunit gene, whereas N-terminal variants seemed to be related to milder phenotypes. SIGNIFICANCE GABAA -receptor subunit variants are associated with highly variable phenotypes despite their molecular and physiological proximity. None of the genes described here was associated with a specific phenotype. On the other hand, it appears that the location of the variant on the protein may be a marker of severity. Variant location may have important weight in the development of targeted therapeutics.
Collapse
Affiliation(s)
- Pierre‐Yves Maillard
- Department of Medical GeneticsIGMA, Hôpitaux Universitaires de StrasbourgStrasbourgFrance,Present address:
Institut Jérome LejeuneParisFrance
| | - Sarah Baer
- Department of NeuropediatricsERN EpiCare, Hôpitaux Universitaires de StrasbourgStrasbourgFrance,Institute for Genetics and Molecular and Cellular Biology (IGBMC), University of Strasbourg, CNRS UMR7104, INSERM U1258IllkirchFrance
| | - Élise Schaefer
- Department of Medical GeneticsIGMA, Hôpitaux Universitaires de StrasbourgStrasbourgFrance
| | - Béatrice Desnous
- Department of Pediatric NeurologyAP‐HM, La Timone Children's HospitalMarseilleFrance
| | - Nathalie Villeneuve
- Department of Pediatric NeurologyAP‐HM, La Timone Children's HospitalMarseilleFrance
| | - Anne Lépine
- Department of Pediatric NeurologyAP‐HM, La Timone Children's HospitalMarseilleFrance
| | - Alexandre Fabre
- Pediatric Multidisciplinary UnitAP‐HM, Timone EnfantMarseilleFrance,Aix‐Marseille University, INSERM, GMGFMarseilleFrance
| | - Caroline Lacoste
- Department of Medical GeneticsLa Timone Children's HospitalMarseilleFrance
| | - Salima El Chehadeh
- Department of Medical GeneticsIGMA, Hôpitaux Universitaires de StrasbourgStrasbourgFrance,Institute for Genetics and Molecular and Cellular Biology (IGBMC), University of Strasbourg, CNRS UMR7104, INSERM U1258IllkirchFrance
| | - Amélie Piton
- Institute for Genetics and Molecular and Cellular Biology (IGBMC), University of Strasbourg, CNRS UMR7104, INSERM U1258IllkirchFrance,Laboratory of Genetic DiagnosisInstitut de Génétique Médicale d'Alsace, Hôpitaux Universitaires de StrasbourgStrasbourgFrance
| | - Louise Frances Porter
- Department of Medical GeneticsInstitut de Génétique Médicale d'Alsace, Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO)StrasbourgFrance
| | - Caroline Perriard
- Department of NeuropediatricsERN EpiCare, Hôpitaux Universitaires de StrasbourgStrasbourgFrance
| | - Marie‐Thérèse Abi Wardé
- Department of NeuropediatricsERN EpiCare, Hôpitaux Universitaires de StrasbourgStrasbourgFrance
| | - Marie‐Aude Spitz
- Department of NeuropediatricsERN EpiCare, Hôpitaux Universitaires de StrasbourgStrasbourgFrance
| | - Vincent Laugel
- Department of NeuropediatricsERN EpiCare, Hôpitaux Universitaires de StrasbourgStrasbourgFrance
| | - Gaëtan Lesca
- Department of GeneticsHospices Civils de LyonBronFrance
| | - Audrey Putoux
- Department of GeneticsHospices Civils de LyonBronFrance
| | - Dorothée Ville
- Pediatric Neurology Department and Reference Center of Rare EpilepsiesMother Child Women's Hospital, Lyon University HospitalLyonFrance
| | - Cyril Mignot
- Department of GeneticsGroupe Hospitalier Pitié‐Salpêtrière and Hôpital Armand Trousseau, APHP‐Sorbonne UniversitéParisFrance,Centre de Référence Déficiences Intellectuelles de Causes RaresParisFrance
| | - Delphine Héron
- Department of GeneticsGroupe Hospitalier Pitié‐Salpêtrière and Hôpital Armand Trousseau, APHP‐Sorbonne UniversitéParisFrance,Centre de Référence Déficiences Intellectuelles de Causes RaresParisFrance
| | - Rima Nabbout
- Department of Pediatric NeurologyReference Centre for Rare Epilepsies, Necker Enfants Malades University Hospital, APHP, Université de ParisParisFrance
| | - Giulia Barcia
- Department of Medical GeneticsNecker‐Enfants Malades Hospital, Université de ParisParisFrance
| | - Marlène Rio
- Department of Medical GeneticsNecker‐Enfants Malades Hospital, Université de ParisParisFrance
| | - Agathe Roubertie
- Pediatric Neurology DepartmentINM, INSERM, CHU Montpellier, University of MontpellierMontpellierFrance
| | - Pierre Meyer
- Pediatric Neurology DepartmentINM, INSERM, CHU Montpellier, University of MontpellierMontpellierFrance
| | | | - Olivier Patat
- Department of Medical GeneticsCHU Toulouse PurpanToulouseFrance
| | | | - Marion Gerard
- Department of Medical GeneticsCentre Hospitalier Universitaire de CaenCaenFrance
| | | | - Julietta de Bellescize
- Paediatric Clinical Epileptology and Functional Neurology DepartmentReference Center of Rare Epilepsies, Member of the ERN EpiCARE, University Hospitals of Lyon (HCL)LyonFrance
| | - Laurent Villard
- Pediatric Multidisciplinary UnitAP‐HM, Timone EnfantMarseilleFrance,Faculté de Médecine TimoneAix Marseille Univ, INSERM, MMG, U1251, ERN EpicareMarseilleFrance
| | - Anne De Saint Martin
- Department of NeuropediatricsERN EpiCare, Hôpitaux Universitaires de StrasbourgStrasbourgFrance,Institute for Genetics and Molecular and Cellular Biology (IGBMC), University of Strasbourg, CNRS UMR7104, INSERM U1258IllkirchFrance
| | - Mathieu Milh
- Department of Pediatric NeurologyAP‐HM, La Timone Children's HospitalMarseilleFrance,Faculté de Médecine TimoneAix Marseille Univ, INSERM, MMG, U1251, ERN EpicareMarseilleFrance
| |
Collapse
|
19
|
Johannesen KM, Liu Y, Koko M, Gjerulfsen CE, Sonnenberg L, Schubert J, Fenger CD, Eltokhi A, Rannap M, Koch NA, Lauxmann S, Krüger J, Kegele J, Canafoglia L, Franceschetti S, Mayer T, Rebstock J, Zacher P, Ruf S, Alber M, Sterbova K, Lassuthová P, Vlckova M, Lemke JR, Platzer K, Krey I, Heine C, Wieczorek D, Kroell-Seger J, Lund C, Klein KM, Au PYB, Rho JM, Ho AW, Masnada S, Veggiotti P, Giordano L, Accorsi P, Hoei-Hansen CE, Striano P, Zara F, Verhelst H, Verhoeven JS, Braakman HMH, van der Zwaag B, Harder AVE, Brilstra E, Pendziwiat M, Lebon S, Vaccarezza M, Le NM, Christensen J, Grønborg S, Scherer SW, Howe J, Fazeli W, Howell KB, Leventer R, Stutterd C, Walsh S, Gerard M, Gerard B, Matricardi S, Bonardi CM, Sartori S, Berger A, Hoffman-Zacharska D, Mastrangelo M, Darra F, Vøllo A, Motazacker MM, Lakeman P, Nizon M, Betzler C, Altuzarra C, Caume R, Roubertie A, Gélisse P, Marini C, Guerrini R, Bilan F, Tibussek D, Koch-Hogrebe M, Perry MS, Ichikawa S, Dadali E, Sharkov A, Mishina I, Abramov M, Kanivets I, Korostelev S, Kutsev S, Wain KE, Eisenhauer N, Wagner M, Savatt JM, Müller-Schlüter K, Bassan H, Borovikov A, Nassogne MC, Destrée A, Schoonjans AS, Meuwissen M, Buzatu M, Jansen A, Scalais E, Srivastava S, Tan WH, Olson HE, Loddenkemper T, Poduri A, Helbig KL, Helbig I, Fitzgerald MP, Goldberg EM, Roser T, Borggraefe I, Brünger T, May P, Lal D, Lederer D, Rubboli G, Heyne HO, Lesca G, Hedrich UBS, Benda J, Gardella E, Lerche H, Møller RS. Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications. Brain 2022; 145:2991-3009. [PMID: 34431999 PMCID: PMC10147326 DOI: 10.1093/brain/awab321] [Citation(s) in RCA: 45] [Impact Index Per Article: 22.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 06/24/2021] [Accepted: 07/22/2021] [Indexed: 11/13/2022] Open
Abstract
We report detailed functional analyses and genotype-phenotype correlations in 392 individuals carrying disease-causing variants in SCN8A, encoding the voltage-gated Na+ channel Nav1.6, with the aim of describing clinical phenotypes related to functional effects. Six different clinical subgroups were identified: Group 1, benign familial infantile epilepsy (n = 15, normal cognition, treatable seizures); Group 2, intermediate epilepsy (n = 33, mild intellectual disability, partially pharmaco-responsive); Group 3, developmental and epileptic encephalopathy (n = 177, severe intellectual disability, majority pharmaco-resistant); Group 4, generalized epilepsy (n = 20, mild to moderate intellectual disability, frequently with absence seizures); Group 5, unclassifiable epilepsy (n = 127); and Group 6, neurodevelopmental disorder without epilepsy (n = 20, mild to moderate intellectual disability). Those in Groups 1-3 presented with focal or multifocal seizures (median age of onset: 4 months) and focal epileptiform discharges, whereas the onset of seizures in patients with generalized epilepsy was later (median: 42 months) with generalized epileptiform discharges. We performed functional studies expressing missense variants in ND7/23 neuroblastoma cells and primary neuronal cultures using recombinant tetrodotoxin-insensitive human Nav1.6 channels and whole-cell patch-clamping. Two variants causing developmental and epileptic encephalopathy showed a strong gain-of-function (hyperpolarizing shift of steady-state activation, strongly increased neuronal firing rate) and one variant causing benign familial infantile epilepsy or intermediate epilepsy showed a mild gain-of-function (defective fast inactivation, less increased firing). In contrast, all three variants causing generalized epilepsy induced a loss-of-function (reduced current amplitudes, depolarizing shift of steady-state activation, reduced neuronal firing). Functional effects were known for 170 individuals. All 136 individuals carrying a functionally tested gain-of-function variant had either focal (n = 97, Groups 1-3) or unclassifiable (n = 39) epilepsy, whereas 34 individuals with a loss-of-function variant had either generalized (n = 14), no (n = 11) or unclassifiable (n = 6) epilepsy; only three had developmental and epileptic encephalopathy. Computational modelling in the gain-of-function group revealed a significant correlation between the severity of the electrophysiological and clinical phenotypes. Gain-of-function variant carriers responded significantly better to sodium channel blockers than to other anti-seizure medications, and the same applied for all individuals in Groups 1-3. In conclusion, our data reveal clear genotype-phenotype correlations between age at seizure onset, type of epilepsy and gain- or loss-of-function effects of SCN8A variants. Generalized epilepsy with absence seizures is the main epilepsy phenotype of loss-of-function variant carriers and the extent of the electrophysiological dysfunction of the gain-of-function variants is a main determinant of the severity of the clinical phenotype in focal epilepsies. Our pharmacological data indicate that sodium channel blockers present a treatment option in SCN8A-related focal epilepsy with onset in the first year of life.
Collapse
Affiliation(s)
- Katrine M Johannesen
- Department of Epilepsy Genetics and Personalized Treatment, The Danish Epilepsy Center, 4293 Dianalund, Denmark
- Institute for Regional Health Services, University of Southern Denmark, 5230 Odense, Denmark
| | - Yuanyuan Liu
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72072 Tuebingen, Germany
| | - Mahmoud Koko
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72072 Tuebingen, Germany
| | - Cathrine E Gjerulfsen
- Department of Epilepsy Genetics and Personalized Treatment, The Danish Epilepsy Center, 4293 Dianalund, Denmark
| | - Lukas Sonnenberg
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72072 Tuebingen, Germany
- Institute for Neurobiology, University of Tuebingen, 72072 Tuebingen, Germany
| | - Julian Schubert
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72072 Tuebingen, Germany
| | - Christina D Fenger
- Department of Epilepsy Genetics and Personalized Treatment, The Danish Epilepsy Center, 4293 Dianalund, Denmark
| | - Ahmed Eltokhi
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72072 Tuebingen, Germany
| | - Maert Rannap
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72072 Tuebingen, Germany
| | - Nils A Koch
- Institute for Neurobiology, University of Tuebingen, 72072 Tuebingen, Germany
| | - Stephan Lauxmann
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72072 Tuebingen, Germany
- Institute for Neurobiology, University of Tuebingen, 72072 Tuebingen, Germany
| | - Johanna Krüger
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72072 Tuebingen, Germany
| | - Josua Kegele
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72072 Tuebingen, Germany
| | - Laura Canafoglia
- Department of Diagnostics and Technology, Fondazione IRCCS Istituto Neurologio Carlo Besta, 20125 Milan, Italy
| | - Silvana Franceschetti
- Department of Diagnostics and Technology, Fondazione IRCCS Istituto Neurologio Carlo Besta, 20125 Milan, Italy
| | - Thomas Mayer
- Epilepsy Center Kleinwachau, 01454 Dresden-Radeberg, Germany
| | | | - Pia Zacher
- Epilepsy Center Kleinwachau, 01454 Dresden-Radeberg, Germany
| | - Susanne Ruf
- Department of Pediatric Neurology and Developmental Medicine, University Children’s Hospital, 72072 Tuebingen, Germany
| | - Michael Alber
- Department of Pediatric Neurology and Developmental Medicine, University Children’s Hospital, 72072 Tuebingen, Germany
| | - Katalin Sterbova
- Department of Child Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, 10000 Prague, Czech Republic
| | - Petra Lassuthová
- Department of Child Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, 10000 Prague, Czech Republic
| | - Marketa Vlckova
- Department of Child Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, 10000 Prague, Czech Republic
| | - Johannes R Lemke
- Institute of Human Genetics, University of Leipzig Hospitals and Clinics, 4275 Leipzig, Germany
| | - Konrad Platzer
- Institute of Human Genetics, University of Leipzig Hospitals and Clinics, 4275 Leipzig, Germany
| | - Ilona Krey
- Institute of Human Genetics, University of Leipzig Hospitals and Clinics, 4275 Leipzig, Germany
| | - Constanze Heine
- Institute of Human Genetics, University of Leipzig Hospitals and Clinics, 4275 Leipzig, Germany
| | - Dagmar Wieczorek
- Institute of Human Genetics, University Clinic, Heinrich-Heine-University, 40210 Düsseldorf, Germany
| | - Judith Kroell-Seger
- Children’s Department, Swiss Epilepsy Centre, Clinic Lengg, 8001 Zurich, Switzerland
| | - Caroline Lund
- National Centre for Rare Epilepsy-Related Disorders, Oslo University Hospital, 0001 Oslo, Norway
| | - Karl Martin Klein
- Departments of Clinical Neurosciences, Medical Genetics and Community Health Sciences, Hotchkiss Brain Institute and Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2P 0A1, Canada
| | - P Y Billie Au
- Department of Medical Genetics, Alberta Children’s Hospital Research Institute, University of Calgary, AB T6G 2T4, Canada
| | - Jong M Rho
- Section of Pediatric Neurology, Alberta Children’s Hospital, Cumming School of Medicine, University of Calgary, Calgary, AB T2P 0A1, Canada
| | - Alice W Ho
- Section of Pediatric Neurology, Alberta Children’s Hospital, Cumming School of Medicine, University of Calgary, Calgary, AB T2P 0A1, Canada
| | - Silvia Masnada
- Department of Child Neurology, V. Buzzi Children’s Hospital, 20125 Milan, Italy
| | - Pierangelo Veggiotti
- Department of Child Neurology, V. Buzzi Children’s Hospital, 20125 Milan, Italy
- ‘L. Sacco’ Department of Biomedical and Clinical Sciences, University of Milan, 20157 Milan, Italy
| | - Lucio Giordano
- Child Neuropsychiatric Unit, Civilian Hospital, 25100 Brescia, Italy
| | - Patrizia Accorsi
- Child Neuropsychiatric Unit, Civilian Hospital, 25100 Brescia, Italy
| | - Christina E Hoei-Hansen
- Department of Pediatrics, Copenhagen University Hospital Rigshospitalet, 2200 Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark
| | - Pasquale Striano
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, 16121 Genova, Italy
- IRCCS ‘G. Gaslini’ Institute, 16121 Genoa, Italy
| | | | - Helene Verhelst
- Department of Pediatrics, Division of Pediatric Neurology, Gent University Hospital, 9042 Gent, Belgium
| | - Judith S Verhoeven
- Academic Center for Epileptology, Kempenhaeghe/Maastricht University Medical Center, 5591 Heeze, The Netherlands
| | - Hilde M H Braakman
- Department of Pediatric Neurology, Amalia Children’s Hospital, Radboud University Medical Center, 6525 Nijmegen, The Netherlands
| | - Bert van der Zwaag
- Department of Genetics, University Medical Center Utrecht, Utrecht University, 3553 Utrecht, The Netherlands
| | - Aster V E Harder
- Department of Genetics, University Medical Center Utrecht, Utrecht University, 3553 Utrecht, The Netherlands
| | - Eva Brilstra
- Department of Genetics, University Medical Center Utrecht, Utrecht University, 3553 Utrecht, The Netherlands
| | - Manuela Pendziwiat
- Department of Neuropediatrics, Universitätsklinikum Schleswig Holstein Campus Kiel, 24106 Kiel, Germany
| | - Sebastian Lebon
- Pediatric Neurology and Neurorehabilitation Unit, Woman Mother Child Department, Lausanne University Hospital (CHUV), 1000 Lausanne, Switzerland
- University of Lausanne, 1000 Lausanne, Switzerland
| | - Maria Vaccarezza
- Department of Pediatric Neurology, Hospital Italiano de Buenos Aires, C1428 Buenos Aires, Argentina
| | - Ngoc Minh Le
- Center for Pediatric Neurology, Cleveland Clinic, Cleveland, OH 44102, USA
| | - Jakob Christensen
- Department of Neurology, Aarhus University Hospital, 8000 Aarhus, Denmark
| | - Sabine Grønborg
- Center for Rare Diseases, Department of Pediatrics and Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet, 2200 Copenhagen, Denmark
| | - Stephen W Scherer
- McLaughlin Centre and Department of Molecular Genetics, University of Toronto, Toronto, ON 66777, Canada
- The Centre for Applied Genomics and Department of Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON 66777, Canada
| | - Jennifer Howe
- Department of Neuropediatrics, University Hospital Bonn, 53229 Bonn, Germany
| | - Walid Fazeli
- Institute for Molecular and Behavioral Neuroscience, University of Cologne, 50667 Cologne, Germany
- Neurology Department, The Royal Children’s Hospital Melbourne, 3002 Melbourne, Australia
| | - Katherine B Howell
- Neurology Department, The Royal Children’s Hospital Melbourne, 3002 Melbourne, Australia
- Murdoch Children’s Research Institute, 3052 Parkville, Australia
- Department of Pediatrics, University of Melbourne, Royal Children’s Hospital, 3052 Parkville, Australia
| | - Richard Leventer
- Neurology Department, The Royal Children’s Hospital Melbourne, 3002 Melbourne, Australia
- Murdoch Children’s Research Institute, 3052 Parkville, Australia
- Department of Pediatrics, University of Melbourne, Royal Children’s Hospital, 3052 Parkville, Australia
| | - Chloe Stutterd
- Murdoch Children’s Research Institute, 3052 Parkville, Australia
- Department of Pediatrics, University of Melbourne, Royal Children’s Hospital, 3052 Parkville, Australia
| | - Sonja Walsh
- Department of Neuropediatrics, Children’s Hospital, University Hospital Carl Gustav Carus, Technical University, 1099 Dresden, Germany
| | - Marion Gerard
- Genetics Department, CHU Côte de Nacre, 14118 Caen, France
| | | | - Sara Matricardi
- Child Neurology and Psychiatry Unit, Children’s Hospital G. Salesi, 60121 Ancona, Italy
| | - Claudia M Bonardi
- Department of Woman’s and Child’s Health, Padova University Hospital, 35100 Padova, Italy
| | - Stefano Sartori
- Child Neurology and Clinical Neurophysiology Unit, Padova University Hospital, 35100 Padova, Italy
| | - Andrea Berger
- Department of Neuropediatrics, Klinikum Weiden, Kliniken Nordoberpfalz AG, 92637 Weiden, Germany
| | | | - Massimo Mastrangelo
- Pediatric Neurology Unit, Vittore Buzzi Hospital, ASST Fatebenefratelli Sacco, 20100 Milan, Italy
| | - Francesca Darra
- Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, 37121 Verona, Italy
| | - Arve Vøllo
- Department of Pediatrics, Oestfold Hospital, 1712 Graalum, Norway
| | - M Mahdi Motazacker
- Laboratory of Genome Diagnostics, Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, 1019 Amsterdam, Netherlands
| | - Phillis Lakeman
- Department of Clinical Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, 1019 Amsterdam, Netherlands
| | - Mathilde Nizon
- Service de Génétique Médicale, CHU Nantes, 44093 Nantes, France
| | - Cornelia Betzler
- Clinic for Neuropediatrics and Neurorehabilitation, Epilepsy Center for Children and Adolescents, Schön Klinik, 83569 Vogtareuth, Germany
- Research Institute ‘Rehabilitation, Transition, Palliation’, PMU Salzburg, 5020 Salzburg, Austria
| | - Cecilia Altuzarra
- Department of Pediatrics, St. Jacques Hospital, 25000 Besançon, France
| | - Roseline Caume
- Clinique de Génétique Guy Fontaine, CHU Lille, 59000, Lille, France
| | - Agathe Roubertie
- Département de Neuropédiatrie, INSERM, CHU Montpellier, 34000 Montpellier, France
| | - Philippe Gélisse
- Département de Neuropédiatrie, INSERM, CHU Montpellier, 34000 Montpellier, France
| | - Carla Marini
- Pediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Meyer Children’s Hospital, University of Florence, 50131 Florence, Italy
| | | | - Frederic Bilan
- Service de Génétique, Centre Hospitalier Universitaire de Poitiers, 86021 Poitiers, France
| | - Daniel Tibussek
- Child Neurology, Center for Pediatric and Teenage Health Care, 53757 Sankt Augustin, Germany
| | | | - M Scott Perry
- Justin Neurosciences Center, Cook Children’s Medical Center, Fort Worth, TX 76101, USA
| | - Shoji Ichikawa
- Department of Clinical Diagnostics, Ambry Genetics, Aliso Viejo, CA 92637, USA
| | - Elena Dadali
- Research Centre for Medical Genetics, 115522 Moscow, Russia
- Veltischev Research and Clinical Institute for Pediatrics, Pirogov Russian National Research Medical University, 125412 Moscow, Russia
| | - Artem Sharkov
- Veltischev Research and Clinical Institute for Pediatrics, Pirogov Russian National Research Medical University, 125412 Moscow, Russia
- Genomed Ltd., 100000 Moscow, Russia
| | - Irina Mishina
- Research Centre for Medical Genetics, 115522 Moscow, Russia
| | - Mikhail Abramov
- Veltischev Research and Clinical Institute for Pediatrics, Pirogov Russian National Research Medical University, 125412 Moscow, Russia
| | - Ilya Kanivets
- Svt. Luka’s Institute of Child Neurology & Epilepsy, 100000 Moscow, Russia
- Russian Medical Academy of Continuous Professional Education, 100000 Moscow, Russia
| | - Sergey Korostelev
- Svt. Luka’s Institute of Child Neurology & Epilepsy, 100000 Moscow, Russia
- I.M. Sechenov First Moscow State Medical University, 100000 Moscow, Russia
| | - Sergey Kutsev
- Research Centre for Medical Genetics, 115522 Moscow, Russia
| | - Karen E Wain
- Geisinger Autism & Developmental Medicine Institute, Lewisburg, PA 17837, USA
| | - Nancy Eisenhauer
- Geisinger Autism & Developmental Medicine Institute, Lewisburg, PA 17837, USA
| | - Monisa Wagner
- Geisinger Autism & Developmental Medicine Institute, Lewisburg, PA 17837, USA
| | - Juliann M Savatt
- Geisinger Autism & Developmental Medicine Institute, Lewisburg, PA 17837, USA
| | - Karen Müller-Schlüter
- Epilepsy Center for Children, University Hospital Neuruppin, Brandenburg Medical School, 16816 Neuruppin, Germany
| | - Haim Bassan
- Pediatric Neurology & Development Center, Shamir Medical Center (Assaf Harofe), Be'er Ya'akov, Israel
- Sackler Faculty of Medicine, Tel Aviv University, 5296001 Tel Aviv, Israel
| | | | - Marie Cecile Nassogne
- Pediatric Neurology Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1000 Brussels, Belgium
| | - Anne Destrée
- Institute for Pathology and Genetics, 6040 Gosselies, Belgium
| | - An Sofie Schoonjans
- Department of Pediatrics and Pediatric Neurology, Antwerp University Hospital, University of Antwerp, 2650 Edegem, Belgium
| | - Marije Meuwissen
- Pediatric Neurology, Marie Curie Hospital—CHU Charleroi, 6032 Charleroi, Belgium
| | - Marga Buzatu
- Pediatric Neurology, Marie Curie Hospital—CHU Charleroi, 6032 Charleroi, Belgium
| | - Anna Jansen
- Pediatric Neurology Unit, Department of Pediatrics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 1050 Brussels, Belgium
| | - Emmanuel Scalais
- Pediatric Neurology Unit, Department of Pediatrics, Centre Hospitalier de Luxembourg, 1313 Luxembourg, Luxembourg
| | - Siddharth Srivastava
- Department of Neurology, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02108, USA
| | - Wen Hann Tan
- Department of Genetics, Boston Children’s Hospital, Boston, MA 02108, USA
| | - Heather E Olson
- Department of Neurology, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02108, USA
- Epilepsy Genetics Program, Boston Children’s Hospital, Boston, MA 02108, USA
| | - Tobias Loddenkemper
- Department of Neurology, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02108, USA
| | - Annapurna Poduri
- Department of Neurology, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02108, USA
- Epilepsy Genetics Program, Boston Children’s Hospital, Boston, MA 02108, USA
| | - Katherine L Helbig
- Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
- The Epilepsy Neurogenetics Initiative (ENGIN), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Ingo Helbig
- Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
- The Epilepsy Neurogenetics Initiative (ENGIN), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Department of Biomedical and Health Informatics (DBHi), Children’s Hospital of Philadelphia, Philadelphia, PA 19104 USA
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA
- Institute of Clinical Molecular Biology, Kiel University, 24105 Kiel, Germany
- Department of Neuropediatrics, Kiel University, 24105 Kiel, Germany
| | - Mark P Fitzgerald
- Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
- The Epilepsy Neurogenetics Initiative (ENGIN), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Department of Biomedical and Health Informatics (DBHi), Children’s Hospital of Philadelphia, Philadelphia, PA 19104 USA
- Institute of Clinical Molecular Biology, Kiel University, 24105 Kiel, Germany
| | - Ethan M Goldberg
- Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
- The Epilepsy Neurogenetics Initiative (ENGIN), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Timo Roser
- Division of Pediatric Neurology, Developmental Medicine and Social Pediatrics, Department of Pediatrics, Dr. von Haunersches Children’s Hospital, Ludwig-Maximilian-University of Munich, 80331 Munich, Germany
| | - Ingo Borggraefe
- Division of Pediatric Neurology, Developmental Medicine and Social Pediatrics, Department of Pediatrics, Dr. von Haunersches Children’s Hospital, Ludwig-Maximilian-University of Munich, 80331 Munich, Germany
- Comprehensive Epilepsy Center, Ludwig-Maximilian- University of Munich, 80331 Munich, Germany
| | - Tobias Brünger
- Luxembourg Centre for Systems Biomedicine (LCSB), University Luxembourg, L-4243 Esch-sur-Alzette, Luxembourg
| | - Patrick May
- Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44102, USA
| | - Dennis Lal
- Luxembourg Centre for Systems Biomedicine (LCSB), University Luxembourg, L-4243 Esch-sur-Alzette, Luxembourg
- Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, OH 44102, USA
- Stanley Center for Psychiatric Research, Broad Institute of Harvard and M.I.T., Cambridge, MA 02138, USA
- Cologne Center for Genomics (CCG), University of Cologne, 50667 Cologne, Germany
| | - Damien Lederer
- Institute for Pathology and Genetics, 6040 Gosselies, Belgium
| | - Guido Rubboli
- Department of Epilepsy Genetics and Personalized Treatment, The Danish Epilepsy Center, 4293 Dianalund, Denmark
- University of Copenhagen, 2200 Copenhagen, Denmark
| | - Henrike O Heyne
- Institute of Human Genetics, University of Leipzig Hospitals and Clinics, 4275 Leipzig, Germany
- Finnish Institute for Molecular Medicine (FIMM), University of Helsinki, 320 Helsinki, Finland
- Program for Medical and Population Genetics/Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02138, USA
- Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02108, USA
| | - Gaetan Lesca
- Department of Medical Genetics, Groupement Hospitalier Est and ERN EpiCARE, University Hospitals of Lyon (HCL), 69001 Lyon, France
- Institut Neuromyogène, CNRS UMR 5310 - INSERM U1217, Université de Lyon, Université Claude Bernard Lyon 1, 69001 Lyon, France
| | - Ulrike B S Hedrich
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72072 Tuebingen, Germany
| | - Jan Benda
- Institute for Neurobiology, University of Tuebingen, 72072 Tuebingen, Germany
| | - Elena Gardella
- Department of Epilepsy Genetics and Personalized Treatment, The Danish Epilepsy Center, 4293 Dianalund, Denmark
- Institute for Regional Health Services, University of Southern Denmark, 5230 Odense, Denmark
| | - Holger Lerche
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72072 Tuebingen, Germany
| | - Rikke S Møller
- Department of Epilepsy Genetics and Personalized Treatment, The Danish Epilepsy Center, 4293 Dianalund, Denmark
- Institute for Regional Health Services, University of Southern Denmark, 5230 Odense, Denmark
| |
Collapse
|
20
|
François‐Heude M, Lebigot E, Roze E, Abi Warde MT, Cances C, Damaj L, Espil C, Fluss J, de Lonlay P, Kern I, Lenaers G, Munnich A, Meyer P, Spitz M, Torre S, Doummar D, Touati G, Leboucq N, Roubertie A. Movement disorders in valine catabolism diseases (
HIBCH
and
ECHS1
deficiencies
). Eur J Neurol 2022; 29:3229-3242. [DOI: 10.1111/ene.15515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 05/13/2022] [Accepted: 07/19/2022] [Indexed: 11/29/2022]
Affiliation(s)
| | - Elise Lebigot
- APHP Paris Saclay, Bicêtre Hospital, Biochemistry department, Le Kremlin‐Bicêtre Paris France
| | - Emmanuel Roze
- Sorbonne University Inserm U1127, CNRS UMR7225, UM75, Paris Brain Institute, Assistance Publique – Hôpitaux de Paris, DMU Neurosciences Paris France
| | - Marie Thérèse Abi Warde
- CHRU Strasbourg Service de Neuropédiatrie et Maladies Héréditaires du métabolisme Strasbourg FRANCE
| | - Claude Cances
- Reference Center for Neuromuscular Diseases AOC, Pediatric Neurology Department Toulouse University Hospital Toulouse France
| | - Lena Damaj
- Department of Pediatrics, Competence Center of Inherited Metabolic Disorders Rennes Hospital
| | - Caroline Espil
- Service de Neuropédiatrie Centre Hospitalier de Bordeaux, Centre de Référence des Maladies Neuromusculaires AOC (Atlantique‐Occitanie‐Caraïbe), Bordeaux France
| | - Joel Fluss
- HUG Genève, Service des spécialités pédiatriques, Unité de neuropédiatrie Genève, Suisse
| | - Pascale de Lonlay
- Reference Center of inherited Metabolic Diseases, Necker‐Enfants‐Malades University hospital, APHP Université de Paris Paris France
| | - Ilse Kern
- HUG Genève, Service des spécialités pédiatriques, Unité de néphrologie et métabolisme pédiatrique Genève, Suisse
| | - Guy Lenaers
- UMR CNRS 6015 ‐ INSERM U1083, University of Angers MitoLab Team University Hospital of Angers Angers France
| | | | - Pierre Meyer
- CHU Montpellier, Département de Neuropédiatrie, Univ Montpellier Montpellier France
- Phymedexp Université de Montpellier Montpellier France
| | - Marie‐Aude Spitz
- Sorbonne University Inserm U1127, CNRS UMR7225, UM75, Paris Brain Institute, Assistance Publique – Hôpitaux de Paris, DMU Neurosciences Paris France
| | - Stéphanie Torre
- Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, UNIROUEN, INSERM U1245, CHU Rouen Normandie University Rouen France
| | - Diane Doummar
- Reference Center of inherited Metabolic Diseases, Necker‐Enfants‐Malades University hospital, APHP Université de Paris Paris France
| | - Guy Touati
- Department of Pediatric Neurology, Hôpital Armand‐Trousseau Paris France
| | - Nicolas Leboucq
- Centre de référence en maladies héréditaires du métabolisme, Hôpital des Enfants, CHU de Toulouse Toulouse France
| | - Agathe Roubertie
- CHU Montpellier, Département de Neuropédiatrie, Univ Montpellier Montpellier France
- INM, Univ Montpellier, INSERM U 1298 Montpellier France
| |
Collapse
|
21
|
Secco LP, Coubes C, Meyer P, Chenine L, Roubertie A, Malinge MC, Bessis D. Dermatological and genetic data in tuberous sclerosis: A prospective single-center study of 38 patients. Ann Dermatol Venereol 2022; 149:241-244. [PMID: 35527063 DOI: 10.1016/j.annder.2022.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 11/20/2021] [Accepted: 02/09/2022] [Indexed: 11/15/2022]
Abstract
BACKGROUND Tuberous sclerosis complex (TSC) is a genetic disorder involving the TSC1 or TSC2 gene. Skin signs are prominent, but dermatological data are scarce. This study aims to describe the cutaneous signs of TSC with the genotype. METHODS We studied the dermatological characteristics of 38 patients with TSC at the University Hospital of Montpellier. We collected details of genotypic features. RESULTS All the patients presented at least one cutaneous sign. The dermatological examination alone was sufficient to establish a definite diagnosis of TSC based on the diagnostic criteria for 34/38 patients. No association was found between cutaneous signs and the presence of a TSC1 or TSC2 mutation. We noted skin signs that were poorly described in the disease, namely epidermal nevus in 3 patients, vascular malformation in 2 patients, and keratosis pilaris in 9 patients. DISCUSSION While several studies demonstrate a more severe neurological phenotype in TSC2 mutated patients, skin expression does not appear to differ according to the mutated gene. Further case reports and molecular genetic studies are needed to determine the link between epidermal nevus, vascular malformations, keratosis pilaris and TSC.
Collapse
Affiliation(s)
- L-P Secco
- Department of Dermatology, Montpellier University Hospital Center, 34295 Montpellier, France.
| | - C Coubes
- Department of Genetics, Montpellier University Hospital Center, 34295 Montpellier, France
| | - P Meyer
- Department of Pediatric Neurology, Montpellier University Hospital Center, 34295 Montpellier, France
| | - L Chenine
- Department of Nephrology, Montpellier University Hospital Center, 34295 Montpellier, France
| | - A Roubertie
- Department of Pediatric Neurology, Montpellier University Hospital Center, 34295 Montpellier, France
| | - M-C Malinge
- Department of Genetics, Angers University Hospital Center, 49100 Angers, France
| | - D Bessis
- Department of Dermatology, Montpellier University Hospital Center, 34295 Montpellier, France
| |
Collapse
|
22
|
Gorce M, Lebigot E, Arion A, Brassier A, Cano A, De Lonlay P, Feillet F, Gay C, Labarthe F, Nassogne MC, Roche S, Roubertie A, Sacaze E, Touati G, Broué P. Fructose-1,6-bisphosphatase deficiency causes fatty liver disease and requires long-term hepatic follow-up. J Inherit Metab Dis 2022; 45:215-222. [PMID: 34687058 DOI: 10.1002/jimd.12452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 10/15/2021] [Accepted: 10/20/2021] [Indexed: 11/06/2022]
Abstract
Liver disease, occurring during pediatric or adult age, is often of undetermined cause. Some cases are probably related to undiagnosed inherited metabolic disorders. Hepatic disorders associated with fructose-1,6-bisphosphatase deficiency, a gluconeogenesis defect, are not reported in the literature. These symptoms are mainly described during acute crises, and many reports do not mention them because hypoglycemia and hyperlactatemia are more frequently in the forefront. Herein, the liver manifestations of 18 patients affected with fructose-1,6-bisphosphatase deficiency are described and the corresponding literature is reviewed. Interestingly, all 18 patients had liver abnormalities either during follow-up (hepatomegaly [n = 8/18], elevation of transaminases [n = 6/15], bright liver [n = 7/11]) or during acute crises (hepatomegaly [n = 10/17], elevation of transaminases [n = 13/16], acute liver failure [n = 6/14], bright liver [n = 4/14]). Initial reports described cases of liver steatosis, when liver biopsy was necessary to confirm the diagnosis by an enzymatic study. There is no clear pathophysiological basis for this fatty liver disease but we postulate that endoplasmic reticulum stress and de novo lipogenesis activation could be key factors, as observed in FBP1 knockout mice. Liver steatosis may expose patients to severe long-term liver complications. As hypoglycemia becomes less frequent with age, most adult patients are no longer monitored by hepatologist. Signs of fructose-1,6-bisphosphatase deficiency may be subtle and can be missed in childhood. We suggest that fructose-1,6-bisphosphatase deficiency should be considered as an etiology of hepatic steatosis, and a liver monitoring protocol should be set up for these patients, during lifelong follow-up.
Collapse
Affiliation(s)
- Magali Gorce
- Centre de référence des maladies héréditaires du métabolisme, Unité pédiatrique de Gastro-entérologie, hépatologie, nutrition et Maladies héréditaires du métabolisme, CHU de Toulouse-Hôpital des Enfants, Toulouse, France
| | - Elise Lebigot
- APHP, CHU Bicêtre, Service de biochimie, Le Kremlin-Bicêtre, Paris, France
| | - Alina Arion
- Centre de compétence des maladies héréditaires du métabolisme, Service de pédiatrie médicale, CHU de Caen - Hôpital de la Côte de Nacre, Caen, France
| | - Anaïs Brassier
- Centre de référence des maladies héréditaires du métabolisme, Institut Imagine, Hôpital Necker, Université Paris-Descartes, Paris, France
| | - Aline Cano
- Centre de référence des maladies héréditaires du métabolisme, Service de neurologie pédiatrique, Pédiatrie spécialisée et médecine infantile, CHU de Marseille-Hôpital de la Timone, Marseille, France
| | - Pascale De Lonlay
- Centre de référence des maladies héréditaires du métabolisme, Institut Imagine, Hôpital Necker, Université Paris-Descartes, Paris, France
| | - François Feillet
- Centre de référence des maladies héréditaires du métabolisme, Service de médecine infantile, CHU Brabois Enfants, Vandœuvre-lès-Nancy, France
| | - Claire Gay
- Centre de compétence des maladies héréditaires du métabolisme, Service de Pédiatrie, CHU de Saint-Etienne-Hôpital Nord, Saint Etienne, France
| | - François Labarthe
- Centre de référence des maladies héréditaires du métabolisme, Service de Médecine pédiatrique, Pediatrics Departement, CHRU de Tours-Hôpital Clocheville, Tours, France
| | - Marie-Cécile Nassogne
- Service de neurologie pédiatrique et Centre de référence des maladies métaboliques héréditaires-Cliniques Universitaires Saint-Luc, UCLouvain, Bruxelles, Belgium
| | - Sandrine Roche
- Centre de compétence des maladies héréditaires du métabolisme, Service de pédiatrie médicale, CHU Bordeaux, hôpital Pellegrin, Bordeaux, France
| | - Agathe Roubertie
- Centre de compétence des maladies héréditaires du métabolisme, Département de neuropédiatrie, Pôle Femme Mère Enfant, CHRU de Montpellier-Hôpital Gui de Chauliac, Montpellier, France
| | - Elise Sacaze
- Centre de compétence des maladies héréditaires du métabolisme, Service de Pédiatrie, Pôle Femme-Mère-Enfant, CHRU de Brest-Hôpital Morvan, Brest, France
| | - Guy Touati
- Centre de référence des maladies héréditaires du métabolisme, Unité pédiatrique de Gastro-entérologie, hépatologie, nutrition et Maladies héréditaires du métabolisme, CHU de Toulouse-Hôpital des Enfants, Toulouse, France
| | - Pierre Broué
- Centre de référence des maladies héréditaires du métabolisme, Unité pédiatrique de Gastro-entérologie, hépatologie, nutrition et Maladies héréditaires du métabolisme, CHU de Toulouse-Hôpital des Enfants, Toulouse, France
| |
Collapse
|
23
|
Ekmen A, Meneret A, Valabregue R, Beranger B, Worbe Y, Lamy JC, Mehdi S, Herve A, Adanyeguh I, Temiz G, Damier P, Gras D, Roubertie A, Piard J, Navarro V, Mutez E, Riant F, Welniarz Q, Vidailhet M, Lehericy S, Meunier S, Gallea C, Roze E. Cerebellum Dysfunction in Patients With PRRT2-Related Paroxysmal Dyskinesia. Neurology 2022; 98:e1077-e1089. [DOI: 10.1212/wnl.0000000000200060] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Accepted: 01/03/2022] [Indexed: 11/15/2022] Open
Abstract
Background and Objectives:The main culprit gene for paroxysmal kinesigenic dyskinesia, characterized by brief and recurrent attacks of involuntary movements, is PRRT2. The location of the primary dysfunction associated with paroxysmal dyskinesia remains a matter of debate and may vary depending on the etiology. While striatal dysfunction has often been implicated in these patients, evidence from preclinical models indicate that the cerebellum could also play a role. We aimed to investigate the role of the cerebellum in the pathogenesis of PRRT2-related dyskinesia in humans.Methods:We enrolled 22 consecutive right-handed patients with paroxysmal kinesigenic dyskinesia with a pathogenic variant of PRRT2, and their matched controls. Participants underwent a multi-modal neuroimaging protocol. We recorded anatomic and diffusion-weighted MRI, as well as resting-state functional MRI during which we tested the after-effects of sham and repetitive transcranial magnetic stimulation applied to the cerebellum on endogenous brain activity. We quantified: (i) the structural integrity of gray matter using voxel-based morphometry; (ii) the structural integrity of white matter using fixel-based analysis; (iii) the strength and direction of functional cerebellar connections using spectral dynamic causal modeling.Results:PRRT2 patients had: (i) decreased gray matter volume in the cerebellar lobule VI and in the medial prefrontal cortex; (ii) microstructural alterations of white matter in the cerebellum and along the tracts connecting the cerebellum to the striatum and the cortical motor areas; (iii) dysfunction of cerebellar motor pathways to the striatum and the cortical motor areas, as well as abnormal communication between the associative cerebellum (Crus I) and the medial prefrontal cortex. Cerebellar stimulation modulated communication within the motor and associative cerebellar networks, and tended to restore this communication to the level observed in healthy controls.Discussion:Patients with PRRT2-related dyskinesia have converging structural alterations of the motor cerebellum and related pathways with a dysfunction of cerebellar output towards the cerebello-thalamo-striato-cortical network. We hypothesize that abnormal cerebellar output is the primary dysfunction in patients with a PRRT2 pathogenic variant, resulting in striatal dysregulation and paroxysmal dyskinesia. More broadly, striatal dysfunction in paroxysmal dyskinesia might be secondary to aberrant cerebellar output transmitted by thalamic relays in certain disorders.Clinical trial number:NCT03481491 (https://ichgcp.net/clinical-trials-registry/NCT03481491)
Collapse
|
24
|
Badr M, Goulard M, Theret B, Roubertie A, Badiou S, Pifre R, Bres V, Cambonie G. Fatal accidental lipid overdose with intravenous composite lipid emulsion in a premature newborn: a case report. BMC Pediatr 2021; 21:584. [PMID: 34930217 PMCID: PMC8686371 DOI: 10.1186/s12887-021-03064-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 12/08/2021] [Indexed: 01/30/2023] Open
Abstract
Background Tenfold or more overdose of a drug or preparation is a dreadful adverse event in neonatology, often due to an error in programming the infusion pump flow rate. Lipid overdose is exceptional in this context and has never been reported during the administration of a composite intravenous lipid emulsion (ILE). Case presentation Twenty-four hours after birth, a 30 weeks’ gestation infant with a birthweight of 930 g inadvertently received 28 ml of a composite ILE over 4 h. The ILE contained 50% medium-chain triglycerides and 50% soybean oil, corresponding to 6 g/kg of lipids (25 mg/kg/min). The patient developed acute respiratory distress with echocardiographic markers of pulmonary hypertension and was treated with inhaled nitric oxide and high-frequency oscillatory ventilation. Serum triglyceride level peaked at 51.4 g/L, 17 h after the lipid overload. Triple-volume exchange transfusion was performed twice, decreasing the triglyceride concentration to < 10 g/L. The infant’s condition remained critical, with persistent bleeding and shock despite supportive treatment and peritoneal dialysis. Death occurred 69 h after the overdose in a context of refractory lactic acidosis. Conclusions Massive ILE overdose is life-threatening in the early neonatal period, particularly in premature and hypotrophic infants. This case highlights the vigilance required when ILEs are administered separately from other parenteral intakes. Exchange transfusion should be considered at the first signs of clinical or biological worsening to avoid progression to multiple organ failure. Supplementary Information The online version contains supplementary material available at 10.1186/s12887-021-03064-6.
Collapse
Affiliation(s)
- Maliha Badr
- Department of Neonatal Medicine and Paediatric Intensive Care, Arnaud de Villeneuve Hospital, Montpellier University Hospital, University of Montpellier, 371 Avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France
| | - Marion Goulard
- Department of Neonatal Medicine and Paediatric Intensive Care, Arnaud de Villeneuve Hospital, Montpellier University Hospital, University of Montpellier, 371 Avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France
| | - Bénédicte Theret
- Department of Neonatal Medicine and Paediatric Intensive Care, Arnaud de Villeneuve Hospital, Montpellier University Hospital, University of Montpellier, 371 Avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France
| | - Agathe Roubertie
- Department of Neuropaediatrics, Gui de Chauliac Hospital, Montpellier University Hospital, University of Montpellier, Montpellier, France
| | - Stéphanie Badiou
- Department of Biochemistry and Hormonology, Lapeyronie Hospital, Montpellier University Hospital, University of Montpellier, Montpellier, France
| | - Roselyne Pifre
- Department of Neonatal Medicine and Paediatric Intensive Care, Arnaud de Villeneuve Hospital, Montpellier University Hospital, University of Montpellier, 371 Avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France
| | - Virginie Bres
- Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, University of Montpellier, Montpellier, France
| | - Gilles Cambonie
- Department of Neonatal Medicine and Paediatric Intensive Care, Arnaud de Villeneuve Hospital, Montpellier University Hospital, University of Montpellier, 371 Avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France. .,Pathogenesis and Control of Chronic Infection, INSERM UMR 1058, University of Montpellier, Montpellier, France.
| |
Collapse
|
25
|
Mengel E, Patterson MC, Da Riol RM, Del Toro M, Deodato F, Gautschi M, Grunewald S, Grønborg S, Harmatz P, Héron B, Maier EM, Roubertie A, Santra S, Tylki‐Szymanska A, Day S, Andreasen AK, Geist MA, Havnsøe Torp Petersen N, Ingemann L, Hansen T, Blaettler T, Kirkegaard T, í Dali C. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment. J Inherit Metab Dis 2021; 44:1463-1480. [PMID: 34418116 PMCID: PMC9293014 DOI: 10.1002/jimd.12428] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 08/11/2021] [Accepted: 08/19/2021] [Indexed: 12/13/2022]
Abstract
Niemann-Pick disease type C (NPC) is a rare, genetic, progressive neurodegenerative disorder with high unmet medical need. We investigated the safety and efficacy of arimoclomol, which amplifies the heat shock response to target NPC protein misfolding and improve lysosomal function, in patients with NPC. In a 12-month, prospective, randomised, double-blind, placebo-controlled, phase 2/3 trial (ClinicalTrials.gov identifier: NCT02612129), patients (2-18 years) were randomised 2:1 to arimoclomol:placebo, stratified by miglustat use. Routine clinical care was maintained. Arimoclomol was administered orally three times daily. The primary endpoint was change in 5-domain NPC Clinical Severity Scale (NPCCSS) score from baseline to 12 months. Fifty patients enrolled; 42 completed. At month 12, the mean progression from baseline in the 5-domain NPCCSS was 0.76 with arimoclomol vs 2.15 with placebo. A statistically significant treatment difference in favour of arimoclomol of -1.40 (95% confidence interval: -2.76, -0.03; P = .046) was observed, corresponding to a 65% reduction in annual disease progression. In the prespecified subgroup of patients receiving miglustat as routine care, arimoclomol resulted in stabilisation of disease severity over 12 months with a treatment difference of -2.06 in favour of arimoclomol (P = .006). Adverse events occurred in 30/34 patients (88.2%) receiving arimoclomol and 12/16 (75.0%) receiving placebo. Fewer patients had serious adverse events with arimoclomol (5/34, 14.7%) vs placebo (5/16, 31.3%). Treatment-related serious adverse events (n = 2) included urticaria and angioedema. Arimoclomol provided a significant and clinically meaningful treatment effect in NPC and was well tolerated.
Collapse
Affiliation(s)
- Eugen Mengel
- SphinCS GmbHInstitute of Clinical Science for LSDHochheimGermany
| | - Marc C. Patterson
- Departments of Neurology, Pediatrics and Medical GeneticsMayo ClinicRochesterMinnesotaUSA
| | - Rosalia M. Da Riol
- Regional Coordination Center for Rare DiseasesAcademic Hospital ‘Santa Maria della Misericordia’UdineItaly
| | - Mireia Del Toro
- Pediatric Neurology DepartmentVall d'Hebron University HospitalBarcelonaSpain
| | - Federica Deodato
- Division of MetabolismOspedale Pediatrico Bambino Gesù, IRCCSRomeItaly
| | - Matthias Gautschi
- Department of Paediatrics, Division of Endocrinology, Diabetology and Metabolism, and Institute of Clinical Chemistry, InselspitalUniversity Hospital Bern, University of BernBernSwitzerland
| | - Stephanie Grunewald
- Department of Metabolic MedicineGreat Ormond Street Hospital, Institute of Child Health, UCL, NIHR Biomedical Research CenterLondonUK
| | - Sabine Grønborg
- Centre for Inherited Metabolic DiseasesCopenhagen University Hospital (Rigshospitalet)CopenhagenDenmark
| | - Paul Harmatz
- Gastroenterology and HepatologyUCSF Benioff Children's Hospital OaklandOaklandCaliforniaUSA
| | - Bénédicte Héron
- Department of Pediatric Neurology, Reference Centre for Lysosomal DiseasesUniversity Hospital Armand TrousseauParisFrance
| | - Esther M. Maier
- Department of Inborn Errors of MetabolismUniversity of Munich Children's HospitalMunichGermany
| | - Agathe Roubertie
- Department of NeuropediatricsCentre Hospitalier Universitaire de MontpellierMontpellierFrance
| | - Saikat Santra
- Department of Inherited Metabolic DisordersBirmingham Children's HospitalBirminghamUK
| | - Anna Tylki‐Szymanska
- Department of Paediatrics, Nutrition and Metabolic DiseasesThe Children's Memorial InstituteWarsawPoland
| | - Simon Day
- BiostatisticsClinical Trials Consulting & Training LimitedBuckinghamUK
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Verdura E, Rodríguez-Palmero A, Vélez-Santamaria V, Planas-Serra L, de la Calle I, Raspall-Chaure M, Roubertie A, Benkirane M, Saettini F, Pavinato L, Mandrile G, O'Leary M, O'Heir E, Barredo E, Chacón A, Michaud V, Goizet C, Ruiz M, Schlüter A, Rouvet I, Sala-Coromina J, Fossati C, Iascone M, Canonico F, Marcé-Grau A, de Souza P, Adams DR, Casasnovas C, Rehm HL, Mefford HC, González Gutierrez-Solana L, Brusco A, Koenig M, Macaya A, Pujol A. Biallelic PI4KA variants cause a novel neurodevelopmental syndrome with hypomyelinating leukodystrophy. Brain 2021; 144:2659-2669. [PMID: 34415322 PMCID: PMC8557332 DOI: 10.1093/brain/awab124] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 02/10/2021] [Accepted: 02/15/2021] [Indexed: 11/14/2022] Open
Abstract
Phosphoinositides are lipids that play a critical role in processes such as cellular signalling, ion channel activity and membrane trafficking. When mutated, several genes that encode proteins that participate in the metabolism of these lipids give rise to neurological or developmental phenotypes. PI4KA is a phosphoinositide kinase that is highly expressed in the brain and is essential for life. Here we used whole exome or genome sequencing to identify 10 unrelated patients harbouring biallelic variants in PI4KA that caused a spectrum of conditions ranging from severe global neurodevelopmental delay with hypomyelination and developmental brain abnormalities to pure spastic paraplegia. Some patients presented immunological deficits or genito-urinary abnormalities. Functional analyses by western blotting and immunofluorescence showed decreased PI4KA levels in the patients’ fibroblasts. Immunofluorescence and targeted lipidomics indicated that PI4KA activity was diminished in fibroblasts and peripheral blood mononuclear cells. In conclusion, we report a novel severe metabolic disorder caused by PI4KA malfunction, highlighting the importance of phosphoinositide signalling in human brain development and the myelin sheath.
Collapse
Affiliation(s)
- Edgard Verdura
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
| | - Agustí Rodríguez-Palmero
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Pediatric Neurology Unit, Department of Pediatrics, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Catalonia, Spain
| | - Valentina Vélez-Santamaria
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Laura Planas-Serra
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
| | - Irene de la Calle
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain
| | - Miquel Raspall-Chaure
- Neurology Research Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.,Department of Paediatric Neurology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Agathe Roubertie
- Département de Neuropédiatrie, Hôpital Gui de Chauliac Pôle Neurosciences Tête et Cou, Montpellier, France.,INSERM U1051, Institut des Neurosciences de Montpellier, Montpellier, France
| | - Mehdi Benkirane
- Laboratoire de Génétique de Maladies Rares EA7402, Institut Universitaire de Recherche Clinique, Université de Montpellier, CHU Montpellier, CEDEX 5, 34295 Montpellier, France
| | - Francesco Saettini
- Paediatric Hematology Department, Fondazione MBBM, University of Milano Bicocca, Monza, Italy
| | - Lisa Pavinato
- Department of Medical Sciences, University of Torino, 10126 Torino, Italy
| | - Giorgia Mandrile
- Thalassemia Centre and Medical Genetics Unit, San Luigi Gonzaga University Hospital, Orbassano, Italy
| | - Melanie O'Leary
- Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Emily O'Heir
- Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Estibaliz Barredo
- Neuropediatric Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - Almudena Chacón
- Neuropediatric Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - Vincent Michaud
- Molecular Genetics Laboratory, Bordeaux University Hospital, Bordeaux, Aquitaine, France.,INSERM U1211, Rare Diseases Laboratory: Genetics and Metabolism, University of Bordeaux, Talence, Aquitaine, France
| | - Cyril Goizet
- INSERM U1211, Rare Diseases Laboratory: Genetics and Metabolism, University of Bordeaux, Talence, Aquitaine, France.,Reference Center for Rare Neurogenetic Diseases, Department of Medical Genetics, University Hospital Centre Bordeaux Pellegrin Hospital Group, Bordeaux, Aquitaine, France
| | - Montserrat Ruiz
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
| | - Agatha Schlüter
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
| | - Isabelle Rouvet
- Cellular Biotechnology Department and Biobank, Hospices Civils de Lyon, CHU de Lyon, Lyon, France
| | - Julia Sala-Coromina
- Neurology Research Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.,Department of Paediatric Neurology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Chiara Fossati
- Department of Paediatrics, Fondazione MBBM, Monza, Italy
| | - Maria Iascone
- Molecular Genetics Laboratory, USSD LGM, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - Francesco Canonico
- Department of Neuroradiology, University of Milan-Bicocca, San Gerardo Hospital, ASST di Monza, Monza, Italy
| | - Anna Marcé-Grau
- Neurology Research Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Precilla de Souza
- Office of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, MD, USA
| | - David R Adams
- Office of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, MD, USA.,Undiagnosed Diseases Program, The Common Fund, NIH, Bethesda, MD, USA
| | - Carlos Casasnovas
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain.,Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Heidi L Rehm
- Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Heather C Mefford
- Division of Genetic Medicine, Department of Paediatrics, University of Washington, Seattle, WA 98195, USA
| | - Luis González Gutierrez-Solana
- Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain.,Pediatric Neurology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | - Alfredo Brusco
- Department of Medical Sciences, University of Torino, 10126 Torino, Italy.,Medical Genetics Unit, Città della Salute e della Scienza, University Hospital, 10126 Turin, Italy
| | - Michel Koenig
- Laboratoire de Génétique de Maladies Rares EA7402, Institut Universitaire de Recherche Clinique, Université de Montpellier, CHU Montpellier, CEDEX 5, 34295 Montpellier, France
| | - Alfons Macaya
- Neurology Research Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.,Department of Paediatric Neurology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Aurora Pujol
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain.,Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Catalonia, Spain
| |
Collapse
|
27
|
Riant F, Roos C, Roubertie A, Barbance C, Hadjadj J, Auvin S, Baille G, Beltramone M, Boulanger C, Cahn A, Cata F, Cheuret E, Cuvellier JC, Defo A, Demarquay G, Donnet A, Gaillard N, Massardier E, Guy N, Lamoureux S, Le Moigno L, Lucas C, Ratiu D, Redon S, Rey C, Thauvin C, Viallet F, Tournier-Lasserve E, Ducros A. Hemiplegic Migraine Associated With PRRT2 Mutations: A Clinical and Genetic Study. Neurology 2021; 98:e51-e61. [PMID: 34649875 DOI: 10.1212/wnl.0000000000012947] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 10/04/2021] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AND OBJECTIVE PRRT2 variants have been reported in a few cases of patients with hemiplegic migraine. To clarify the role of PRRT2 in familial hemiplegic migraine, we studied this gene in a large cohort of affected probands. METHODS PRRT2 was analyzed in 860 probands with hemiplegic migraine and PRRT2 mutations were identified in 30 probands. Genotyping of relatives identified a total of 49 persons with mutations whose clinical manifestations were detailed. RESULTS PRRT2 mutations were found in 12 of 163 probands previously tested negative for CACNA1A, ATP1A2 and SCN1A mutations, and in 18 of 697 consecutive probands screened simultaneously on the four genes. In this second group, pathogenic variants were found in 105 subjects, mostly in ATP1A2 (42%), followed by CACNA1A (26%), PRRT2 (17%) and SCN1A (15%). The PRRT2 mutations included seven distinct variants, five of which already described in persons with paroxysmal kinesigenic dyskinesia, and two new variants. Eight probands had a deletion of the whole PRRT2 gene.Among the 49 PRRT2 mutated patients, 26 had pure hemiplegic migraine, 16 had hemiplegic migraine associated with another manifestation: epilepsy (8), learning disabilities (5), hypersomnia (4) or abnormal movement (3). Three patients had epilepsy without migraine, two had paroxysmal kinesigenic dyskinesia without migraine, and one was asymptomatic. CONCLUSION PRRT2 should be regarded as the fourth autosomal dominant gene for hemiplegic migraine, and screened in any affected patient, together with the three other main genes. Further studies are needed to understand how the same loss of function PRRT2 mutations can lead to a wide range of neurologic phenotypes including paroxysmal movement disorder, epilepsy, learning disabilities, sleep disorder and hemiplegic migraine.
Collapse
Affiliation(s)
- Florence Riant
- Service de Génétique Moléculaire, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris, Paris, France .,INSERM UMR-S1141, Université Paris, France
| | - Caroline Roos
- Emergency Headache Centre, Lariboisière Hospital, Paris, France
| | - Agathe Roubertie
- INM, Univ Montpellier, INSERM, CHU Montpellier, Département de Neuropédiatrie, Montpellier, France
| | - Cécile Barbance
- Service de Génétique Moléculaire, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Jessica Hadjadj
- Service de Génétique Moléculaire, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Stéphane Auvin
- Service de Neurologie Pédiatrique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Guillaume Baille
- Service de Neurologie et Pathologie du Mouvement, CHRU de Lille, Lille, France
| | - Marion Beltramone
- Pain Department, FHU INNOVPAIN, Hôpital La Timone, Marseille, France
| | - Cécile Boulanger
- Equipe Douleur et Soins Palliatifs Pédiatriques, Hôpital des Enfants, CHU Toulouse, Toulouse, France
| | - Alice Cahn
- Service de Neuropédiatrie, Centre Hospitalier d'Arras, Arras, France
| | - Florina Cata
- Service de Pédiatrie - Néonatologie du CH Remiremont, Remiremont, France
| | - Emmanuel Cheuret
- Service de Neurologie Pédiatrique, Hôpital des Enfants, CHU de Toulouse, Toulouse,France
| | | | - Antoine Defo
- Service de Neuropédiatrie, CH de Cayenne, Guyane Française
| | - Genevieve Demarquay
- Department of Neurology, Hospices Civils de Lyon, Lyon, and Lyon Neuroscience Research Center (CRNL), Brain Dynamics and Cognition Team (Dycog), INSERM U1028, CNRS UMR5292, Lyon
| | - Anne Donnet
- Pain Department, FHU INNOVPAIN, Hôpital La Timone, Marseille, France
| | - Nicolas Gaillard
- Neurology Department, Montpellier University Hospital, Montpellier, France
| | | | - Nathalie Guy
- Service de Neurologie, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Sylvie Lamoureux
- Service de Pédiatrie, Centre Hospitalier d'Avignon, Avignon, France
| | - Laurence Le Moigno
- Service de Pédiatrie et Unité d'Urgence Pédiatrique, Centre Hospitalier de Cornouaille, Quimper, France
| | - Christian Lucas
- Centre d'Evaluation et de Traitement de la Douleur dans le service de Neurochirurgie, CHU de Lille, Lille, France
| | - Diana Ratiu
- Service de Neurologie Centre Hospitalier de Narbonne, Narbonne, France
| | - Sylvain Redon
- Pain Department, FHU INNOVPAIN, Hôpital La Timone, Marseille, France
| | - Caroline Rey
- Service de Neurologie Vasculaire, CHU Timone, Marseille, France
| | - Christel Thauvin
- Centre de Génétique et Centre de Référence des Anomalies du Développement et Syndromes Malformatifs de l'Interrégion Est, Centre Hospitalier Universitaire Dijon, France
| | - François Viallet
- Département de Neurologie, Centre Hospitalier Intercommunal d'Aix-Pertuis, Aix-en-Provence, France
| | - Elisabeth Tournier-Lasserve
- Service de Génétique Moléculaire, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.,INSERM UMR-S1141, Université Paris, France
| | - Anne Ducros
- Neurology Department, Montpellier University Hospital, Montpellier, France.,Charles Coulomb Laboratory, UMR 5221 CNRS-UM, Montpellier University, Montpellier, France
| |
Collapse
|
28
|
Spitz MA, Lenaers G, Charif M, Wirth T, Chelly J, Abi-Warde MT, Meyer P, Leboucq N, Schaefer E, Anheim M, Roubertie A. Paroxysmal Dyskinesias Revealing 3-Hydroxy-Isobutyryl-CoA Hydrolase (HIBCH) Deficiency. Neuropediatrics 2021; 52:410-414. [PMID: 33506479 DOI: 10.1055/s-0040-1722678] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Paroxysmal dyskinesias (PD) are rare movement disorders characterized by recurrent attacks of dystonia, chorea, athetosis, or their combination, with large phenotypic and genetic heterogeneity. 3-Hydroxy-isobutyryl-CoA hydrolase (HIBCH) deficiency is a neurodegenerative disease characterized in most patients by a continuous decline in psychomotor abilities or a secondary regression triggered by febrile infections and metabolic crises.We describe two PD patients from two pedigrees, both carrying a homozygous c.913A > G, p.Thr305Ala mutation in the HIBCH gene, associated with an unusual clinical presentation. The first patient presented in the second year of life with right paroxysmal hemidystonia lasting for 30 minutes, without any loss of consciousness and without any triggering factor. The second patient has presented since the age of 3 recurrent exercise-induced PD episodes which have been described as abnormal equinovarus, contractures of the lower limbs, lasting for 1 to 4 hours, associated with choreic movements of the hands. Their neurological examination and metabolic screening were normal, while brain magnetic resonance imaging showed abnormal signal of the pallidi.We suggest that HIBCH deficiency, through the accumulation of metabolic intermediates of the valine catabolic pathway, leads to a secondary defect in respiratory chain activity and pyruvate dehydrogenase (PDH) activity and to a broad phenotypic spectrum ranging from Leigh syndrome to milder phenotypes. The two patients presented herein expand the spectrum of the disease to include unusual paroxysmal phenotypes and HIBCH deficiency should be considered in the diagnostic strategy of PD to enable adequate preventive treatment.
Collapse
Affiliation(s)
| | - Guy Lenaers
- Équipe Mitolab, Institut MITOVASC, INSERM U1083, CNRS 6015, Université d'Angers, Angers, France
| | - Majida Charif
- Équipe Mitolab, Institut MITOVASC, INSERM U1083, CNRS 6015, Université d'Angers, Angers, France
| | - Thomas Wirth
- Service de Neurologie, CHRU Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), UMR 7104 CNRS/Unistra, INSERM U1258, Illkirch, France.,Unit of Functional Neurosurgery, National Hospital for Neurology and Neurosurgery, London, United Kingdom
| | - Jameleddine Chelly
- Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), UMR 7104 CNRS/Unistra, INSERM U1258, Illkirch, France
| | | | - Pierre Meyer
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France
| | - Nicolas Leboucq
- Service de Neuroradiologie, Hôpital Gui de Chauliac, CHRU Montpellier, Montpellier, France
| | - Elise Schaefer
- Service de Génétique Médicale, CHRU Strasbourg, Strasbourg, France
| | - Mathieu Anheim
- Service de Neurologie, CHRU Strasbourg, Strasbourg, France
| | - Agathe Roubertie
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France.,INSERM U 1051, Institut des Neurosciences de Montpellier, Montpellier, France
| |
Collapse
|
29
|
Hwu PWL, Kiening K, Anselm I, Compton DR, Nakajima T, Opladen T, Pearl PL, Roubertie A, Roujeau T, Muramatsu SI. Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease. EMBO Mol Med 2021; 13:e14712. [PMID: 34423905 PMCID: PMC8422070 DOI: 10.15252/emmm.202114712] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Revised: 07/09/2021] [Accepted: 07/27/2021] [Indexed: 11/28/2022] Open
Abstract
This commentary provides an overview of the putamen as an established target site for gene therapy in treating aromatic l‐amino acid decarboxylase (AADC) deficiency and Parkinson’s disease, two debilitating neurological disorders that involve motor dysfunction caused by dopamine deficiencies. The neuroanatomy and the function of the putamen in motor control provide good rationales for targeting this brain structure. Additionally, the efficacy and safety of intraputaminal gene therapy demonstrate that restoration of dopamine synthesis in the putamen by using low doses of adeno‐associated viral vector serotype 2 to deliver the hAADC gene is well tolerated. This restoration leads to sustained improvements in motor and nonmotor symptoms of AADC deficiency and improved uptake and conversion of exogenous l‐DOPA into dopamine in Parkinson’s patients.
Collapse
Affiliation(s)
- Paul Wuh-Liang Hwu
- Department of Medical Genetics and Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.,Department of Pediatrics, National Taiwan University College of Medicine, Taipei, Taiwan
| | - Karl Kiening
- Division of Stereotactic Neurosurgery, Department of Neurosurgery, University of Heidelberg Medical Center, Heidelberg, Germany
| | - Irina Anselm
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - David R Compton
- Preclinical Development (Gene Therapy), PTC Therapeutics, South Plainfield, NJ, USA
| | - Takeshi Nakajima
- Department of Neurosurgery, Jichi Medical University, Tochigi, Japan.,Jichi Medical University Hospital, Rehabilitation Center, Tochigi, Japan
| | - Thomas Opladen
- Division of Child Neurology and Metabolic Disorders, University Children's Hospital, Heidelberg, Germany
| | - Phillip L Pearl
- Epilepsy and Clinical Neurophysiology, William G. Lennox Chair and Professor of Neurology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA
| | - Agathe Roubertie
- Pediatric Neurology Department, INM, INSERM, CHU Montpellier, University of Montpellier, Montpellier, France
| | - Thomas Roujeau
- Department of Neurosurgery, Gui-de-Chauliac Hospital, Montpellier University Hospital, Montpellier, France.,Institute of Neurosciences, University Hospital of Montpellier, Montpellier, France
| | - Shin-Ichi Muramatsu
- Division of Neurological Gene Therapy, Jichi Medical University, Shimotsuke, Tochigi, Japan.,Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
30
|
Toquet S, Spodenkiewicz M, Douillard C, Maillot F, Arnoux JB, Damaj L, Odent S, Moreau C, Redonnet-Vernhet I, Mesli S, Servais A, Noel E, Charriere S, Rigalleau V, Lavigne C, Kaphan E, Roubertie A, Besson G, Bigot A, Servettaz A, Mochel F, Garnotel R. Adult-onset diagnosis of urea cycle disorders: Results of a French cohort of 71 patients. J Inherit Metab Dis 2021; 44:1199-1214. [PMID: 34014557 DOI: 10.1002/jimd.12403] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 05/14/2021] [Accepted: 05/18/2021] [Indexed: 12/19/2022]
Abstract
Urea cycle disorders (UCD) are rare diseases that usually affect neonates or young children. During decompensations, hyperammonemia is neurotoxic, leading to severe symptoms and even coma and death if not treated rapidly. The aim was to describe a cohort of patients with adult onset of UCDs in a multicentric, retrospective and descriptive study of French adult patients with a diagnosis after 16 years of age of UCDs due to a deficiency in one of the 6 enzymes (arginase, ASL, ASS, CPS1, NAGS, OTC) or the two transporters (ORNT1 or citrin). Seventy-one patients were included (68% female, 32% male). The diagnosis was made in the context of (a) a metabolic decompensation (42%), (b) family history (55%), or (c) chronic symptoms (3%). The median age at diagnosis was 33 years (range 16-86). Eighty-nine percent of patients were diagnosed with OTC deficiency, 7% CPS1 deficiency, 3% HHH syndrome and 1% argininosuccinic aciduria. For those diagnosed during decompensations (including 23 OTC cases, mostly female), 89% required an admission in intensive care units. Seven deaths were attributed to UCD-6 decompensations and 1 epilepsy secondary to inaugural decompensation. This is the largest cohort of UCDs diagnosed in adulthood, which confirms the triad of neurological, gastrointestinal and psychiatric symptoms during hyperammonemic decompensations. We stress that females with OTC deficiency can be symptomatic. With 10% of deaths in this cohort, UCDs in adults remain a life-threatening condition. Physicians working in adult care must be aware of late-onset presentations given the implications for patients and their families.
Collapse
Affiliation(s)
- Ségolène Toquet
- Service de Médecine Interne, Hôpital Robert Debré, CHU Reims, France
| | | | - Claire Douillard
- Service d'Endocrinologie et Métabolismes, Hôpital Claude Huriez, Centre de Référence des Maladies Héréditaires du métabolisme, CHU Lille, France
| | - François Maillot
- Service de Médecine Interne, Hôpital Bretonneau, CHRU de Tours, France
| | - Jean-Baptiste Arnoux
- Centre de Référence des Maladies Héréditaires du Métabolisme, Hôpital Necker-Enfants Malades, CHU Paris, France
| | - Lena Damaj
- Service de Pédiatrie, CHU Hôpital Sud, Rennes, France
| | - Sylvie Odent
- Service de Génétique Clinique, CHU Hôpital Sud, Rennes, France
| | - Caroline Moreau
- Service de Biochimie et Toxicologie, CHU Pontchaillou, Rennes, France
| | | | - Samir Mesli
- Laboratoire de Biochimie, Hôpital Pellegrin, CHU Bordeaux, France
| | - Aude Servais
- Service de Néphrologie adulte, Hôpital Necker-Enfants Malades, CHU Paris, France
| | - Esther Noel
- Service de Médecine Interne, Hôpital Universitaire de Strasbourg, CHRU Strasbourg, France
| | - Sybill Charriere
- Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Centre de Référence des Maladies Héréditaires du Métabolisme, Bron, France
| | | | | | - Elsa Kaphan
- Pôle de Neurosciences Cliniques, CHU Timone, AP-HM, Marseille, France
| | - Agathe Roubertie
- Département de neuropédiatrie, Hôpital Gui de Chauliac, CHU Montpellier, France
| | | | - Adrien Bigot
- Service de Médecine Interne, Hôpital Bretonneau, CHRU de Tours, France
| | - Amélie Servettaz
- Service de Médecine Interne, Hôpital Robert Debré, CHU Reims, France
| | - Fanny Mochel
- Département de génétique, Hôpital Pitié-Salpêtrière, CHU Paris, France
| | - Roselyne Garnotel
- Laboratoire de Biochimie-Pharmacologie-Toxicologie, CHU Reims, France
| |
Collapse
|
31
|
Olivier G, Corton M, Intartaglia D, Verbakel SK, Sergouniotis PI, Le Meur G, Dhaenens CM, Naacke H, Avila-Fernández A, Hoyng CB, Klevering J, Bocquet B, Roubertie A, Sénéchal A, Banfi S, Muller A, Hamel CL, Black GC, Conte I, Roosing S, Zanlonghi X, Ayuso C, Meunier I, Manes G. Pathogenic variants in IMPG1 cause autosomal dominant and autosomal recessive retinitis pigmentosa. J Med Genet 2021; 58:570-578. [PMID: 32817297 DOI: 10.1136/jmedgenet-2020-107150] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Revised: 06/09/2020] [Accepted: 06/24/2020] [Indexed: 11/04/2022]
Abstract
BACKGROUND Inherited retinal disorders are a clinically and genetically heterogeneous group of conditions and a major cause of visual impairment. Common disease subtypes include vitelliform macular dystrophy (VMD) and retinitis pigmentosa (RP). Despite the identification of over 90 genes associated with RP, conventional genetic testing fails to detect a molecular diagnosis in about one third of patients with RP. METHODS Exome sequencing was carried out for identifying the disease-causing gene in a family with autosomal dominant RP. Gene panel testing and exome sequencing were performed in 596 RP and VMD families to identified additional IMPG1 variants. In vivo analysis in the medaka fish system by knockdown assays was performed to screen IMPG1 possible pathogenic role. RESULTS Exome sequencing of a family with RP revealed a splice variant in IMPG1. Subsequently, the same variant was identified in individuals from two families with either RP or VMD. A retrospective study of patients with RP or VMD revealed eight additional families with different missense or nonsense variants in IMPG1. In addition, the clinical diagnosis of the IMPG1 retinopathy-associated variant, originally described as benign concentric annular macular dystrophy, was also revised to RP with early macular involvement. Using morpholino-mediated ablation of Impg1 and its paralog Impg2 in medaka fish, we confirmed a phenotype consistent with that observed in the families, including a decreased length of rod and cone photoreceptor outer segments. CONCLUSION This study discusses a previously unreported association between monoallelic or biallelic IMPG1 variants and RP. Notably, similar observations have been reported for IMPG2.
Collapse
Affiliation(s)
- Guillaume Olivier
- Institute for Neurosciences of Montpellier, University of Montpellier, Montpellier, France
- Institute for Neurosciences of Montpellier, INSERM U1051, Montpellier, France
| | - Marta Corton
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM)-Center for Biomedical Network Research on Rare Diseases-(CIBERER), Madrid, Spain
| | - Daniela Intartaglia
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Telethon Institute of Genetics and Medicine, Pozzuoli (NA), and Medical Genetics, Naples, Italy
| | - Sanne K Verbakel
- Department of Ophthalmology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Panagiotis I Sergouniotis
- Manchester Royal Eye Hospital, Manchester Academic Health Science Centre, Central Manchester NHS Foundation Trust, Manchester Royal Eye Hospital, Manchester, M13 9WL, UK
| | - Guylène Le Meur
- Service Ophtalmologie, CHU Nantes, Nantes Université, Nantes, France
| | - Claire-Marie Dhaenens
- University Lille-Nord de France, INSERM U837, Lille, France
- Lille Neuroscience & Cognition, LilNCog, Lille, France
| | - Hélène Naacke
- Service d'ophtalmologie, Clinique Saint Joseph, Angouleme, Nouvelle Aquitaine, France
| | - Almudena Avila-Fernández
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM)-Center for Biomedical Network Research on Rare Diseases-(CIBERER), Madrid, Spain
| | - Carel B Hoyng
- Department of Ophthalmology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Jeroen Klevering
- Department of Ophthalmology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Béatrice Bocquet
- Institute for Neurosciences of Montpellier, University of Montpellier, Montpellier, France
- Institute for Neurosciences of Montpellier, INSERM U1051, Montpellier, France
| | - Agathe Roubertie
- Département de Neuropédiatrie, CHU Montpellier, Hôpital Gui de Chauliac, Montpellier, Hérault, France
- Institute for Neurosciences of Montpellier, INSERM U1051, Montpellier, Hérault, France
| | - Audrey Sénéchal
- Institute for Neurosciences of Montpellier, University of Montpellier, Montpellier, France
- Institute for Neurosciences of Montpellier, INSERM U1051, Montpellier, France
| | - Sandro Banfi
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Telethon Institute of Genetics and Medicine, Naples, Italy
| | - Agnès Muller
- Institute for Neurosciences of Montpellier, University of Montpellier, Montpellier, France
- Institute for Neurosciences of Montpellier, INSERM U1051, Montpellier, France
| | - Christian L Hamel
- Service d'ophtalmologie, Hôpital Gui de Chauliac, CHU Montpellier, Montpellier, France
| | - Graeme C Black
- Department of Genetic Medicine, University of Manchester, Manchester, UK
| | - Ivan Conte
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Telethon Institute of Genetics and Medicine, Pozzuoli (NA), and Medical Genetics, Naples, Italy
- Department of Biology, University of Naples Federico II, Napoli, Campania, Italy
| | - Susanne Roosing
- Department of Ophthalmology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Xavier Zanlonghi
- Institut Ophtalmologique de l'Ouest, Eye Clinic Jules Verne, Nantes, France
| | - Carmen Ayuso
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM)-Center for Biomedical Network Research on Rare Diseases-(CIBERER), Madrid, Spain
- Department of Genetics & Genomics, Centro de Investigacion Biomedica en Red (CIBER) de Enfermedades Raras, ISCIII, Madrid, Spain
| | - Isabelle Meunier
- Institute for Neurosciences of Montpellier, University of Montpellier, Montpellier, France
- National Centre in Rare Diseases, Genetics of Sensory Diseases, CHU Montpellier, Montpellier, Languedoc-Roussillon, France
| | - Gaël Manes
- Institute for Neurosciences of Montpellier, University of Montpellier, Montpellier, France
- Institute for Neurosciences of Montpellier, INSERM U1051, Montpellier, France
| |
Collapse
|
32
|
Meunier I, Bocquet B, Charif M, Dhaenens CM, Manes G, Amati-Bonneau P, Roubertie A, Zanlonghi X, Lenaers G. A ROD-CONE DYSTROPHY IS SYSTEMATICALLY ASSOCIATED TO THE RTN4IP1 RECESSIVE OPTIC ATROPHY. Retina 2021; 41:1771-1779. [PMID: 33315831 PMCID: PMC8297537 DOI: 10.1097/iae.0000000000003054] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE RTN4IP1 biallelic mutations cause a recessive optic atrophy, sometimes associated to more severe neurological syndromes, but so far, no retinal phenotype has been reported in RTN4IP1 patients, justifying their reappraisal. METHODS Seven patients from four families carrying biallelic RTN4IP1 variants were retrospectively reviewed, with emphasis on their age of onset, visual acuity, multimodal imaging including color and autofluorescence frames, spectral-domain optical coherence tomography with RNFL and macular analyses. RESULTS Seven patients from four RTN4IP1 families developed in their first decade of life a bilateral recessive optic atrophy with severe central visual loss, and primary nystagmus developed in 5 of 7 patients. Six patients were legally blind. In a second stage, the seven individuals developed a rod-cone dystrophy, sparing the macular zone and the far periphery. This retinal damage was identified by 55° field fundus autofluorescence frames and also by spectral-domain optical coherence tomography scans of the temporal part of the macular zone in five of the seven patients. Full-field electroretinography measurements disclosed reduced b-wave amplitude of the rod responses in all patients but two. Family 4 with the p.R103H and c.601A > T (p.K201*) truncating mutation had further combined neurological signs with cerebellar ataxia, seizures, and intellectual disability. CONCLUSION RTN4IP1 recessive optic atrophy is systematically associated to a rod-cone dystrophy, which suggests that both the retinal ganglion cells and the rods are affected as a result of a deficit in the mitochondrial respiratory chain. Thus, systematic widefield autofluorescence frames and temporal macular scans are recommended for the evaluation of patients with optic neuropathies.
Collapse
Affiliation(s)
- Isabelle Meunier
- Institute for Neurosciences of Montpellier U1051, University of Montpellier, Montpellier, France
- National Center in Rare Diseases, Genetics of Sensory Diseases, University Hospital, Montpellier, France
| | - Béatrice Bocquet
- Institute for Neurosciences of Montpellier U1051, University of Montpellier, Montpellier, France
- National Center in Rare Diseases, Genetics of Sensory Diseases, University Hospital, Montpellier, France
| | - Majida Charif
- Genetics, and Immuno-cell Therapy Team, Mohammed First University, Oujda, Morocco
| | - Claire-Marie Dhaenens
- Biochemistry and Molecular Biology Department—UF Génopathies, Univ Lille, Lille, France
| | - Gael Manes
- Institute for Neurosciences of Montpellier U1051, University of Montpellier, Montpellier, France
| | | | - Agathe Roubertie
- Institute for Neurosciences of Montpellier U1051, University of Montpellier, Montpellier, France
- National Center in Rare Diseases, Genetics of Sensory Diseases, University Hospital, Montpellier, France
| | | | - Guy Lenaers
- MitoLab Team, UMR CNRS 6015—INSERM U1083, Institut MitoVasc, Angers University and Hospital, Angers, France
| |
Collapse
|
33
|
Benkirane M, Marelli C, Guissart C, Roubertie A, Ollagnon E, Choumert A, Fluchère F, Magne FO, Halleb Y, Renaud M, Larrieu L, Baux D, Patat O, Bousquet I, Ravel JM, Cuntz-Shadfar D, Sarret C, Ayrignac X, Rolland A, Morales R, Pointaux M, Lieutard-Haag C, Laurens B, Tillikete C, Bernard E, Mallaret M, Carra-Dallière C, Tranchant C, Meyer P, Damaj L, Pasquier L, Acquaviva C, Chaussenot A, Isidor B, Nguyen K, Camu W, Eusebio A, Carrière N, Riquet A, Thouvenot E, Gonzales V, Carme E, Attarian S, Odent S, Castrioto A, Ewenczyk C, Charles P, Kremer L, Sissaoui S, Bahi-Buisson N, Kaphan E, Degardin A, Doray B, Julia S, Remerand G, Fraix V, Haidar LA, Lazaro L, Laugel V, Villega F, Charlin C, Frismand S, Moreira MC, Witjas T, Francannet C, Walther-Louvier U, Fradin M, Chabrol B, Fluss J, Bieth E, Castelnovo G, Vergnet S, Meunier I, Verloes A, Brischoux-Boucher E, Coubes C, Geneviève D, Lebouc N, Azulay JP, Anheim M, Goizet C, Rivier F, Labauge P, Calvas P, Koenig M. High rate of hypomorphic variants as the cause of inherited ataxia and related diseases: study of a cohort of 366 families. Genet Med 2021; 23:2160-2170. [PMID: 34234304 DOI: 10.1038/s41436-021-01250-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 06/08/2021] [Accepted: 06/08/2021] [Indexed: 11/09/2022] Open
Abstract
PURPOSE Diagnosis of inherited ataxia and related diseases represents a real challenge given the tremendous heterogeneity and clinical overlap of the various causes. We evaluated the efficacy of molecular diagnosis of these diseases by sequencing a large cohort of undiagnosed families. METHODS We analyzed 366 unrelated consecutive patients with undiagnosed ataxia or related disorders by clinical exome-capture sequencing. In silico analysis was performed with an in-house pipeline that combines variant ranking and copy-number variant (CNV) searches. Variants were interpreted according to American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines. RESULTS We established the molecular diagnosis in 46% of the cases. We identified 35 mildly affected patients with causative variants in genes that are classically associated with severe presentations. These cases were explained by the occurrence of hypomorphic variants, but also rarely suspected mechanisms such as C-terminal truncations and translation reinitiation. CONCLUSION A significant fraction of the clinical heterogeneity and phenotypic overlap is explained by hypomorphic variants that are difficult to identify and not readily predicted. The hypomorphic C-terminal truncation and translation reinitiation mechanisms that we identified may only apply to few genes, as it relies on specific domain organization and alterations. We identified PEX10 and FASTKD2 as candidates for translation reinitiation accounting for mild disease presentation.
Collapse
Affiliation(s)
- Mehdi Benkirane
- PhyMedExp, Institut Universitaire de Recherche Clinique, UMR_CNRS-Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France
| | - Cecilia Marelli
- Expert Centre for Neurogenetic Diseases and Adult Mitochondrial and Metabolic Diseases, Department of Neurology, Gui de Chauliac Hospital, CHU de Montpellier; Molecular Mechanisms of Neurodegenerative Dementia (MMDN), EPHE, INSERM, Université de Montpellier, Montpellier, France
| | - Claire Guissart
- PhyMedExp, Institut Universitaire de Recherche Clinique, UMR_CNRS-Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France
| | - Agathe Roubertie
- Department of Pediatrics, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France.,INSERM, Institut des Neurosciences de Montpellier, Montpellier, France
| | - Elizabeth Ollagnon
- Department of Medical Genetics and Reference Centre for Neurological and Neuromuscular Diseases, Croix-Rousse Hospital, Lyon, France
| | - Ariane Choumert
- Department of Rare Neurological Diseases, CHU de la Réunion, Saint-Pierre, France
| | - Frédérique Fluchère
- Department of Neurology, La Timone Hospital, CHU de Marseille, Marseille, France
| | - Fabienne Ory Magne
- Department of Neurology, Purpan Hospital, CHU de Toulouse, Toulouse, France
| | - Yosra Halleb
- PhyMedExp, Institut Universitaire de Recherche Clinique, UMR_CNRS-Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France
| | - Mathilde Renaud
- Departments of Genetics and of Neurology, CHU de Nancy, Nancy, France
| | - Lise Larrieu
- PhyMedExp, Institut Universitaire de Recherche Clinique, UMR_CNRS-Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France
| | - David Baux
- PhyMedExp, Institut Universitaire de Recherche Clinique, UMR_CNRS-Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France
| | - Olivier Patat
- Department of Clinical Genetics, Purpan Hospital, CHU de Toulouse, Toulouse, France
| | - Idriss Bousquet
- Department of Medical Genetics and Reference Centre for Neurological and Neuromuscular Diseases, Croix-Rousse Hospital, Lyon, France
| | - Jean-Marie Ravel
- Departments of Genetics and of Neurology, CHU de Nancy, Nancy, France
| | - Danielle Cuntz-Shadfar
- Department of Pediatrics, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Catherine Sarret
- Department of Medical Genetics, Estaing Hospital, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Xavier Ayrignac
- Department of Neurology, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Anne Rolland
- Department of Pediatrics, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Raoul Morales
- Department of Neurology, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Morgane Pointaux
- PhyMedExp, Institut Universitaire de Recherche Clinique, UMR_CNRS-Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France
| | - Cathy Lieutard-Haag
- PhyMedExp, Institut Universitaire de Recherche Clinique, UMR_CNRS-Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France
| | - Brice Laurens
- Departement of Neurology, Groupe Hospitalier Pellegrin, CHU de Bordeaux, Institute for Neurodegenerative Diseases, CNRS-UMR, Université de Bordeaux, Bordeaux, France
| | - Caroline Tillikete
- Department of Neurology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France
| | - Emilien Bernard
- Department of Neurology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France.,Institut NeuroMyoGène, INSERM-CNRS-UMR, Université Claude Bernard, Lyon, France
| | - Martial Mallaret
- Department of Functional Explorations of the Nervous System, CHU de Grenoble, Grenoble, France
| | | | - Christine Tranchant
- Department of Neurology, Hautepierre Hospital, CHU de Strasbourg, Strasbourg, France
| | - Pierre Meyer
- Department of Pediatrics, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France.,PhyMedExp, INSERM, University of Montpellier, CNRS, Montpellier, France
| | - Lena Damaj
- Department of Clinical Genetics, Centre de Référence Maladies Rares Anomalies du Développement, CHU de Rennes, Rennes, France
| | - Laurent Pasquier
- Department of Clinical Genetics, Centre de Référence Maladies Rares Anomalies du Développement, CHU de Rennes, Rennes, France
| | - Cecile Acquaviva
- Department of Hereditary Metabolic Diseases, Centre de Biologie et Pathologie Est, CHU de Lyon et UMR, Bron, France
| | - Annabelle Chaussenot
- Department of Medical Genetics, National Centre for Mitochondrial Diseases, CHU de Nice, Nice, France
| | - Bertrand Isidor
- Department of Medical Genetics, CHU de Nantes, Nantes, France
| | - Karine Nguyen
- Department of Neurology, La Timone Hospital, CHU de Marseille, Marseille, France
| | - William Camu
- Department of Neurology, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Alexandre Eusebio
- Department of Neurology, La Timone Hospital, CHU de Marseille, Marseille, France
| | - Nicolas Carrière
- Department of Neurology, Roger Salengro Hospital, CHU de Lille, Lille, France
| | - Audrey Riquet
- Department of Pediatrics Neurology, Roger Salengro Hospital, CHU de Lille, Lille, France
| | | | - Victoria Gonzales
- Department of Neurology, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Emilie Carme
- Department of Pediatrics, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Shahram Attarian
- Department of Neurology, La Timone Hospital, CHU de Marseille, Marseille, France
| | - Sylvie Odent
- Department of Clinical Genetics, Centre de Référence Maladies Rares Anomalies du Développement, CHU de Rennes, Rennes, France
| | - Anna Castrioto
- Department of Functional Explorations of the Nervous System, CHU de Grenoble, Grenoble, France
| | - Claire Ewenczyk
- Neurogenetics Reference Centre, Hôpital de la Pitié-Salpêtrière, Assistance Publique- Hôpitaux de Paris (AP-HP), Paris, France
| | - Perrine Charles
- Neurogenetics Reference Centre, Hôpital de la Pitié-Salpêtrière, Assistance Publique- Hôpitaux de Paris (AP-HP), Paris, France
| | - Laurent Kremer
- Department of Neurology, La Timone Hospital, CHU de Marseille, Marseille, France
| | - Samira Sissaoui
- Department of Pediatrics, Hôpital Necker-Enfant Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Nadia Bahi-Buisson
- Department of Pediatrics, Hôpital Necker-Enfant Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Elsa Kaphan
- Department of Neurology, La Timone Hospital, CHU de Marseille, Marseille, France
| | - Adrian Degardin
- Department of Neurology, Roger Salengro Hospital, CHU de Lille, Lille, France
| | - Bérénice Doray
- Department of Medical Genetics, CHU de la Réunion, Saint-Denis, France
| | - Sophie Julia
- Department of Clinical Genetics, Purpan Hospital, CHU de Toulouse, Toulouse, France
| | - Ganaëlle Remerand
- Department of Neonatology, Estaing Hospital, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Valerie Fraix
- Department of Functional Explorations of the Nervous System, CHU de Grenoble, Grenoble, France
| | - Lydia Abou Haidar
- Department of Pediatrics, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Leila Lazaro
- Department of Pediatrics, CH de la Côte Basque-Bayonne, Bayonne, France
| | - Vincent Laugel
- Department of Pediatrics, Hautepierre Hospital, CHU de Strasbourg, Strasbourg, France
| | - Frederic Villega
- Department of Pediatrics, Groupe Hospitalier Pellegrin, CHU de Bordeaux; Institute for Interdisciplinary Neurosciences (IINS), CNRS -UMR, Université de Bordeaux, Bordeaux, France
| | - Cyril Charlin
- Department of Rare Neurological Diseases, CHU de la Réunion, Saint-Pierre, France
| | - Solène Frismand
- Departments of Genetics and of Neurology, CHU de Nancy, Nancy, France
| | - Marinha Costa Moreira
- Department of Pediatrics, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Tatiana Witjas
- Department of Neurology, La Timone Hospital, CHU de Marseille, Marseille, France
| | - Christine Francannet
- Department of Medical Genetics, Estaing Hospital, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Ulrike Walther-Louvier
- Department of Pediatrics, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Mélanie Fradin
- Department of Clinical Genetics, Centre de Référence Maladies Rares Anomalies du Développement, CHU de Rennes, Rennes, France
| | - Brigitte Chabrol
- Departement of Pediatrics, La Timone Hospital, CHU de Marseille, Marseille, France
| | - Joel Fluss
- Pediatric Neurology Unit, Geneva Children's Hospital, Genève, Switzerland
| | - Eric Bieth
- Department of Clinical Genetics, Purpan Hospital, CHU de Toulouse, Toulouse, France
| | | | - Sylvain Vergnet
- Departement of Neurology, Groupe Hospitalier Pellegrin, CHU de Bordeaux, Institute for Neurodegenerative Diseases, CNRS-UMR, Université de Bordeaux, Bordeaux, France
| | - Isabelle Meunier
- INSERM, Institut des Neurosciences de Montpellier, Montpellier, France.,Genetics of Sensory Diseases, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Alain Verloes
- Federation of Genetics, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Elise Brischoux-Boucher
- Department of Medical Genetics, Hôpital Saint-Jacques, CHU de Besançon, Centre de Génétique Humaine, Université de Franche-Comté, Besançon, France
| | - Christine Coubes
- Department of Medical Genetics, Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France
| | - David Geneviève
- Department of Medical Genetics, Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France
| | - Nicolas Lebouc
- Department of Neuroradiology, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Jean Phillipe Azulay
- Department of Neurology, La Timone Hospital, CHU de Marseille, Marseille, France
| | - Mathieu Anheim
- Department of Neurology, Hautepierre Hospital, CHU de Strasbourg, Strasbourg, France
| | - Cyril Goizet
- Department of Medical Genetics, Pellegrin Hospital, CHU de Bordeaux, Bordeaux, France
| | - François Rivier
- Department of Pediatrics, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France.,PhyMedExp, INSERM, University of Montpellier, CNRS, Montpellier, France
| | - Pierre Labauge
- Department of Neurology, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France
| | - Patrick Calvas
- Department of Clinical Genetics, Purpan Hospital, CHU de Toulouse, Toulouse, France
| | - Michel Koenig
- PhyMedExp, Institut Universitaire de Recherche Clinique, UMR_CNRS-Université de Montpellier, INSERM, CHU de Montpellier, Montpellier, France.
| |
Collapse
|
34
|
Héron B, Billette de Villemeur T, Dufaure Garé I, Brassier A, Chabrol B, Pichard S, Feillet F, Guemann A, Barth M, Tardieu M, Nadjar Y, Belmatoug N, Sacaze E, Roubertie A, Cador B, Beze-Beyrie P, Klising E, Guéguen S, Amselem S. Étude des mucopolysaccharidoses en France : constitution de la cohorte RaDiCo-MPS. Rev Epidemiol Sante Publique 2021. [DOI: 10.1016/j.respe.2021.05.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
35
|
Mengel E, Bembi B, Del Toro M, Deodato F, Gautschi M, Grunewald S, Grønborg S, Héron B, Maier EM, Roubertie A, Santra S, Tylki-Szymanska A, Day S, Symonds T, Hudgens S, Patterson MC, Guldberg C, Ingemann L, Petersen NHT, Kirkegaard T, Dali CÍ. Correction to: Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study. Orphanet J Rare Dis 2021; 16:246. [PMID: 34074315 PMCID: PMC8168003 DOI: 10.1186/s13023-021-01855-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Affiliation(s)
- Eugen Mengel
- SphinCS GmbH, Institute of Clinical Science for LSD, Hochheim, Germany.
| | - Bruno Bembi
- Regional Coordinator Centre for Rare Diseases, Academic Hospital Santa Maria Della Misericordia, Udine, Italy
| | | | | | | | - Stephanie Grunewald
- Metabolic Department, Great Ormond Street Hospital NHS Foundation Trust, Institute for Child Health, NIHR Biomedical Research Centre UCL, London, UK
| | - Sabine Grønborg
- Centre for Inherited Metabolic Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark
| | - Bénédicte Héron
- Reference Centre for Lysosomal Disease, Trousseau University Hospital, Paris, France
| | - Esther M Maier
- Dr. Von Hauner Children's Hospital, University of Munich, Munich, Germany
| | - Agathe Roubertie
- Institute of Neurosciences, University Hospital of Montpellier, Montpellier, France
| | | | | | - Simon Day
- Clinical Trials Consulting and Training Limited, Buckingham, UK
| | - Tara Symonds
- Clinical Outcomes Solutions Limited, Folkestone, UK
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Gueguen N, Piarroux J, Sarzi E, Benkirane M, Manes G, Delettre C, Amedro P, Leboucq N, Koenig M, Meyer P, Meunier I, Reynier P, Lenaers G, Roubertie A. Optic neuropathy linked to ACAD9 pathogenic variants: A potentially riboflavin-responsive disorder? Mitochondrion 2021; 59:169-174. [PMID: 34023438 DOI: 10.1016/j.mito.2021.05.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 05/19/2021] [Accepted: 05/19/2021] [Indexed: 12/14/2022]
Abstract
Mitochondrial complex I (CI) deficiencies (OMIM 252010) are the commonest inherited mitochondrial disorders in children. Acyl-CoA dehydrogenase 9 (ACAD9) is a flavoenzyme involved chiefly in CI assembly and possibly in fatty acid oxidation. Biallelic pathogenic variants result in CI dysfunction, with a phenotype ranging from early onset and sometimes fatal mitochondrial encephalopathy with lactic acidosis to late-onset exercise intolerance. Cardiomyopathy is often associated. We report a patient with childhood-onset optic and peripheral neuropathy without cardiac involvement, related to CI deficiency. Genetic analysis revealed compound heterozygous pathogenic variants in ACAD9, expanding the clinical spectrum associated to ACAD9 mutations. Importantly, riboflavin treatment (15 mg/kg/day) improved long-distance visual acuity and demonstrated significant rescue of CI activity in vitro.
Collapse
Affiliation(s)
- Naig Gueguen
- Department of Biochemistry and Molecular Biology, CHU Angers, 49933 Angers, France; University of Angers, Unité Mixte de Recherche (UMR) MITOVASC, Centre National de la Recherche Scientifique (CNRS) 6015, Institut National de la Santé et de la Recherche Médicale (INSERM) U1083, 49933 Angers, France
| | - Julie Piarroux
- CHU Montpellier, Département de Neuropédiatrie, Montpellier, France
| | - Emmanuelle Sarzi
- NeuroMyoGene Institute-UCBL/CNRS UMR5310/INSERM U1217-Lyon, France
| | - Mehdi Benkirane
- PhyMedExp, CNRS, INSERM, University of Montpellier, Montpellier, France; Laboratoire de Génétique Moléculaire, Institut Universitaire de Recherche Clinique, CHU de Montpellier, France
| | - Gael Manes
- INM, University Montpellier, INSERM, Montpellier, France
| | | | - Pascal Amedro
- PhyMedExp, CNRS, INSERM, University of Montpellier, Montpellier, France; Pediatric and Adult Congenital Cardiology Department, M3C Rare Cardiac Disease Reference Center, CHU Montpellier, France
| | - Nicolas Leboucq
- Département de Neuroradiologie, CHU Montpellier, Montpellier, France
| | - Michel Koenig
- PhyMedExp, CNRS, INSERM, University of Montpellier, Montpellier, France; Laboratoire de Génétique Moléculaire, Institut Universitaire de Recherche Clinique, CHU de Montpellier, France
| | - Pierre Meyer
- CHU Montpellier, Département de Neuropédiatrie, Montpellier, France; PhyMedExp, CNRS, INSERM, University of Montpellier, Montpellier, France
| | - Isabelle Meunier
- National Center in Rare Diseases, Genetics of Sensory Diseases, University Hospital, Montpellier, France
| | - Pascal Reynier
- Department of Biochemistry and Molecular Biology, CHU Angers, 49933 Angers, France; University of Angers, Unité Mixte de Recherche (UMR) MITOVASC, Centre National de la Recherche Scientifique (CNRS) 6015, Institut National de la Santé et de la Recherche Médicale (INSERM) U1083, 49933 Angers, France
| | - Guy Lenaers
- University of Angers, Unité Mixte de Recherche (UMR) MITOVASC, Centre National de la Recherche Scientifique (CNRS) 6015, Institut National de la Santé et de la Recherche Médicale (INSERM) U1083, 49933 Angers, France
| | - Agathe Roubertie
- CHU Montpellier, Département de Neuropédiatrie, Montpellier, France; INM, University Montpellier, INSERM, Montpellier, France; National Center in Rare Diseases, Genetics of Sensory Diseases, University Hospital, Montpellier, France.
| |
Collapse
|
37
|
Tebani A, Sudrié-Arnaud B, Dabaj I, Torre S, Domitille L, Snanoudj S, Heron B, Levade T, Caillaud C, Vergnaud S, Saugier-Veber P, Coutant S, Dranguet H, Froissart R, Al Khouri M, Alembik Y, Baruteau J, Arnoux JB, Brassier A, Brehin AC, Busa T, Cano A, Chabrol B, Coubes C, Desguerre I, Doco-Fenzy M, Drenou B, Elcioglu NH, Elsayed S, Fouilhoux A, Poirsier C, Goldenberg A, Jouvencel P, Kuster A, Labarthe F, Lazaro L, Pichard S, Rivera S, Roche S, Roggerone S, Roubertie A, Sigaudy S, Spodenkiewicz M, Tardieu M, Vanhulle C, Marret S, Bekri S. Disentangling molecular and clinical stratification patterns in beta-galactosidase deficiency. J Med Genet 2021; 59:377-384. [PMID: 33737400 DOI: 10.1136/jmedgenet-2020-107510] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 01/16/2021] [Accepted: 01/19/2021] [Indexed: 11/04/2022]
Abstract
INTRODUCTION This study aims to define the phenotypic and molecular spectrum of the two clinical forms of β-galactosidase (β-GAL) deficiency, GM1-gangliosidosis and mucopolysaccharidosis IVB (Morquio disease type B, MPSIVB). METHODS Clinical and genetic data of 52 probands, 47 patients with GM1-gangliosidosis and 5 patients with MPSIVB were analysed. RESULTS The clinical presentations in patients with GM1-gangliosidosis are consistent with a phenotypic continuum ranging from a severe antenatal form with hydrops fetalis to an adult form with an extrapyramidal syndrome. Molecular studies evidenced 47 variants located throughout the sequence of the GLB1 gene, in all exons except 7, 11 and 12. Eighteen novel variants (15 substitutions and 3 deletions) were identified. Several variants were linked specifically to early-onset GM1-gangliosidosis, late-onset GM1-gangliosidosis or MPSIVB phenotypes. This integrative molecular and clinical stratification suggests a variant-driven patient assignment to a given clinical and severity group. CONCLUSION This study reports one of the largest series of b-GAL deficiency with an integrative patient stratification combining molecular and clinical features. This work contributes to expand the community knowledge regarding the molecular and clinical landscapes of b-GAL deficiency for a better patient management.
Collapse
Affiliation(s)
- Abdellah Tebani
- Department of Metabolic Biochemistry, Rouen University Hospital, Rouen, France.,Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | | | - Ivana Dabaj
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France.,Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, Rouen, France
| | - Stéphanie Torre
- Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, Rouen, France
| | - Laur Domitille
- Pediatric Neurology Department, Robert Debré Hospital, Public Hospital Network of Paris, Paris, France
| | - Sarah Snanoudj
- Department of Metabolic Biochemistry, Rouen University Hospital, Rouen, France.,Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Benedicte Heron
- Reference Center for Lysosomal Diseases, Pediatric Neurology Department, UH Armand Trousseau-La Roche Guyon, APHP, GUEP, Paris, France
| | - Thierry Levade
- Laboratoire de Biochimie Métabolique, Institut Fédératif de Biologie, CHU Purpan, Toulouse, France.,Cancer Research Center, INSERM UMR1037 CRCT, Toulouse, France
| | - Catherine Caillaud
- Biochemistry, Metabolomic and Proteomic Department, Necker Enfants Malades University Hospital, Assistance Publique Hôpitaux de Paris, UMRS 1151, INSERM, Institute Necker Enfants Malades, Paris Descartes University, Paris, France
| | - Sabrina Vergnaud
- UF Maladies Héréditaires Enzymatiques Rares-CGD, Institut de Biologie et de Pathologies, CHU de Grenoble Alpes, Grenoble, France
| | - Pascale Saugier-Veber
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Sophie Coutant
- Department of Genetics, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F76000, Normandy Centre for Genomic and Personalized Medicine, ROUEN, France
| | - Hélène Dranguet
- Department of Metabolic Biochemistry, Rouen University Hospital, Rouen, France
| | - Roseline Froissart
- Biochemical and Molecular Biology Department, Centre de Biologie et de Pathologie Est Hospices Civils de Lyon, Lyon, France
| | - Majed Al Khouri
- Department of Pediatric Gastroenterology, hepatology and Nutrition, University hospital of Montpellier, Montpellier, France
| | - Yves Alembik
- Department of Clinical Genetic, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Julien Baruteau
- Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street Institute of Child Health, University College London, London, UK
| | - Jean-Baptiste Arnoux
- Department of Inherited Metabolic Disease, Necker-Enfants Malades University Hospital, AP-HP, Paris, France
| | - Anais Brassier
- Reference Center of Inherited Metabolic Diseases, Necker Enfants Malades Hospital, Imagine Institute, University Paris Descartes, Paris, France
| | - Anne-Claire Brehin
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Tiffany Busa
- Département de Génétique Médicale, Hôpital Timone Enfant, Marseille, France
| | - Aline Cano
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neuropédiatrie, CHU La Timone Enfants, APHM, Marseille, France
| | - Brigitte Chabrol
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neuropédiatrie, CHU La Timone Enfants, APHM, Marseille, France
| | - Christine Coubes
- Genetic Services, A. de Villeneuve Hospital, Montpellier, France
| | - Isabelle Desguerre
- Department of Paediatric Neurology, Hopital universitaire Necker-Enfants malades Service de Pediatrie generale, Paris, Île-de-France, France
| | - Martine Doco-Fenzy
- Service de génétique, CHRU Reims, Reims, France.,EA3801, UFR médecine, France
| | - Bernard Drenou
- Department of Hematolog, Hôpital Emile Muller - CH de Mulhouse, Mulhouse, France
| | - Nursel H Elcioglu
- Pediatric Genetics, Marmara University Medical School, Istanbul, Turkey
| | - Solaf Elsayed
- Genetics, Children's Hospital, Ain Shams University, Cairo, Egypt
| | - Alain Fouilhoux
- Department of Pediatric Metabolism, Reference Center of Inherited Metabolic Disorders, Femme Mère Enfant Hospital, Lyon, France
| | - Céline Poirsier
- Genetic department, CHU-Reims, EA3801, SFR CAP santé, Reims, France
| | - Alice Goldenberg
- Department of Genetics, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F76000, Normandy Centre for Genomic and Personalized Medicine, ROUEN, France
| | - Philippe Jouvencel
- Department of Neonatology and Paediatrics, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - Alice Kuster
- Pediatric Critical Care Unit, Femme-Enfants-Adolescents Hospital, Nantes University, Nantes, France
| | | | - Leila Lazaro
- Department of Neonatology and Paediatrics, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - Samia Pichard
- Reference Centre for Inborn Errors of Metabolism, Robert-Debré University Hospital, APHP, Paris, France
| | - Serge Rivera
- Department of Neonatology and Paediatrics, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - Sandrine Roche
- Department of Pediatrics, Bordeaux University Hospital, Bordeaux, France
| | | | - Agathe Roubertie
- INSERM U 1051, Institut des Neurosciences de Montpellier, Montpellier, Hérault, France.,Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France
| | - Sabine Sigaudy
- Genetics, Hôpital d'Enfants de la Timone, Marseille, France
| | | | - Marine Tardieu
- Department of Pediatrics, Reference Center of Inherited Metabolic Disorders, Clocheville Hospital, Tours, France
| | - Catherine Vanhulle
- Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, Rouen, France
| | - Stéphane Marret
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France.,Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, Rouen, France
| | - Soumeya Bekri
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France .,Department of Metabolic Biochemistry, University Hospital Centre Rouen, Rouen, Normandie, France
| |
Collapse
|
38
|
Cif L, Demailly D, Lin JP, Barwick KE, Sa M, Abela L, Malhotra S, Chong WK, Steel D, Sanchis-Juan A, Ngoh A, Trump N, Meyer E, Vasques X, Rankin J, Allain MW, Applegate CD, Attaripour Isfahani S, Baleine J, Balint B, Bassetti JA, Baple EL, Bhatia KP, Blanchet C, Burglen L, Cambonie G, Seng EC, Bastaraud SC, Cyprien F, Coubes C, d'Hardemare V, Doja A, Dorison N, Doummar D, Dy-Hollins ME, Farrelly E, Fitzpatrick DR, Fearon C, Fieg EL, Fogel BL, Forman EB, Fox RG, Gahl WA, Galosi S, Gonzalez V, Graves TD, Gregory A, Hallett M, Hasegawa H, Hayflick SJ, Hamosh A, Hully M, Jansen S, Jeong SY, Krier JB, Krystal S, Kumar KR, Laurencin C, Lee H, Lesca G, François LL, Lynch T, Mahant N, Martinez-Agosto JA, Milesi C, Mills KA, Mondain M, Morales-Briceno H, Ostergaard JR, Pal S, Pallais JC, Pavillard F, Perrigault PF, Petersen AK, Polo G, Poulen G, Rinne T, Roujeau T, Rogers C, Roubertie A, Sahagian M, Schaefer E, Selim L, Selway R, Sharma N, Signer R, Soldatos AG, Stevenson DA, Stewart F, Tchan M, Verma IC, de Vries BBA, Wilson JL, Wong DA, Zaitoun R, Zhen D, Znaczko A, Dale RC, de Gusmão CM, Friedman J, Fung VSC, King MD, Mohammad SS, Rohena L, Waugh JL, Toro C, Raymond FL, Topf M, Coubes P, Gorman KM, Kurian MA. KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation. Brain 2021; 143:3242-3261. [PMID: 33150406 DOI: 10.1093/brain/awaa304] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Revised: 06/28/2020] [Accepted: 07/13/2020] [Indexed: 12/31/2022] Open
Abstract
Heterozygous mutations in KMT2B are associated with an early-onset, progressive and often complex dystonia (DYT28). Key characteristics of typical disease include focal motor features at disease presentation, evolving through a caudocranial pattern into generalized dystonia, with prominent oromandibular, laryngeal and cervical involvement. Although KMT2B-related disease is emerging as one of the most common causes of early-onset genetic dystonia, much remains to be understood about the full spectrum of the disease. We describe a cohort of 53 patients with KMT2B mutations, with detailed delineation of their clinical phenotype and molecular genetic features. We report new disease presentations, including atypical patterns of dystonia evolution and a subgroup of patients with a non-dystonic neurodevelopmental phenotype. In addition to the previously reported systemic features, our study has identified co-morbidities, including the risk of status dystonicus, intrauterine growth retardation, and endocrinopathies. Analysis of this study cohort (n = 53) in tandem with published cases (n = 80) revealed that patients with chromosomal deletions and protein truncating variants had a significantly higher burden of systemic disease (with earlier onset of dystonia) than those with missense variants. Eighteen individuals had detailed longitudinal data available after insertion of deep brain stimulation for medically refractory dystonia. Median age at deep brain stimulation was 11.5 years (range: 4.5-37.0 years). Follow-up after deep brain stimulation ranged from 0.25 to 22 years. Significant improvement of motor function and disability (as assessed by the Burke Fahn Marsden's Dystonia Rating Scales, BFMDRS-M and BFMDRS-D) was evident at 6 months, 1 year and last follow-up (motor, P = 0.001, P = 0.004, and P = 0.012; disability, P = 0.009, P = 0.002 and P = 0.012). At 1 year post-deep brain stimulation, >50% of subjects showed BFMDRS-M and BFMDRS-D improvements of >30%. In the long-term deep brain stimulation cohort (deep brain stimulation inserted for >5 years, n = 8), improvement of >30% was maintained in 5/8 and 3/8 subjects for the BFMDRS-M and BFMDRS-D, respectively. The greatest BFMDRS-M improvements were observed for trunk (53.2%) and cervical (50.5%) dystonia, with less clinical impact on laryngeal dystonia. Improvements in gait dystonia decreased from 20.9% at 1 year to 16.2% at last assessment; no patient maintained a fully independent gait. Reduction of BFMDRS-D was maintained for swallowing (52.9%). Five patients developed mild parkinsonism following deep brain stimulation. KMT2B-related disease comprises an expanding continuum from infancy to adulthood, with early evidence of genotype-phenotype correlations. Except for laryngeal dysphonia, deep brain stimulation provides a significant improvement in quality of life and function with sustained clinical benefit depending on symptoms distribution.
Collapse
Affiliation(s)
- Laura Cif
- Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France.,Faculté de médecine, Université de Montpellier, France
| | - Diane Demailly
- Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France.,Faculté de médecine, Université de Montpellier, France
| | - Jean-Pierre Lin
- Complex Motor Disorder Service, Children's Neurosciences Department, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.,Children's Neuromodulation Group, Women and Children's Health Institute, Faculty of life Sciences and Medicine (FOLSM), King's Health Partners, London, UK
| | - Katy E Barwick
- Molecular Neurosciences, Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK
| | - Mario Sa
- Complex Motor Disorder Service, Children's Neurosciences Department, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - Lucia Abela
- Molecular Neurosciences, Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK
| | - Sony Malhotra
- Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, University of London, London, UK
| | - Wui K Chong
- Developmental Imaging and Biophysics, UCL Great Ormond Street Institute of Child Health, London, UK
| | - Dora Steel
- Molecular Neurosciences, Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK.,Department of Neurology, Great Ormond Street Hospital, London, UK
| | - Alba Sanchis-Juan
- NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.,Department of Haematology, NHS Blood and Transplant Centre, University of Cambridge, Cambridge, UK
| | - Adeline Ngoh
- Molecular Neurosciences, Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK.,Department of Neurology, Great Ormond Street Hospital, London, UK
| | - Natalie Trump
- Molecular Neurosciences, Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK
| | - Esther Meyer
- Molecular Neurosciences, Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK
| | | | - Julia Rankin
- Clinical Genetics, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
| | - Meredith W Allain
- Division of Medical Genetics, Department of Pediatrics, Stanford University, Palo Alto, CA, USA
| | - Carolyn D Applegate
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Sanaz Attaripour Isfahani
- Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
| | - Julien Baleine
- Unité de Soins Intensifs et Réanimation Pédiatrique et Néonatale, Hôpital Universitaire de Montpellier, Montpellier, France
| | - Bettina Balint
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.,Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany
| | - Jennifer A Bassetti
- Division of Medical Genetics, Department of Pediatrics, Weill Cornell Medical College, New York, NY, USA
| | - Emma L Baple
- Clinical Genetics, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.,Institute of Biomedical and Clinical Science RILD Wellcome Wolfson Centre, University of Exeter Medical School, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
| | - Kailash P Bhatia
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
| | - Catherine Blanchet
- Département d'Oto-Rhino-Laryngologie et Chirurgie Cervico-Faciale, Hôpital Universitaire de Montpellier, Montpellier, France
| | - Lydie Burglen
- Département de génétique médicale, APHP Hôpital Armand Trousseau, Paris, France
| | - Gilles Cambonie
- Unité de Soins Intensifs et Réanimation Pédiatrique et Néonatale, Hôpital Universitaire de Montpellier, Montpellier, France
| | - Emilie Chan Seng
- Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France.,Faculté de médecine, Université de Montpellier, France
| | | | - Fabienne Cyprien
- Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France.,Faculté de médecine, Université de Montpellier, France
| | - Christine Coubes
- Département de Génétique médicale, Maladies rares et médecine personnalisée, CHU Montpellier, Montpellier, France
| | - Vincent d'Hardemare
- Unité Dyspa, Neurochirurgie Pédiatrique, Hôpital Fondation Rothschild, Paris, France
| | | | - Asif Doja
- Division of Neurology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada
| | - Nathalie Dorison
- Unité Dyspa, Neurochirurgie Pédiatrique, Hôpital Fondation Rothschild, Paris, France
| | - Diane Doummar
- Neuropédiatrie, Centre de référence neurogénétique mouvement anormaux de l'enfant, Hôpital Armand Trousseau, AP-HP, Sorbonne Université, France
| | - Marisela E Dy-Hollins
- Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.,Department of Neurology, Harvard Medical School, Boston, MA, USA
| | - Ellyn Farrelly
- Division of Medical Genetics, Department of Pediatrics, Stanford University, Palo Alto, CA, USA.,Department of Pediatrics, Lucile Packard Children's Hospital at Stanford, CA, USA
| | - David R Fitzpatrick
- Human Genetics Unit, Medical and Developmental Genetics, University of Edinburgh Western General Hospital, Edinburgh, Scotland, UK
| | - Conor Fearon
- Department of Neurology, The Dublin Neurological Institute at the Mater Misericordiae University Hospital, Dublin, Ireland
| | - Elizabeth L Fieg
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Brent L Fogel
- Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.,Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | - Eva B Forman
- Department of Paediatric Neurology and Clinical Neurophysiology, Children's Health Ireland at Temple Street, Dublin, Ireland
| | - Rachel G Fox
- Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, USA
| | | | - William A Gahl
- Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Serena Galosi
- Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy
| | - Victoria Gonzalez
- Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France.,Faculté de médecine, Université de Montpellier, France
| | - Tracey D Graves
- Department of Neurology, Hinchingbrooke Hospital, North West Anglia NHS Foundation Trust, Huntingdon, UK
| | - Allison Gregory
- Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, USA
| | - Mark Hallett
- Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
| | - Harutomo Hasegawa
- Complex Motor Disorder Service, Children's Neurosciences Department, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.,Children's Neuromodulation Group, Women and Children's Health Institute, Faculty of life Sciences and Medicine (FOLSM), King's Health Partners, London, UK
| | - Susan J Hayflick
- Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, USA.,Department of Paediatrics, Oregon Health and Science University, Portland, OR, USA
| | - Ada Hamosh
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Marie Hully
- Département de Neurologie, APHP-Necker-Enfants Malades, Paris, France
| | - Sandra Jansen
- Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Suh Young Jeong
- Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, USA
| | - Joel B Krier
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Sidney Krystal
- Département de Neuroradiologie, Hôpital Fondation Rothschild, Paris
| | - Kishore R Kumar
- Translational Genomics Group, Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.,Department of Neurogenetics, Kolling Institute, University of Sydney and Royal North Shore Hospital, St Leonards, NSW, Australia.,Molecular Medicine Laboratory, Concord Hospital, Sydney, NSW, Australia
| | - Chloé Laurencin
- Département de Neurologie, Hôpital Neurologique Pierre Wertheimer, Lyon, France
| | - Hane Lee
- Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.,Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | - Gaetan Lesca
- Département de Génétique, Hôpital Universitaire de Lyon, Lyon, France
| | | | - Timothy Lynch
- Department of Neurology, The Dublin Neurological Institute at the Mater Misericordiae University Hospital, Dublin, Ireland.,UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
| | - Neil Mahant
- Movement Disorders Unit, Department of Neurology, Westmead Hospital, Westmead, NSW, Australia
| | - Julian A Martinez-Agosto
- Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.,Division of Medical Genetics, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | - Christophe Milesi
- Unité de Soins Intensifs et Réanimation Pédiatrique et Néonatale, Hôpital Universitaire de Montpellier, Montpellier, France
| | - Kelly A Mills
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Michel Mondain
- Département d'Oto-Rhino-Laryngologie et Chirurgie Cervico-Faciale, Hôpital Universitaire de Montpellier, Montpellier, France
| | - Hugo Morales-Briceno
- Movement Disorders Unit, Department of Neurology, Westmead Hospital, Westmead, NSW, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, Australia
| | | | - John R Ostergaard
- Centre for Rare Diseases, Aarhus University Hospital, Aarhus, Denmark
| | - Swasti Pal
- Institute of Genetics and Genomics, Sir Ganga Ram Hospital, Rajender Nagar, New Delhi, India
| | - Juan C Pallais
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Frédérique Pavillard
- Département d'Anesthésie-Réanimation Gui de Chauliac, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Pierre-Francois Perrigault
- Département d'Anesthésie-Réanimation Gui de Chauliac, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | | | - Gustavo Polo
- Département de Neurochirurgie Fonctionnelle, Hôpital Neurologique et Neurochirurgical, Pierre Wertheimer, Lyon, France
| | - Gaetan Poulen
- Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France.,Faculté de médecine, Université de Montpellier, France
| | - Tuula Rinne
- Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Thomas Roujeau
- Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France
| | - Caleb Rogers
- Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, USA
| | - Agathe Roubertie
- Département de Neuropédiatrie, Hôpital Universitaire de Montpellier, Montpellier, France.,INSERM U1051, Institut des Neurosciences de Montpellier, Montpellier, France
| | - Michelle Sahagian
- Division of Neurology, Rady Children's Hospital San Diego, CA, USA.,Department of Neuroscience, University of California San Diego, CA, USA
| | - Elise Schaefer
- Medical Genetics, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Laila Selim
- Cairo University Children Hospital, Pediatric Neurology and Metabolic division, Cairo, Egypt
| | - Richard Selway
- Department of Neurosurgery, King's College Hospital, London, UK
| | - Nutan Sharma
- Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.,Department of Neurology, Harvard Medical School, Boston, MA, USA.,Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA
| | - Rebecca Signer
- Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | - Ariane G Soldatos
- Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - David A Stevenson
- Division of Medical Genetics, Department of Pediatrics, Stanford University, Palo Alto, CA, USA
| | - Fiona Stewart
- Department of Genetic Medicine, Belfast Health and Social Care Trust, Belfast, UK
| | - Michel Tchan
- Sydney Medical School, University of Sydney, Sydney, NSW, Australia.,Department of Genetics, Westmead Hospital, Westmead, NSW, Australia
| | | | - Ishwar C Verma
- Institute of Genetics and Genomics, Sir Ganga Ram Hospital, Rajender Nagar, New Delhi, India
| | - Bert B A de Vries
- Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Jenny L Wilson
- Division of Pediatric Neurology, Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA
| | - Derek A Wong
- Division of Medical Genetics, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | - Raghda Zaitoun
- Department of Paediatrics, Neurology Division, Ain Shams University Hospital, Cairo, Egypt
| | - Dolly Zhen
- Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, USA
| | - Anna Znaczko
- Department of Genetic Medicine, Belfast Health and Social Care Trust, Belfast, UK
| | - Russell C Dale
- Department of Paediatric Neurology, The Children's Hospital at Westmead, NSW, Australia.,Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney NSW, Australia
| | - Claudio M de Gusmão
- Department of Neurology, Harvard Medical School, Boston, MA, USA.,Department of Neurology, Boston Children's Hospital, Boston, MA, USA
| | - Jennifer Friedman
- Division of Neurology, Rady Children's Hospital San Diego, CA, USA.,Department of Neuroscience, University of California San Diego, CA, USA.,Departments of Paediatrics, University of California, San Diego, CA, USA.,Rady Children's Institute for Genomic Medicine, San Diego, CA, USA
| | - Victor S C Fung
- Movement Disorders Unit, Department of Neurology, Westmead Hospital, Westmead, NSW, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, Australia
| | - Mary D King
- Department of Paediatric Neurology and Clinical Neurophysiology, Children's Health Ireland at Temple Street, Dublin, Ireland.,UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
| | - Shekeeb S Mohammad
- Department of Paediatric Neurology, The Children's Hospital at Westmead, NSW, Australia.,Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney NSW, Australia
| | - Luis Rohena
- Division of Medical Genetics, Department of Pediatrics, San Antonio Military Medical Center, San Antonio, TX, USA.,Department of Pediatrics, Long School of Medicine, UT Health, San Antonio, TX, USA
| | - Jeff L Waugh
- Division of Pediatric Neurology, Department of Pediatrics, University of Texas Southwestern, Dallas, TX, USA
| | - Camilo Toro
- Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - F Lucy Raymond
- NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.,Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
| | - Maya Topf
- Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, University of London, London, UK
| | - Philippe Coubes
- Département de Neurochirurgie, Unité des Pathologies Cérébrales Résistantes, Unité de Recherche sur les Comportements et Mouvements Anormaux, Hôpital Gui de Chauliac, Centre Hospitalier Régional Montpellier, Montpellier, France.,Faculté de médecine, Université de Montpellier, France
| | - Kathleen M Gorman
- Molecular Neurosciences, Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK.,Department of Neurology, Great Ormond Street Hospital, London, UK
| | - Manju A Kurian
- Molecular Neurosciences, Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK.,Department of Neurology, Great Ormond Street Hospital, London, UK
| |
Collapse
|
39
|
Gur-Hartman T, Berkowitz O, Yosovich K, Roubertie A, Zanni G, Macaya A, Heimer G, Dueñas BP, Sival DA, Pode-Shakked B, López-Laso E, Humbertclaude V, Riant F, Bosco L, Cayron LB, Nissenkorn A, Nicita F, Bertini E, Hassin S, Ben Zeev B, Zerem A, Libzon S, Lev D, Linder I, Lerman-Sagie T, Blumkin L. Clinical phenotypes of infantile onset CACNA1A-related disorder. Eur J Paediatr Neurol 2021; 30:144-154. [PMID: 33349592 DOI: 10.1016/j.ejpn.2020.10.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Revised: 10/11/2020] [Accepted: 10/14/2020] [Indexed: 12/27/2022]
Abstract
BACKGROUND CACNA1A-related disorders present with persistent progressive and non-progressive cerebellar ataxia and paroxysmal events: epileptic seizures and non-epileptic attacks. These phenotypes overlap and co-exist in the majority of patients. OBJECTIVE To describe phenotypes in infantile onset CACNA1A-related disorder and to explore intra-familial variations and genotype-phenotype correlations. MATERIAL AND METHODS This study was a multicenter international collaboration. A retrospective chart review of CACNA1A patients was performed. Clinical, radiological, and genetic data were collected and analyzed in 47 patients with infantile-onset disorder. RESULTS Paroxysmal non-epileptic events (PNEE) were observed in 68% of infants, with paroxysmal tonic upward gaze (PTU) noticed in 47% of infants. Congenital cerebellar ataxia (CCA) was diagnosed in 51% of patients including four patients with developmental delay and only one neurological sign. PNEEs were found in 63% of patients at follow-up, with episodic ataxia (EA) in 40% of the sample. Cerebellar ataxia was found in 58% of the patients at follow-up. Four patients had epilepsy in infancy and nine in childhood. Seven infants had febrile convulsions, three of which developed epilepsy later; all three patients had CCA. Cognitive difficulties were demonstrated in 70% of the children. Cerebellar atrophy was found in only one infant but was depicted in 64% of MRIs after age two. CONCLUSIONS Nearly all of the infants had CCA, PNEE or both. Cognitive difficulties were frequent and appeared to be associated with CCA. Epilepsy was more frequent after age two. Febrile convulsions in association with CCA may indicate risk of epilepsy in later childhood. Brain MRI was normal in infancy. There were no genotype-phenotype correlations found.
Collapse
Affiliation(s)
- Tamar Gur-Hartman
- Pediatric Neurology Unit, Wolfson Medical Center, Holon, Israel; Pediatric Movement Disorders Service, Wolfson Medical Center, Holon, Israel; School of Psychological Sciences, Tel-Aviv University, Israel
| | - Oren Berkowitz
- Department of Health Systems Management, Ariel University, Ariel, Israel
| | - Keren Yosovich
- Molecular Genetics Laboratory, Wolfson Medical Center, Holon, Israel
| | - Agathe Roubertie
- Departement de Neuropediatrie, CHU Gui de Chauliac, Institut des Neurosciences de Montpellier, Montpellier, France
| | - Ginevra Zanni
- Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, IRCCS Bambino Gesu' Children's Hospital, Rome, Italy
| | - Alfons Macaya
- Vall d'Hebron Research Institute, Pediatric Neurology Research Group, Autonomous University of Barcelona, Barcelona, Spain
| | - Gali Heimer
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Pediatric Neurology Unit, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Belén Pérez Dueñas
- Vall d'Hebron Research Institute, Pediatric Neurology Research Group, Autonomous University of Barcelona, Barcelona, Spain
| | - Deborah A Sival
- Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Ben Pode-Shakked
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; The Institute for Rare Diseases, Edmond and Lily Safra Children's Hospital; Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan, Israel
| | - Eduardo López-Laso
- University Hospital Reina Sofía, Pediatric Neurology Unit, IMIBIC and CIBERER, Córdoba, Spain
| | - Véronique Humbertclaude
- Service de Médecine Psychologique Enfants et Adolescents, CHU Saint Eloi, Montpellier, France
| | - Florence Riant
- AP-HP, GH Saint Louis-Lariboisière-Fernand Widal, Service de Génétique Moléculaire Neurovasculaire, Paris, France
| | - Luca Bosco
- Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, IRCCS Bambino Gesu' Children's Hospital, Rome, Italy
| | | | - Andreea Nissenkorn
- Pediatric Neurology Unit, Wolfson Medical Center, Holon, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Francesco Nicita
- Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, IRCCS Bambino Gesu' Children's Hospital, Rome, Italy
| | - Enrico Bertini
- Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, IRCCS Bambino Gesu' Children's Hospital, Rome, Italy
| | - Sharon Hassin
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Movement Disorders Institute and Department of Neurology, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Bruria Ben Zeev
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Pediatric Neurology Unit, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - Ayelet Zerem
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Pediatric Neurology Unit TASMC, Tel-Aviv University, Israel
| | | | - Dorit Lev
- Molecular Genetics Laboratory, Wolfson Medical Center, Holon, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Institute of Medical Genetics, Wolfson Medical Center, Holon, Israel
| | - Ilan Linder
- Pediatric Epilepsy & Neurology Service, Barzilay Medical Center, Ashkelon, Israel
| | - Tally Lerman-Sagie
- Pediatric Neurology Unit, Wolfson Medical Center, Holon, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Lubov Blumkin
- Pediatric Neurology Unit, Wolfson Medical Center, Holon, Israel; Pediatric Movement Disorders Service, Wolfson Medical Center, Holon, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
| |
Collapse
|
40
|
Gibaud M, Barth M, Lefranc J, Mention K, Villeneuve N, Schiff M, Maurey H, Barthez MA, Caubel I, Chouchane M, Doummar D, Kossorotoff M, Lamblin MD, Roubertie A, Nabbout R, Van Bogaert P. West Syndrome Is an Exceptional Presentation of Pyridoxine- and Pyridoxal Phosphate-Dependent Epilepsy: Data From a French Cohort and Review of the Literature. Front Pediatr 2021; 9:621200. [PMID: 33748042 PMCID: PMC7973036 DOI: 10.3389/fped.2021.621200] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Accepted: 01/04/2021] [Indexed: 12/04/2022] Open
Abstract
Objective: To characterize the electro-clinical presentation of patients with pyridoxine-dependent epilepsy (PDE) and pyridoxal phosphate (PLP)-dependent epilepsy in order to determine whether some of them could be diagnosed as de novo West syndrome, i. e., West syndrome that starts after the age of 2 months without other types of seizures (focal seizures for instance) before the onset of epileptic spasms. Methods: We analyzed data from an unpublished cohort of 28 genetically confirmed cases of PDE with antiquitine (ATQ) deficiency and performed a review of the literature looking for description of West syndrome in patients with either PDE with ATQ deficiency or PLP-dependent epilepsy with Pyridox(am)ine phosphate oxidase (PNPO) deficiency. Results: Of the 28 cases from the ATQ deficiency French cohort, 5 had spasms. In four cases, spasms were associated with other types of seizures (myoclonus, focal seizures). In the last case, seizures started on the day of birth. None of these cases corresponded to de novo West syndrome. The review of the literature found only one case of PNPO deficiency presenting as de novo West syndrome and no case of ATQ deficiency. Significance: The presentation of PDE- and PLP-dependent epilepsy as de novo West syndrome is so exceptional that it probably does not justify a systematic trial of pyridoxine or PLP. We propose considering a therapeutic trial with these vitamins in West syndrome if spasms are associated with other seizure types or start before the age of 2 months.
Collapse
Affiliation(s)
- Marc Gibaud
- Service de neuropédiatrie, CHU d'Angers, Angers, France
| | - Magalie Barth
- Service de génétique médicale, CHU d'Angers, Angers, France
| | | | - Karine Mention
- Centre de référence des Maladies Héréditaires du métabolisme, Hôpital Jeanne de Flandre CHRU Lille, Lille, France
| | - Nathalie Villeneuve
- Service de neuropédiatrie, Hôpital de la Timone, APHM Marseille, Marseille, France
| | - Manuel Schiff
- Centre de référence maladies héréditaires du métabolisme Hôpital Robert Debré, APHP Paris, Paris, France
| | - Hélène Maurey
- Service de neuropédiatrie Hôpital Kremlin-Bicêtre APHP Paris, Paris, France
| | | | | | | | - Diane Doummar
- Service de neuropédiatrie, Hôpital d'Enfants Armand-Trousseau APHP Paris, Paris, France
| | - Manoëlle Kossorotoff
- Service de neuropédiatrie et maladies métaboliques, Hôpital Necker-Enfants Malades APHP Paris, Paris, France
| | - Marie-Dominique Lamblin
- Service de physiologie et explorations fonctionnelles, Hôpital Jeanne de Flandre CHRU Lille, Lille, France
| | - Agathe Roubertie
- Service de neuropédiatrie, CHU de Montpellier, Montpellier, France
| | - Rima Nabbout
- Service de neuropédiatrie et maladies métaboliques, Hôpital Necker-Enfants Malades APHP Paris, Paris, France
| | - Patrick Van Bogaert
- Service de neuropédiatrie, CHU d'Angers, Angers, France.,Laboratoire Angevin de Recherche en Ingénierie des Systèmes (LARIS), Université d'Angers, Angers, France
| |
Collapse
|
41
|
Pappalardo P, Benoist JF, Bax BE, Carra-Dallière C, Marelli C, Levene M, Begue L, Rolland A, Flori N, Rivier F, Blanchet C, Munnich A, Altwegg R, Meyer P, Roubertie A. Pregnancy in MNGIE: a clinical and metabolic honeymoon. Ann Clin Transl Neurol 2020; 7:2484-2488. [PMID: 33159497 PMCID: PMC7732247 DOI: 10.1002/acn3.51202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 09/01/2020] [Accepted: 09/01/2020] [Indexed: 02/05/2023] Open
Abstract
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an inherited disease caused by a deficiency in thymidine phosphorylase and characterized by elevated systemic deoxyribonucleotides and gastrointestinal (GI) and neurological manifestations. We report the clinical and biochemical manifestations that were evaluated in a single patient before, during, and after pregnancy, over a period of 7 years. GI symptoms significantly improved, and plasma deoxyribonucleotide concentrations decreased during pregnancy. Within days after delivery, the patient's digestive symptoms recurred, coinciding with a rapid increase in plasma deoxyribonucleotide concentrations. We hypothesize that the clinico-metabolic improvements could be attributed to the enzyme replacement action of the placental thymidine phosphorylase.
Collapse
Affiliation(s)
| | | | - Bridget E Bax
- Molecular and Clinical Sciences, St George's University of London, London, SW17 0RE, UK
| | - Clarisse Carra-Dallière
- Département de Neurologie, CHU Gui de Chauliac, Inserm U1198 MMDN, Univ Montpellier, Montpellier, France
| | - Cecilia Marelli
- Département de Neurologie, CHU Gui de Chauliac, Inserm U1198 MMDN, Univ Montpellier, Montpellier, France
| | - Michele Levene
- Molecular and Clinical Sciences, St George's University of London, London, SW17 0RE, UK
| | - Laetitia Begue
- Département de Gynéco-obstétrique, CHU Arnaud de Villeneuve, Montpellier, France
| | - Anne Rolland
- Département de Pédiatrie, CHU Nantes, Nantes, France
| | - Nicolas Flori
- Département des Soins de Support, Institut du Cancer de Montpellier (ICM), Montpellier, France
| | - François Rivier
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France
- U1046 INSERM, UMR9214 CNRS, Université de Montpellier, Montpellier, France
| | - Catherine Blanchet
- Service d'ORL et Chirurgie Cervico Faciale, CHU Gui de Chauliac, Montpellier, France
| | | | - Romain Altwegg
- Département de Gastroentérologie, CHU St Eloi, Montpellier, France
| | - Pierre Meyer
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France
- U1046 INSERM, UMR9214 CNRS, Université de Montpellier, Montpellier, France
| | - Agathe Roubertie
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France
- Institut des Neurosciences de Montpellier, INSERM U1051, Université de Montpellier, Montpellier, France
| |
Collapse
|
42
|
Mengel E, Bembi B, Del Toro M, Deodato F, Gautschi M, Grunewald S, Grønborg S, Héron B, Maier EM, Roubertie A, Santra S, Tylki-Szymanska A, Day S, Symonds T, Hudgens S, Patterson MC, Guldberg C, Ingemann L, Petersen NHT, Kirkegaard T, Í Dali C. Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study. Orphanet J Rare Dis 2020; 15:328. [PMID: 33228797 PMCID: PMC7684888 DOI: 10.1186/s13023-020-01616-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Accepted: 11/10/2020] [Indexed: 01/09/2023] Open
Abstract
Background Niemann–Pick disease type C (NPC) is a rare, progressive, neurodegenerative disease associated with neurovisceral manifestations resulting from lysosomal dysfunction and aberrant lipid accumulation. A multicentre, prospective observational study (Clinical Trials.gov ID: NCT02435030) of individuals with genetically confirmed NPC1 or NPC2 receiving routine clinical care was conducted, to prospectively characterize and measure NPC disease progression and to investigate potential NPC-related biomarkers versus healthy individuals. Progression was measured using the abbreviated 5-domain NPC Clinical Severity Scale (NPCCSS), 17-domain NPCCSS and NPC clinical database (NPC-cdb) score. Cholesterol esterification and heat shock protein 70 (HSP70) levels were assessed from peripheral blood mononuclear cells (PBMCs), cholestane-3β,5α-,6β-triol (cholestane-triol) from serum, and unesterified cholesterol from both PBMCs and skin biopsy samples. The inter- and intra-rater reliability of the 5-domain NPCCSS was assessed by 13 expert clinicians’ rating of four participants via video recordings, repeated after ≥ 3 weeks. Intraclass correlation coefficients (ICCs) were calculated. Results Of the 36 individuals with NPC (2–18 years) enrolled, 31 (86.1%) completed the 6–14-month observation period; 30/36 (83.3%) were receiving miglustat as part of routine clinical care. A mean (± SD) increase in 5-domain NPCCSS scores of 1.4 (± 2.9) was observed, corresponding to an annualized progression rate of 1.5. On the 17-domain NPCCSS, a mean (± SD) progression of 2.7 (± 4.0) was reported. Compared with healthy individuals, the NPC population had significantly lower levels of cholesterol esterification (p < 0.0001), HSP70 (p < 0.0001) and skin unesterified cholesterol (p = 0.0006). Cholestane-triol levels were significantly higher in individuals with NPC versus healthy individuals (p = 0.008) and correlated with the 5-domain NPCCSS (Spearman’s correlation coefficient = 0.265, p = 0.0411). The 5-domain NPCCSS showed high ICC agreement in inter-rater reliability (ICC = 0.995) and intra-rater reliability (ICC = 0.937). Conclusions Progression rates observed were consistent with other reports on disease progression in NPC. The 5-domain NPCCSS reliability study supports its use as an abbreviated alternative to the 17-domain NPCCSS that focuses on the most relevant domains of the disease. The data support the use of cholestane-triol as a disease monitoring biomarker and the novel methods of measuring unesterified cholesterol could be applicable to support NPC diagnosis. Levels of HSP70 in individuals with NPC were significantly decreased compared with healthy individuals. Trial registration CT-ORZY-NPC-001: ClincalTrials.gov NCT02435030, Registered 6 May 2015, https://clinicaltrials.gov/ct2/show/NCT02435030; EudraCT 2014–005,194-37, Registered 28 April 2015, https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005194-37/DE. OR-REL-NPC-01: Unregistered.
Collapse
Affiliation(s)
- Eugen Mengel
- SphinCS GmbH, Institute of Clinical Science for LSD, Hochheim, Germany.
| | - Bruno Bembi
- Regional Coordinator Centre for Rare Diseases, Academic Hospital Santa Maria Della Misericordia, Udine, Italy
| | | | | | | | - Stephanie Grunewald
- Metabolic Department, Great Ormond Street Hospital NHS Foundation Trust, Institute for Child Health, NIHR Biomedical Research Centre UCL, London, UK
| | - Sabine Grønborg
- Centre for Inherited Metabolic Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark
| | - Bénédicte Héron
- Reference Centre for Lysosomal Disease, Trousseau University Hospital, Paris, France
| | - Esther M Maier
- Dr. Von Hauner Children's Hospital, University of Munich, Munich, Germany
| | - Agathe Roubertie
- Institute of Neurosciences, University Hospital of Montpellier, Montpellier, France
| | | | | | - Simon Day
- Clinical Trials Consulting & Training Limited, Buckingham, UK
| | - Tara Symonds
- Clinical Outcomes Solutions Limited, Folkestone, UK
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Carreau C, Benoit C, Ahle G, Cauquil C, Roubertie A, Lenglet T, Cosgrove J, Meunier I, Veauville-Merllié A, Acquaviva-Bourdain C, Nadjar Y. Late-onset riboflavin transporter deficiency: a treatable mimic of various motor neuropathy aetiologies. J Neurol Neurosurg Psychiatry 2020; 92:jnnp-2020-323304. [PMID: 33087424 DOI: 10.1136/jnnp-2020-323304] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 07/27/2020] [Accepted: 08/18/2020] [Indexed: 11/03/2022]
Abstract
OBJECTIVE Riboflavin transporter deficiencies (RTDs), involving SLC52A3 and SLC52A2 genes, have recently been related to Brown-Vialetto-Van Laere (BVVL) syndrome, a hereditary paediatric condition associating motor neuropathy (MN) and deafness. BVVL/RTD has rarely been reported in adult patients, but is probably underdiagnosed due to poor knowledge and lack of awareness of this form of disease among neurologists. In this study, we aimed to investigate the phenotype and prognosis of RTD patients with late-onset MN. METHODS We retrospectively collected clinical, biological and electrophysiological data from all French RTD patients with MN onset after 10 years of age (n=6) and extracted data from 19 other similar RTD patients from the literature. RESULTS Adult RTD patients with MN had heterogeneous clinical presentations, potentially mimicking amyotrophic lateral sclerosis or distal hereditary motor neuropathy (56%), multinevritis with cranial nerve involvement (16%), Guillain-Barré syndrome (8%) and mixed motor and sensory neuronopathy syndromes (20%, only in SLC52A2 patients). Deafness was often diagnosed before MN (in 44%), but in some patients, onset began only with MN (16%). The pattern of weakness varied widely, and the classic pontobulbar palsy described in BVVL was not constant. Biochemical tests were often normal. The majority of patients improved under riboflavin supplementation (86%). INTERPRETATION Whereas late-onset RTD may mimic different acquired or genetic causes of motor neuropathies, it is a diagnosis not to be missed since high-dose riboflavin per oral supplementation is often highly efficient.
Collapse
Affiliation(s)
- Christophe Carreau
- Department of Neurology, Reference Center for Lysosomal Diseases, Neuro-Metabolism Unit, AP-HP, Hôpital Universitaire Pitié Salpêtrière, Paris, France
| | - Charline Benoit
- Department of Neurology, AP-HP, Hôpital Universitaire Pitié Salpêtrière, Paris, France
| | - Guido Ahle
- Neurology, Hôpital Louis Pasteur, Colmar, Alsace, France
| | - Cécile Cauquil
- Neurology, Hôpital Bicêtre, Le Kremlin-Bicêtre, Île-de-France, France
| | - Agathe Roubertie
- Neuropediatrie, Hôpital Gui de Chauliac Pôle Neurosciences tête et cou, Montpellier, Languedoc-Roussillon Midi, France
| | - Timothée Lenglet
- Department of Neurophysiology, AP-HP, Hôpital Universitaire Pitié Salpêtrière, Paris, France
| | | | - Isabelle Meunier
- Ophthalmology, Hôpital Gui de Chauliac, Montpellier, Languedoc-Roussillon, France
| | - Alice Veauville-Merllié
- Laboratory of Inborn Errors of Metabolism, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France
| | - Cécile Acquaviva-Bourdain
- Laboratory of Inborn Errors of Metabolism, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France
| | - Yann Nadjar
- Department of Neurology, Reference Center for Lysosomal Diseases, Neuro-Metabolism Unit, AP-HP, Hôpital Universitaire Pitié Salpêtrière, Paris, France
| |
Collapse
|
44
|
Ebrahimi-Fakhari D, Teinert J, Behne R, Wimmer M, D'Amore A, Eberhardt K, Brechmann B, Ziegler M, Jensen DM, Nagabhyrava P, Geisel G, Carmody E, Shamshad U, Dies KA, Yuskaitis CJ, Salussolia CL, Ebrahimi-Fakhari D, Pearson TS, Saffari A, Ziegler A, Kölker S, Volkmann J, Wiesener A, Bearden DR, Lakhani S, Segal D, Udwadia-Hegde A, Martinuzzi A, Hirst J, Perlman S, Takiyama Y, Xiromerisiou G, Vill K, Walker WO, Shukla A, Dubey Gupta R, Dahl N, Aksoy A, Verhelst H, Delgado MR, Kremlikova Pourova R, Sadek AA, Elkhateeb NM, Blumkin L, Brea-Fernández AJ, Dacruz-Álvarez D, Smol T, Ghoumid J, Miguel D, Heine C, Schlump JU, Langen H, Baets J, Bulk S, Darvish H, Bakhtiari S, Kruer MC, Lim-Melia E, Aydinli N, Alanay Y, El-Rashidy O, Nampoothiri S, Patel C, Beetz C, Bauer P, Yoon G, Guillot M, Miller SP, Bourinaris T, Houlden H, Robelin L, Anheim M, Alamri AS, Mahmoud AAH, Inaloo S, Habibzadeh P, Faghihi MA, Jansen AC, Brock S, Roubertie A, Darras BT, Agrawal PB, Santorelli FM, Gleeson J, Zaki MS, Sheikh SI, Bennett JT, Sahin M. Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia. Brain 2020; 143:2929-2944. [PMID: 32979048 PMCID: PMC7780481 DOI: 10.1093/brain/awz307] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Revised: 07/25/2019] [Accepted: 08/16/2019] [Indexed: 12/21/2022] Open
Abstract
Bi-allelic loss-of-function variants in genes that encode subunits of the adaptor protein complex 4 (AP-4) lead to prototypical yet poorly understood forms of childhood-onset and complex hereditary spastic paraplegia: SPG47 (AP4B1), SPG50 (AP4M1), SPG51 (AP4E1) and SPG52 (AP4S1). Here, we report a detailed cross-sectional analysis of clinical, imaging and molecular data of 156 patients from 101 families. Enrolled patients were of diverse ethnic backgrounds and covered a wide age range (1.0-49.3 years). While the mean age at symptom onset was 0.8 ± 0.6 years [standard deviation (SD), range 0.2-5.0], the mean age at diagnosis was 10.2 ± 8.5 years (SD, range 0.1-46.3). We define a set of core features: early-onset developmental delay with delayed motor milestones and significant speech delay (50% non-verbal); intellectual disability in the moderate to severe range; mild hypotonia in infancy followed by spastic diplegia (mean age: 8.4 ± 5.1 years, SD) and later tetraplegia (mean age: 16.1 ± 9.8 years, SD); postnatal microcephaly (83%); foot deformities (69%); and epilepsy (66%) that is intractable in a subset. At last follow-up, 36% ambulated with assistance (mean age: 8.9 ± 6.4 years, SD) and 54% were wheelchair-dependent (mean age: 13.4 ± 9.8 years, SD). Episodes of stereotypic laughing, possibly consistent with a pseudobulbar affect, were found in 56% of patients. Key features on neuroimaging include a thin corpus callosum (90%), ventriculomegaly (65%) often with colpocephaly, and periventricular white-matter signal abnormalities (68%). Iron deposition and polymicrogyria were found in a subset of patients. AP4B1-associated SPG47 and AP4M1-associated SPG50 accounted for the majority of cases. About two-thirds of patients were born to consanguineous parents, and 82% carried homozygous variants. Over 70 unique variants were present, the majority of which are frameshift or nonsense mutations. To track disease progression across the age spectrum, we defined the relationship between disease severity as measured by several rating scales and disease duration. We found that the presence of epilepsy, which manifested before the age of 3 years in the majority of patients, was associated with worse motor outcomes. Exploring genotype-phenotype correlations, we found that disease severity and major phenotypes were equally distributed among the four subtypes, establishing that SPG47, SPG50, SPG51 and SPG52 share a common phenotype, an 'AP-4 deficiency syndrome'. By delineating the core clinical, imaging, and molecular features of AP-4-associated hereditary spastic paraplegia across the age spectrum our results will facilitate early diagnosis, enable counselling and anticipatory guidance of affected families and help define endpoints for future interventional trials.
Collapse
Affiliation(s)
- Darius Ebrahimi-Fakhari
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Julian Teinert
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Division of Child Neurology and Metabolic Medicine, Centre for Paediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
| | - Robert Behne
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany
| | - Miriam Wimmer
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Angelica D'Amore
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy
| | - Kathrin Eberhardt
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Barbara Brechmann
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Marvin Ziegler
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Dana M Jensen
- Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA
| | - Premsai Nagabhyrava
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Gregory Geisel
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Erin Carmody
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Uzma Shamshad
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Kira A Dies
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Christopher J Yuskaitis
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Catherine L Salussolia
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Daniel Ebrahimi-Fakhari
- Pediatric Neurology, Saarland University Medical Center, Homburg/Saar, Germany
- Department of General Pediatrics, University Children's Hospital Muenster, Muenster, Germany
| | - Toni S Pearson
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | - Afshin Saffari
- Division of Child Neurology and Metabolic Medicine, Centre for Paediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
| | - Andreas Ziegler
- Division of Child Neurology and Metabolic Medicine, Centre for Paediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
| | - Stefan Kölker
- Division of Child Neurology and Metabolic Medicine, Centre for Paediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
| | - Jens Volkmann
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany
| | - Antje Wiesener
- Institute of Human Genetics, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
| | - David R Bearden
- Child Neurology, University of Rochester School of Medicine, Rochester, NY, USA
| | - Shenela Lakhani
- Center for Neurogenetics, Weill Cornell Medical College, New York, NY, USA
| | - Devorah Segal
- Center for Neurogenetics, Weill Cornell Medical College, New York, NY, USA
- Division of Child Neurology, Weill Cornell Medicine, New York City, NY, USA
| | - Anaita Udwadia-Hegde
- Department of Pediatric Neurology, Jaslok Hospital and Research Centre, Mumbai, India
| | - Andrea Martinuzzi
- Scientific Institute, IRCCS E. Medea, Unità Operativa Conegliano, Treviso, Italy
| | - Jennifer Hirst
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
| | - Seth Perlman
- Division of Neurology, Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, USA
| | | | | | - Katharina Vill
- Pediatric Neurology and Developmental Medicine, Dr. v. Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany
| | - William O Walker
- Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, USA
| | - Anju Shukla
- Department of Medical Genetics, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India
| | | | - Niklas Dahl
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Ayse Aksoy
- Pediatric Neurology, Dr. Sami Ulus Hospital, Ankara, Turkey
| | - Helene Verhelst
- Pediatric Neurology, Ghent University Hospital, Ghent, Belgium
| | - Mauricio R Delgado
- Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Radka Kremlikova Pourova
- Department of Biology and Medical Genetics, Second Medical Faculty, Charles University and UH Motol, Prague, Czech Republic
| | - Abdelrahim A Sadek
- Pediatric Neurology, Faculty of Medicine, Sohag University, Sohag, Egypt
| | | | - Lubov Blumkin
- Movement Disorders Clinic, Pediatric Neurology Unit, Wolfson Medical Center, Holon, Sackler School of Medicine, Tel-Aviv University, Israel
| | | | - David Dacruz-Álvarez
- Neurología Pediátrica, Complexo Hospitalario Universitario, Santiago de Compostela, Spain
| | - Thomas Smol
- CHU Lille, Institut de Génétique Médicale, RADEME, Lille, France
| | - Jamal Ghoumid
- CHU Lille, Institut de Génétique Médicale, RADEME, Lille, France
| | - Diego Miguel
- Serviço de Genética Médica, Universidade Federal da Bahia, Salvador, Brazil
| | - Constanze Heine
- Institute of Human Genetics, University Hospital Leipzig, Leipzig, Germany
| | | | | | - Jonathan Baets
- Neurogenetics Group and Neuromuscular Reference Center, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium
| | - Saskia Bulk
- Medical Genetics, Centre Hospitalier Universitaire de Liège, Liège, Belgium
| | - Hossein Darvish
- Cancer Research Center and Department of Medical Genetics, Semnan University of Medical Sciences, Semnan, Iran
| | - Somayeh Bakhtiari
- Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, AZ, USA
| | - Michael C Kruer
- Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, AZ, USA
| | - Elizabeth Lim-Melia
- Pediatric Medical Genetics, Maria Fareri Children's Hospital, Valhalla, NY, USA
| | - Nur Aydinli
- Pediatric Genetics, Department of Pediatrics, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
| | - Yasemin Alanay
- Pediatric Neurology, Istanbul Medical Faculty, Istanbul, Turkey
| | | | | | - Chirag Patel
- Genetic Health Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | | | | | - Grace Yoon
- Division of Clinical and Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada
| | - Mireille Guillot
- Department of Paediatrics, The Hospital for Sick Children and The University of Toronto, Toronto, Canada
| | - Steven P Miller
- Department of Paediatrics, The Hospital for Sick Children and The University of Toronto, Toronto, Canada
| | - Thomas Bourinaris
- Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
| | - Henry Houlden
- Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
| | - Laura Robelin
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Mathieu Anheim
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Abdullah S Alamri
- Pediatric Neurology, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Adel A H Mahmoud
- Pediatrics, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
| | - Soroor Inaloo
- Neonatal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Parham Habibzadeh
- Persian BayanGene Research and Training Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mohammad Ali Faghihi
- Persian BayanGene Research and Training Center, Shiraz University of Medical Sciences, Shiraz, Iran
- Center for Therapeutic Innovation and Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, USA
| | - Anna C Jansen
- Pediatric Neurology Unit, Department of Pediatrics, UZ Brussel, Brussels, Belgium
| | - Stefanie Brock
- Pediatric Neurology Unit, Department of Pediatrics, UZ Brussel, Brussels, Belgium
| | | | - Basil T Darras
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Pankaj B Agrawal
- Divisions of Newborn Medicine and Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | | | - Joseph Gleeson
- Rady Children's Institute for Genomic Medicine, Rady Children's Hospital, San Diego, CA, USA
| | - Maha S Zaki
- Clinical Genetics, Human Genetics and Genome Research Division, National Research Centre, Cairo, Egypt
| | | | - James T Bennett
- Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA
| | - Mustafa Sahin
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
45
|
Piro-Mégy C, Sarzi E, Tarrés-Solé A, Péquignot M, Hensen F, Quilès M, Manes G, Chakraborty A, Sénéchal A, Bocquet B, Cazevieille C, Roubertie A, Müller A, Charif M, Goudenège D, Lenaers G, Wilhelm H, Kellner U, Weisschuh N, Wissinger B, Zanlonghi X, Hamel C, Spelbrink JN, Sola M, Delettre C. Dominant mutations in mtDNA maintenance gene SSBP1 cause optic atrophy and foveopathy. J Clin Invest 2020; 130:143-156. [PMID: 31550237 PMCID: PMC6934222 DOI: 10.1172/jci128513] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Accepted: 09/19/2019] [Indexed: 01/20/2023] Open
Abstract
Mutations in genes encoding components of the mitochondrial DNA (mtDNA) replication machinery cause mtDNA depletion syndromes (MDSs), which associate ocular features with severe neurological syndromes. Here, we identified heterozygous missense mutations in single-strand binding protein 1 (SSBP1) in 5 unrelated families, leading to the R38Q and R107Q amino acid changes in the mitochondrial single-stranded DNA-binding protein, a crucial protein involved in mtDNA replication. All affected individuals presented optic atrophy, associated with foveopathy in half of the cases. To uncover the structural features underlying SSBP1 mutations, we determined a revised SSBP1 crystal structure. Structural analysis suggested that both mutations affect dimer interactions and presumably distort the DNA-binding region. Using patient fibroblasts, we validated that the R38Q variant destabilizes SSBP1 dimer/tetramer formation, affects mtDNA replication, and induces mtDNA depletion. Our study showing that mutations in SSBP1 cause a form of dominant optic atrophy frequently accompanied with foveopathy brings insights into mtDNA maintenance disorders.
Collapse
Affiliation(s)
- Camille Piro-Mégy
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France
| | - Emmanuelle Sarzi
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France
| | - Aleix Tarrés-Solé
- Structural MitoLab, Department of Structural Biology, "Maria de Maeztu" Unit of Excellence, Molecular Biology Institute Barcelona (IBMB-CSIC), Barcelona, Spain
| | - Marie Péquignot
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France
| | - Fenna Hensen
- Radboud Center for Mitochondrial Medicine, Department of Paediatrics, Radboudumc, Nijmegen, Netherlands
| | - Mélanie Quilès
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France
| | - Gaël Manes
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France
| | - Arka Chakraborty
- Structural MitoLab, Department of Structural Biology, "Maria de Maeztu" Unit of Excellence, Molecular Biology Institute Barcelona (IBMB-CSIC), Barcelona, Spain
| | - Audrey Sénéchal
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France
| | - Béatrice Bocquet
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France.,CHU Montpellier, Centre of Reference for Genetic Sensory Diseases, Gui de Chauliac Hospital, Montpellier, France
| | - Chantal Cazevieille
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France
| | - Agathe Roubertie
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France.,CHU Montpellier, Centre of Reference for Genetic Sensory Diseases, Gui de Chauliac Hospital, Montpellier, France
| | - Agnès Müller
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France.,Faculté de Pharmacie, Université de Montpellier, Montpellier, France
| | - Majida Charif
- UMR CNRS 6015-INSERM U1083, MitoVasc Institute, Angers University, Angers, France
| | - David Goudenège
- UMR CNRS 6015-INSERM U1083, MitoVasc Institute, Angers University, Angers, France
| | - Guy Lenaers
- UMR CNRS 6015-INSERM U1083, MitoVasc Institute, Angers University, Angers, France
| | - Helmut Wilhelm
- University Eye Hospital, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
| | - Ulrich Kellner
- Rare Retinal Disease Center, AugenZentrum Siegburg, MVZ Augenärztliches Diagnostik- und Therapiecentrum Siegburg GmbH, Siegburg, Germany
| | - Nicole Weisschuh
- Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
| | - Bernd Wissinger
- Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
| | - Xavier Zanlonghi
- Centre de Compétence Maladie Rares, Clinique Pluridisciplinaire Jules Verne, Nantes, France
| | - Christian Hamel
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France.,CHU Montpellier, Centre of Reference for Genetic Sensory Diseases, Gui de Chauliac Hospital, Montpellier, France
| | - Johannes N Spelbrink
- Radboud Center for Mitochondrial Medicine, Department of Paediatrics, Radboudumc, Nijmegen, Netherlands
| | - Maria Sola
- Structural MitoLab, Department of Structural Biology, "Maria de Maeztu" Unit of Excellence, Molecular Biology Institute Barcelona (IBMB-CSIC), Barcelona, Spain
| | - Cécile Delettre
- Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France
| |
Collapse
|
46
|
Bah MG, Rodriguez D, Cazeneuve C, Mochel F, Devos D, Suppiej A, Roubertie A, Meunier I, Gitiaux C, Curie A, Klapczynski F, Allani‐Essid N, Carneiro M, Van Minkelen R, Kievit A, Fluss J, Leheup B, Ratbi L, Héron D, Gras D, Do Cao J, Pichard S, Strubi‐Villaume I, Audo I, Lesca G, Charles P, Dubois F, Comet‐Didierjean P, Capri Y, Barondiot C, Barathon M, Ewenczyk C, Durr A, Mignot C. Deciphering the natural history of SCA7 in children. Eur J Neurol 2020; 27:2267-2276. [DOI: 10.1111/ene.14405] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2020] [Accepted: 06/10/2020] [Indexed: 11/30/2022]
|
47
|
Piarroux J, Riant F, Humbertclaude V, Remerand G, Hadjadj J, Rejou F, Coubes C, Pinson L, Meyer P, Roubertie A. FGF14-related episodic ataxia: delineating the phenotype of Episodic Ataxia type 9. Ann Clin Transl Neurol 2020; 7:565-572. [PMID: 32162847 PMCID: PMC7187715 DOI: 10.1002/acn3.51005] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Revised: 02/12/2020] [Accepted: 02/14/2020] [Indexed: 11/09/2022] Open
Abstract
We report four patients from two families who presented attacks of childhood-onset episodic ataxia associated with pathogenic mutations in the FGF14 gene. Attacks were triggered by fever, lasted several days, and had variable frequencies. Nystagmus and/or postural tremor and/or learning disabilities were noticed in individuals harboring FGF14 mutation with or without episodic ataxia. These cases and literature data delineate the FGF14-mutation-related episodic ataxia phenotype: wide range of age at onset (from childhood to adulthood), variable durations and frequencies, triggering factors including fever, and association to chronic symptoms. We propose to add FGF14-related episodic ataxia to the list of primary episodic ataxia as Episodic Ataxia type 9.
Collapse
Affiliation(s)
- Julie Piarroux
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France
| | - Florence Riant
- Service de Génétique Moléculaire Neurovasculaire, Groupe hospitalier Saint-Louis - Lariboisière - Fernand Widal AP-HP, Paris, France
| | - Véronique Humbertclaude
- Service de Médecine Psychologique Enfants et Adolescents, CHU Saint Eloi, Montpellier, France
| | | | - Jessica Hadjadj
- Service de Génétique Moléculaire Neurovasculaire, Groupe hospitalier Saint-Louis - Lariboisière - Fernand Widal AP-HP, Paris, France
| | - Franck Rejou
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France
| | - Christine Coubes
- Service de Génétique Clinique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France
| | - Lucile Pinson
- Service de Génétique Clinique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France
| | - Pierre Meyer
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France.,PhyMedExp, U1046 INSERM, UMR9214 CNRS, Montpellier, France
| | - Agathe Roubertie
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France.,INSERM U 1051, Institut des Neurosciences de Montpellier, Montpellier, France
| |
Collapse
|
48
|
Panagiotakaki E, Doummar D, Nogue E, Nagot N, Lesca G, Riant F, Nicole S, Delaygue C, Barthez MA, Nassogne MC, Dusser A, Vallée L, Billette T, Bourgeois M, Ioos C, Gitiaux C, Laroche C, Milh M, Portes VD, Arzimanoglou A, Roubertie A. Movement disorders in patients with alternating hemiplegia: "Soft" and "stiff" at the same time. Neurology 2020; 94:e1378-e1385. [PMID: 32123049 DOI: 10.1212/wnl.0000000000009175] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Accepted: 09/24/2019] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To assess nonparoxysmal movement disorders in ATP1A3 mutation-positive patients with alternating hemiplegia of childhood (AHC). METHODS Twenty-eight patients underwent neurologic examination with particular focus on movement phenomenology by a specialist in movement disorders. Video recordings were reviewed by another movement disorders specialist and data were correlated with patients' characteristics. RESULTS Ten patients were diagnosed with chorea, 16 with dystonia (nonparoxysmal), 4 with myoclonus, and 2 with ataxia. Nine patients had more than one movement disorder and 8 patients had none. The degree of movement disorder was moderate to severe in 12/28 patients. At inclusion, dystonic patients (n = 16) were older (p = 0.007) than nondystonic patients. Moreover, patients (n = 18) with dystonia or chorea, or both, had earlier disease onset (p = 0.042) and more severe neurologic impairment (p = 0.012), but this did not correlate with genotype. All patients presented with hypotonia, which was characterized as moderate or severe in 16/28. Patients with dystonia or chorea (n = 18) had more pronounced hypotonia (p = 0.011). Bradykinesia (n = 16) was associated with an early age at assessment (p < 0.01). Significant dysarthria was diagnosed in 11/25 cases. A history of acute neurologic deterioration and further regression of motor function, typically after a stressful event, was reported in 7 patients. CONCLUSIONS Despite the relatively limited number of patients and the cross-sectional nature of the study, this detailed categorization of movement disorders in patients with AHC offers valuable insight into their precise characterization. Further longitudinal studies on this topic are needed.
Collapse
Affiliation(s)
- Eleni Panagiotakaki
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Diane Doummar
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Erika Nogue
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Nicolas Nagot
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Gaetan Lesca
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Florence Riant
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Sophie Nicole
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Charlene Delaygue
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Marie Anne Barthez
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Marie Cécile Nassogne
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Anne Dusser
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Louis Vallée
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Thierry Billette
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Marie Bourgeois
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Christine Ioos
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Cyril Gitiaux
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Cécile Laroche
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Mathieu Milh
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Vincent Des Portes
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Alexis Arzimanoglou
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France
| | - Agathe Roubertie
- From Sleep Disorders and Functional Neurology (E.P., A.A.), Department of Paediatric Clinical Epileptology, University Hospitals of Lyon, member of the ERN EpiCARE; Service de Neurologie Pédiatrique (D.D., T.B.), Hôpital Trousseau, APHP, Paris; Centre d'Investigation Clinique (E.N., N.N.), CHU Montpellier; Department of Medical Genetics (G.L.), Centre de Biologie Est, Lyon University Hospital, Hospices Civils de Lyon, member of the ERN EpiCARE; Laboratoire de Génétique (F.R.), Groupe Hospitalier Lariboisière-Fernand Widal AP-HP, Paris; IGF (S.N.), Univ Montpellier, CNRS, INSERM; Département de Neuropédiatrie (C.D., A.R.), CHU Gui de Chauliac, Montpellier; Service de Neuropédiatrie et Handicaps (M.A.B.), Hôpital Gatien de Clocheville, CHU Tours, France; Pediatric Neurology Unit (M.C.N.), Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Service de Neuropédiatrie (A.D.), CHU de Bicêtre, Kremlin-Bicêtre; Service de Neuropédiatrie (L.V.), CHU Lille; Service de Neurochirurgie Pédiatrique (M.B.), Hôpital Necker-Enfants Malades, APHP, Paris; Service de Neurologie Pédiatrique (C.I.), Hôpital Raymond Poincarré, AP-HP, Garches; Service de Neurophysiologie (C.G.), Hôpital Necker, AP-HP, Paris; Département de Pédiatrie (C.L.), CHU Limoges; Service de Neurologie Pédiatrique (M.M.), CHU Timone Enfants, Marseille; Centre de Référence "Déficiences Intellectuelles de Causes Rares" (V.D.P.), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, Université de Lyon; and INSERM U 1051 (A.R.), Institut des Neurosciences de Montpellier, France.
| | | |
Collapse
|
49
|
Humbertclaude V, Riant F, Krams B, Zimmermann V, Nagot N, Annequin D, Echenne B, Tournier-Lasserve E, Roubertie A. Cognitive impairment in children with CACNA1A mutations. Dev Med Child Neurol 2020; 62:330-337. [PMID: 31115040 DOI: 10.1111/dmcn.14261] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/03/2019] [Indexed: 12/26/2022]
Abstract
AIM To describe the clinico-radiological phenotype of children with a CACNA1A mutation and to precisely evaluate their learning ability and cognitive status. METHOD Children between the ages of 3 and 18 years harboring a pathogenic CACNA1A mutation associated with episodic ataxia, hemiplegic migraine, benign paroxysmal torticollis, benign paroxysmal vertigo, or benign paroxysmal tonic upgaze, were enrolled in this cross-sectional study. Data concerning psychomotor development, academic performance, educational management, clinical examination at inclusion, and brain imaging were collected. Cognitive assessment was performed using age-standardized scales. RESULTS Eighteen patients (nine males, nine females; mean age at inclusion: 11y 7mo [SD 4y 5mo; range 3y-17y 11mo]) from 14 families were enrolled. Eleven patients displayed the coexistence or consecutive occurrence of more than one type of episodic event. Nine patients exhibited abnormal neurological examination at inclusion. Brain magnetic resonance imaging (MRI) showed cerebellar atrophy in five patients. Psychomotor development was delayed in nine patients and academic difficulties were reported by the parents in 15 patients; nine patients were in special education. Impairment of intellectual function was assessed in six of the 12 patients with interpretable Full-scale IQ scores and was more frequent when cerebellar atrophy was present on MRI. INTERPRETATION Cognitive impairment is commonly associated with CACNA1A mutations. We suggest that CACNA1A-associated phenotype should be considered a neurodevelopmental disorder. WHAT THIS PAPER ADDS Cognitive disabilities and academic difficulties are common in children with CACNA1A mutations associated with episodic syndromes. Cognitive function ranges from normal to moderate intellectual disorder in wheelchair-dependent children. Patients with vermian atrophy are at a higher risk of cognitive impairment.
Collapse
Affiliation(s)
- Veronique Humbertclaude
- Service de Médecine Psychologique Enfants et Adolescents, CHU Saint Eloi, Montpellier, France
| | - Florence Riant
- Laboratoire de Génétique, Groupe hospitalier Lariboisière-Fernand Widal AP-HP, Paris, France.,INSERM UMR-S740, Université Paris 7 Denis Diderot, Paris, France
| | - Benjamin Krams
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France
| | | | - Nicolas Nagot
- Centre d'Investigation Clinique, CHU Montpellier, Montpellier, France
| | - Daniel Annequin
- Centre de la Migraine de l'Enfant, Hôpital Trousseau, APHP, Paris, France
| | - Bernard Echenne
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France
| | - Elisabeth Tournier-Lasserve
- Laboratoire de Génétique, Groupe hospitalier Lariboisière-Fernand Widal AP-HP, Paris, France.,INSERM UMR-S740, Université Paris 7 Denis Diderot, Paris, France
| | - Agathe Roubertie
- Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France.,INSERM U 1051, Institut des Neurosciences de Montpellier, Montpellier, France
| | | |
Collapse
|
50
|
Behne R, Teinert J, Wimmer M, D’Amore A, Davies AK, Scarrott JM, Eberhardt K, Brechmann B, Chen IPF, Buttermore ED, Barrett L, Dwyer S, Chen T, Hirst J, Wiesener A, Segal D, Martinuzzi A, Duarte ST, Bennett JT, Bourinaris T, Houlden H, Roubertie A, Santorelli FM, Robinson M, Azzouz M, Lipton JO, Borner GHH, Sahin M, Ebrahimi-Fakhari D. Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking. Hum Mol Genet 2020; 29:320-334. [PMID: 31915823 PMCID: PMC7001721 DOI: 10.1093/hmg/ddz310] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Revised: 10/22/2019] [Accepted: 12/05/2019] [Indexed: 12/25/2022] Open
Abstract
Deficiency of the adaptor protein complex 4 (AP-4) leads to childhood-onset hereditary spastic paraplegia (AP-4-HSP): SPG47 (AP4B1), SPG50 (AP4M1), SPG51 (AP4E1) and SPG52 (AP4S1). This study aims to evaluate the impact of loss-of-function variants in AP-4 subunits on intracellular protein trafficking using patient-derived cells. We investigated 15 patient-derived fibroblast lines and generated six lines of induced pluripotent stem cell (iPSC)-derived neurons covering a wide range of AP-4 variants. All patient-derived fibroblasts showed reduced levels of the AP4E1 subunit, a surrogate for levels of the AP-4 complex. The autophagy protein ATG9A accumulated in the trans-Golgi network and was depleted from peripheral compartments. Western blot analysis demonstrated a 3-5-fold increase in ATG9A expression in patient lines. ATG9A was redistributed upon re-expression of AP4B1 arguing that mistrafficking of ATG9A is AP-4-dependent. Examining the downstream effects of ATG9A mislocalization, we found that autophagic flux was intact in patient-derived fibroblasts both under nutrient-rich conditions and when autophagy is stimulated. Mitochondrial metabolism and intracellular iron content remained unchanged. In iPSC-derived cortical neurons from patients with AP4B1-associated SPG47, AP-4 subunit levels were reduced while ATG9A accumulated in the trans-Golgi network. Levels of the autophagy marker LC3-II were reduced, suggesting a neuron-specific alteration in autophagosome turnover. Neurite outgrowth and branching were reduced in AP-4-HSP neurons pointing to a role of AP-4-mediated protein trafficking in neuronal development. Collectively, our results establish ATG9A mislocalization as a key marker of AP-4 deficiency in patient-derived cells, including the first human neuron model of AP-4-HSP, which will aid diagnostic and therapeutic studies.
Collapse
Affiliation(s)
- Robert Behne
- Department of Neurology, The F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Department of Neurology, University Hospital Würzburg, 97080 Würzburg, Germany
| | - Julian Teinert
- Department of Neurology, The F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Division of Pediatric Neurology and Metabolic Medicine, Center for Child and Adolescent Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany
| | - Miriam Wimmer
- Department of Neurology, The F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Angelica D’Amore
- Department of Neurology, The F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Molecular Medicine, IRCCS Fondazione Stella Maris, 56018 Pisa, Italy
| | - Alexandra K Davies
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK
- Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany
| | - Joseph M Scarrott
- Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield S10 2HQ, UK
| | - Kathrin Eberhardt
- Department of Neurology, The F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Barbara Brechmann
- Department of Neurology, The F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Ivy Pin-Fang Chen
- Translational Neuroscience Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Elizabeth D Buttermore
- Translational Neuroscience Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Lee Barrett
- Translational Neuroscience Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Sean Dwyer
- Translational Neuroscience Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Teresa Chen
- Translational Neuroscience Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Jennifer Hirst
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK
| | - Antje Wiesener
- Institute of Human Genetics, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
| | - Devorah Segal
- Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, New York City, NY 10021, USA
| | - Andrea Martinuzzi
- Scientific Institute, IRCCS E. Medea, Unità Operativa Conegliano, 31015 Treviso, Italy
| | - Sofia T Duarte
- Department of Pediatric Neurology, Centro Hospitalar de Lisboa Central, 1169-050 Lisbon, Portugal
| | - James T Bennett
- Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA 98195, USA
| | - Thomas Bourinaris
- Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1E 6BT, UK
| | - Henry Houlden
- Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1E 6BT, UK
| | | | | | - Margaret Robinson
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK
| | - Mimoun Azzouz
- Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield S10 2HQ, UK
| | - Jonathan O Lipton
- Department of Neurology, The F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Division of Sleep Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Georg H H Borner
- Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany
| | - Mustafa Sahin
- Department of Neurology, The F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Translational Neuroscience Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Darius Ebrahimi-Fakhari
- Department of Neurology, The F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| |
Collapse
|